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Summary 
Since the discovery of the DNA double helix, major advances in biology 
have been; the development of recombinant DNA technology in the 1970s, 
methods to amplify DNA and gene targeting technology in the late 1980s. In 
organisms such as yeast and mice, the ability to accurately add or delete 
genetic information transformed biology, allowing an unmatched level of 
precision in studies of gene function. But, the ability to easily and specifically edit 
the genetic material of other cells and organisms remained impossible until 
recently for molecular biologists. The recent advent of programmable nucleases 
has dramatically changed the efficiency and speed of genome manipulation in 
several model organisms including cultured cells, as well as whole animals and 
plants. These tools opened up a powerful technique for biology research now 
called “genome editing” or “genome engineering” (Carroll, 2011; Hsu et al., 
2014; Kim and Kim, 2014). 
In the first half of my doctoral studies, I developed genome-editing strategies 
to discover drug targets for a rare genetic disease called Friedreich´s Ataxia. 
Friedreich’s Ataxia (FRDA) is a neurodegenerative disease caused by deficiency 
of the mitochondrial protein frataxin (FXN) (Campuzano et al., 1997). This 
deficiency results from an expansion of a trinucleotide GAA repeat in the first 
intron of the FXN gene (Campuzano et al., 1996; Durr et al., 1996). 
Therapeutics that reactivate FXN gene expression are expected to be beneficial 
to FRDA patients (Gottesfeld, 2007). However, high-throughput screening (HTS) 
for FXN activators has so far met with limited success because current cellular 
models do not accurately assess endogenous FXN gene regulation. Here I used 
genome-editing technologies to generate a cellular model in which a luciferase 
reporter is introduced into the endogenous FXN locus. Using this system in a 
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high-throughput genomic screen, we discovered novel inhibitors of FXN-
luciferase expression. I confirmed that reducing expression of one of these 
inhibitors, PRKD1, led to an increase in FXN expression in FRDA patient 
fibroblasts (Villasenor et al., 2015). We then used reprogramming technologies 
to create a disease-relevant situation and test small molecules that specifically 
modulate PRKD1. We found that WA-21-JO19, a chemical inhibitor of PRKD1, 
increases FXN expression levels in iPSC-derived FRDA patient neurons. This 
approach, developed at the interface between academic and pharmaceutical 
research, demonstrates how a combination of genome editing, cellular 
reprogramming, and high-throughput biology can generate an effective novel 
drug discovery platform. 
In the second part of my doctoral work, we developed an interface between 
genome editing and proteomics to isolate native protein complexes produced 
from their natural genomic contexts. In many biological processes, proteins act 
as members of protein complexes. Understanding the molecular composition of 
protein complexes is a key task towards explaining their function in the cell. 
Conventional affinity purification followed by mass spectrometry analysis is a 
broadly applicable method to decipher molecular interaction networks and infer 
protein function. However, traditional affinity purification methods are limited by 
a number of factors such as antibody specificity and are sensitive to 
perturbations induced by overexpressed target proteins. Here, we combined 
genome editing with tandem affinity purification to circumvent current limitations. 
I uncovered subunits and interactions among well-characterized complexes and 
report the isolation of novel Mettl3-binding partners. The multi-protein complex 
composed of two active methyltransferases Mettl3 and Mettl14 mediates 
methylation of adenosines at position N6 on RNA molecules (Bokar et al., 1994; 
Bokar et al., 1997; Liu et al., 2014). N6-methyladenosine is the most abundant 
internal modification in eukaryotic mRNA and is often found on introns, which 
implies that methylation occurs co-transcriptionally (Fu et al., 2014). My work 
identified a set of nuclear RNA binding proteins, which specifically interact with 
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the Mettl3-Mettl14 complex. We are currently testing the ability of these factors 
to function as “recruiters” of the Mettl3-Mettl14 complex to nascent mRNAs in 
the cell nucleus.  
In summary, our approach solidly establishes how a combination of genome 
editing and proteomics can simplify explorations of protein complexes as well as 
the study of post-translational modifications. In addition, this approach opens up 
new opportunities to study native protein complexes in a wide variety of cells 
and model organisms and will likely enable the systematic investigation of 
mammalian proteome function. 
  
 
 
 
 
 
 
 
 
1 Introduction 
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1.1 A brief research history of genome editing with 
programmable nucleases 
 
A major goal in genetics is to connect genotypes with phenotypes. Species 
with experimentally manipulable genomes are essential to investigate the role of 
genes in biology and disease. The ability to modify a complex genome with high 
precision transformed biology since the 1980s (Capecchi, 2001; Evans, 2001; 
Smithies, 2001). The underlying technology is known as gene targeting and 
relies on the homologous recombination (HR) machinery found in all eukaryotes. 
In gene targeting, an exogenously introduced DNA fragment replaces an 
endogenous piece of DNA by homologous recombination. The procedure for 
gene replacement was pioneered in baker´s yeast, Saccharomyces cerevisiae, 
more than 35 years ago (Orr-Weaver et al., 1981; Scherer and Davis, 1979). In 
the mid 1980s, gene targeting was demonstrated in human and mouse 
embryonic stem (ES) cells (Doetschman et al., 1987; Mansour et al., 1988; 
Smithies et al., 1985; Thomas et al., 1986), which enabled the production of 
transgenic mice for studying gene function and for creating models of human 
genetic diseases (Kuehn et al., 1987; Wu and Melton, 1993). Similar to the 
process in yeast, gene targeting in mice depends on homologous recombination 
between the donor and the target site. In addition, positive selection for the 
specific integration of the transgene must be applied against the more common 
products of random integration (Capecchi, 2005). This is achieved by double 
selection strategies yielding the desired replacements. The pluripotent nature of 
mouse ES cells allows spreading of the transgene into all cell lineages after 
injection into early embryos (Evans and Kaufman, 1981; Zijlstra et al., 1989). An 
important development in the use of recombination-based methods for gene 
manipulation in yeast and mammals involved the use of polymerase chain 
reaction (PCR), rather than restriction enzymes, to generate DNA fragments 
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with sufficiently long homologous sequences (Baudin et al., 1993; Lubahn et al., 
1993). 
Advances in gene targeting have made this technique routine in yeast and 
nearly routine in mice. The ability to specifically add or delete genetic 
information in yeast enabled an unmatched level of precision in studies of 
eukaryotic gene function leading to breakthrough discoveries in molecular 
biology. In addition, thousands of transgenic mice and ES cell lines with precise 
genomic modifications have been created. Their characterization has increased 
our knowledge of mammalian physiology and the pathogenesis of numerous 
human diseases. 
In both yeast and mouse cells, the frequency of homologous 
recombination events between donor and target site is inherently low – on the 
order of one in every 103 to 109 cells (Bahler et al., 1998; Thomas et al., 1986). 
Applications of gene targeting in other experimental organisms, where 
embryonic stem cells are not available, have been hindered by the low 
frequency of HR and the need for positive selection in cell culture before 
incorporation into whole organisms. The challenge in extending gene targeting 
to other model organisms can be viewed largely as one of increasing the 
frequency of homologous recombination (Carroll, 2011).  
What limits the frequency of homologous recombination in gene targeting? 
Experiments in yeast and mammalian cells demonstrated clearly that 
manipulations of the donor DNA have modest effects, but activation of the 
chromosomal target with a double-strand break (DSB) boosts the frequency of 
HR by several orders of magnitude. These experiments were inspired by the 
discovery that natural recombination events, such as meiotic crossing over and 
mating-type switching in yeast, are initiated by DSBs. Pioneering experiments in 
yeast and mammalian cells demonstrated that induction of a single DSB can 
dramatically increase the frequency of HR at the cleavage site (Choulika et al., 
1995; Rouet et al., 1994; Rudin and Haber, 1988). Both approaches made use 
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of yeast DNA endonucleases that specifically cut a previously inserted 
recognition site in the genome. Further studies revealed the power of a DSB in 
stimulating gene targeting to levels that would be useful in other experimental 
systems (Rong and Golic, 2000; Smih et al., 1995; Taghian and Nickoloff, 1997). 
I-SceI and HO are yeast homing endonucleases that were used to induce 
a DSB and increase the efficiency of gene targeting. A key feature of these 
enzymes is that they create DSBs at recognition sites that are 14 to 40 base-
pairs (bp) long (Chevalier and Stoddard, 2001). These enzymes provided 
important information on the efficiency and mechanisms of DSB repair, but they 
were limited in their utility as programmable gene-targeting reagents. The main 
reason was that their recognition sites had to be introduced in the genome by a 
low-frequency process before they could mediate high-efficiency homologous 
recombination (Carroll, 2011). Therefore, several investigators used protein 
engineering to modify homing endonucleases to recognize target sites in 
mammalian genes (Belfort and Bonocora, 2014; Chevalier et al., 2002).  
To harness the stimulatory power of DSBs in facilitating gene targeting, 
methods for creating site-specific DSBs were required. Several approaches 
were developed such as modified triplex-forming oligonucleotides (Kuan and 
Glazer, 2004), modified polyamides (Dervan and Edelson, 2003; Wurtz and 
Dervan, 2000), modified peptide-nucleic acids (Kaihatsu et al., 2004), modified 
homing endonucleases (Chevalier et al., 2002), and programmable nucleases 
(Kim and Kim, 2014). In this doctoral thesis, I will focus on the recent progress 
made with programmable nucleases to edit eukaryotic genomes. 
 
1.2 Overview of existing genome editing technologies 
 
The currently existing and most utilized programmable nucleases for 
genome editing include zinc-finger nucleases (ZFNs), transcription activator-like 
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effector nucleases (TALENs) and RNA-guided nucleases (RGNs) derived from 
the adaptive immune defense system of bacteria termed “clustered regularly 
interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas)” 
CRISPR-Cas system (Figure 1B&C). In the next chapters, I will review the 
development and applications of programmable nucleases for genome editing 
from a historical perspective. 
 
 
Figure 1. Genome Editing Technologies Exploit Endogenous DNA Repair Machinery 
(A) DNA double-strand breaks (DSBs) are typically repaired by non-homologous end-joining (NHEJ) or 
homology-directed repair (HDR). In the error-prone NHEJ pathway, Ku heterodimers bind to DSB ends and 
serve as a molecular scaffold for associated repair proteins. Indels are introduced when the complementary 
strands undergo end resection and misaligned repair due to microhomology, eventually leading to 
frameshift mutations and gene knockout. Alternatively, Rad51 proteins may bind DSB ends during the initial 
phase of HDR, recruiting accessory factors that direct genomic recombination with homology arms on an 
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exogenous repair template. Bypassing the matching sister chromatid facilitates the introduction of precise 
gene modifications. (B) Zinc finger (ZF) proteins and transcription activator-like effectors (TALEs) are 
naturally occurring DNA-binding domains that can be modularly assembled to target specific sequences. 
ZF and TALE domains each recognize 3 and 1 bp of DNA, respectively. Such DNA-binding proteins can be 
fused to the FokI endonuclease to generate programmable site-specific nucleases. (C) The Cas9 nuclease 
from the microbial CRISPR adaptive immune system is localized to specific DNA sequences via the guide 
sequence on its guide RNA (red), directly base-pairing with the DNA target. Binding of a protospacer-
adjacent motif (PAM, blue) downstream of the target locus helps to direct Cas9-mediated DSBs. Image 
taken from (Hsu et al., 2014). Copyright © 2015 Elsevier B.V. 
 
1.2.1 Zinc-finger Nucleases (ZFNs) 
In 1996, Chandrasegaran and colleagues developed the first zinc-finger 
nucleases (ZFN), originally termed chimeric restriction enzymes (Kim et al., 
1996). They hypothesized that the modular structure of the FokI type II 
restriction endonuclease might allow the creation of hybrid endonucleases with 
novel sequence specificities by linking other DNA-binding proteins to the 
cleavage domain. The first ZFNs consisted of the non sequence-specific 
cleavage domain of the FokI endonuclease fused to zinc-finger DNA-binding 
domain of transcription factors with known consensus sequences (Kim et al., 
1996; Kim et al., 1998). Because of their modular structure, FokI endonucleases 
offered an attractive framework for designing chimeric restriction enzymes with 
tailor-made sequence specificity (Durai et al., 2005).  
Zinc-finger proteins of the Cys2His2-like fold group are found in the DNA-
binding domains of the most abundant family of eukaryotic transcription factors 
(Vaquerizas 2009) (Figure 2A). The crystal structure of the transcription factor 
Zif268 (EGR1) bound to DNA greatly stimulated research into engineered zinc-
finger arrays for ZFNs (Durai et al., 2005). This structure revealed that the DNA-
binding domain of EGR1 consists of three zinc-finger modules of the Cys2His2 
type. Each zinc-finger module consists of 30 amino acids, folds into a ββα 
configuration, and coordinates one Zn2+ ion using two cysteine and two histidine 
residues (Pavletich and Pabo, 1991). Two critical features of the structure made 
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Cys2His2 zinc-fingers of particular interest for the development of ZFNs: the first 
is that each zinc-finger module independently binds three base-pairs of DNA. 
The second is that each nucleotide in the major groove of the DNA target site 
seemed to be contacted by a single amino-acid side chain of the α-helix 
(Porteus and Carroll, 2005). From these features, researchers concluded that 
DNA-binding domains with novel specificities could be designed by altering the 
number of fingers and the nature of critical amino-acid residues that contact 
DNA directly (Smith et al., 2000). 
 
Figure 2. Zinc-Finger Nucleases (ZFNs) 
(A) Crystal structure of the Cys2His2-like zinc-finger domain of transcription factor TFIIIA from frog (Nolte et 
al., 1998). PDB entry 1tf6, shown here, includes 6 of the zinc-fingers (blue) bound to a long stretch of DNA 
(red). Zinc atoms are shown in green. (B) Schematic showing a pair of zinc-finger nucleases targeting a 
piece of DNA (FXN locus). Each ZFN contains the cleavage domain of FokI linked to an array of five zinc-
fingers that have been designed to specifically recognize sequences (black uppercase letters) flanking the 
cleavage site (red letters) in intron 4 of the FXN gene. 
 
Although not recognized initially (Kim et al., 1996), ZFNs cuts DNA more 
efficient when dimers of the FokI cleavage domain are formed (Bitinaite et al., 
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1998; Smith et al., 2000). Further improvements lead to the development of a 
paired heterodimeric nuclease design strategy that increased cleavage 
specificity while minimizing off-target activity (Bibikova et al., 2001; Miller et al., 
2007). The most optimal configuration of a ZFN pair cleaves DNA targets 
containing two 9−12 bp binding sites separated by a 5−6 bp spacer (Handel et 
al., 2009; Shimizu et al., 2011; Urnov et al., 2005) (Figure 2B). The requirement 
of FokI dimerization is important for nuclease specificity because cleavage 
should not occur at single ZFN binding sites. As a result, the overall 18−24 bp 
sequence specificity of a ZFN pair should be sufficient to pick out a unique 
target within a complex eukaryotic genome (Shimizu et al., 2011). 
The first genomic locus successfully targeted with designed ZFNs was 
the yellow gene of the fruit fly D. melanogaster. Bibikova et al. demonstrated 
targeted mutagenesis (Bibikova et al., 2002) and targeted gene replacement 
(Bibikova et al., 2003) at the yellow locus in somatic cells and in the germline. 
Since then, ZFN pairs have been used to target numerous genes in a wide 
variety of organisms including human cells (Carroll, 2011; Urnov et al., 2005). 
However, the initial enthusiasm for the broad application of ZFNs as genome 
editing tools was hampered by difficulties in their design (Cornu et al., 2008; 
Ramirez et al., 2008).  
The most basic design strategy, modular assembly, optimizes individual 
zinc-fingers against target triplet DNA sequences and then links them together 
to target a larger sequence. But, this assembly method suffers from a high 
failure rate when assembled in an array (Bae et al., 2003; Ramirez et al., 2008). 
Zinc-fingers failed to be treated as independent modules in several design 
strategies, mainly because zinc-finger domains exhibit context-dependent 
binding preferences (Kim and Kim, 2014). This made the selection of functional 
ZFNs a labour-intensive and time-consuming screening process (Maeder et al., 
2008; Sander et al., 2011b). Consequently, the available options for academic 
researchers interested in using ZFN technology were limited. Before other 
genome editing tools became widely available, researchers had to purchase 
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customized ZFNs through the Sigma-Aldrich CompoZr service. The downside 
was the cost of these proteins and the legal restrictions when using the ZFN 
technology, which greatly limited the scale and scope of projects that could be 
performed by academic institutions. 
 
1.2.2  Transcription activator-like effector nucleases (TALENs) 
Since the development of the first engineered zinc-finger nuclease, 
researchers spent about 15 years optimizing ZFNs, trying to make their design 
easier and cheaper. In 2009, two seminal studies reported that transcription 
activator-like effectors (TALEs) rely on a previously unknown way to bind DNA 
that is much simpler than that of zinc-finger proteins (Boch et al., 2009; Moscou 
and Bogdanove, 2009). TALEs were first discovered in plant pathogenic bacteria 
of the genus Xanthomonas and are virulence factors that are translocated into 
rice crops via a Type III bacterial secretion system. These factors that act as 
transcriptional activators in the plant cell nucleus, where they directly bind host 
DNA and activate genes that contribute to disease or turn on defence (Boch and 
Bonas, 2010). Target specificity depends on an effector-variable number of 
typically 34 amino-acid repeats in the TALE's central domain (Figure 3A). Boch 
et al. and Moscou and Bogdanove independently discovered that a pair of 
adjacent amino-acid residues at positions 12 and 13 in each repeat, the ‘repeat-
variable di-residue’ (RVD), is crucial to specifically recognize the DNA target site 
(Boch et al., 2009; Moscou and Bogdanove, 2009). The code is simple: one 
RVD binds to one nucleotide of the DNA target. Four of the most commonly 
occurring RVDs in natural TALEs preferentially associate with one of the four 
DNA bases (Moscou and Bogdanove, 2009) (Figure 3A).  
The lessons learned from ZFN design greatly facilitated the development 
of transcription activator-like effector nucleases (TALENs), fusions of 
transcription activator-like effectors (TALE) to the FokI nuclease domain (Figure 
3B & C). Two years after breaking the code for DNA binding specificity of 
  17 
TALEs, subsequent studies revealed the potential of TALENs for genome 
editing (Cermak et al., 2011; Miller et al., 2011). The use of TALENs showed 
superior genome editing efficiencies over ZFNs in a variety of cellular and model 
organisms including human pluripotent stem cells, rats, worms and zebrafish 
(Hockemeyer et al., 2011; Huang et al., 2011; Sander et al., 2011a; Tesson et 
al., 2011; Wood et al., 2011).  
 
Figure 3. TAL Effector And TALEN Structure 
(A) Structure of a naturally occurring TAL effector. A consensus repeat sequence is shown with the repeat-
variable di-residue (RVD) marked in red. The sequence of RVDs determines the target nucleotide 
sequence. The four most common RVDs are shown with their most frequently associated nucleotide (right). 
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(B) Structure of a TALEN. Two monomeric TALENs are required to bind the target site to enable FokI 
(green) to dimerize and cleave DNA. NLS, nuclear localization signal(s); TA, transcriptional activation 
domain. (C) Crystal structure of a TALEN pair bound to DNA (orange). The FokI nuclease domain (PDB 
entry 1fok, shown here in green) is fused to one end of a TAL effector (blue).  
 
What made scientists switch so rapidly from ZFNs to TALENs? The ease 
of use made TALENs an attractive alternative for genome editing (Baker, 2012). 
Unlike ZFNs, the DNA-binding domains of TALEs (repeat monomer with RVD) 
can be assembled in a modular fashion and are easier to customize than those 
of zinc-finger proteins. Current protocols allow the design of TALEN pairs in less 
than 5 days, reducing costs and manpower (Cermak et al., 2011; Sanjana et al., 
2012). In addition, only a few restrictions (see section 1.4.1) have to be taken 
into account when designing synthetic TALEs (Cermak et al., 2011). This offers 
a larger flexibility in the choice of DNA target sequences, which is a great 
advantage over the ZFN technology.  
Since their invention, TALENs and synthetic TALEs have been used in a 
variety of targeted genome engineering applications. In chapter 1.5, I will 
discuss how genome editing technologies are enabling a broad range of 
applications from research to biotechnology and medicine.  
 
1.2.3 Clustered regularly interspaced short palindromic repeat (CRISPR)–
Cas9 system 
In 2013, a genome editing tool referred to as CRISPR-Cas9 (clustered 
regularly interspaced short palindromic repeats/ CRISPR-associated-9 (Cas9) 
system) transformed biology research and spread through laboratories faster 
than any genome editing tool before. Many researchers and scientific journals 
believe that this “powerful gene-editing technology is the biggest game changer 
to hit biology since PCR” (Ledford, 2015). In this chapter, I will briefly review how 
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the CRISPR-Cas9 system developed to a powerful and popular genome editing 
tool. 
The acronym “CRISPR” was invented by Mojica et al. and Jansen et al. 
and used to reflect the characteristic features of a family of repetitive sequences 
commonly found in genomes of prokaryotic organisms (Jansen et al., 2002). 
Genomic analysis of microbial genomes suggested that CRISPR repeats are 
widespread among bacteria and archaea (Mojica et al., 2000). These findings 
stimulated interest in such microbial repeats and whether those repeats have a 
biological function in prokaryotes. Subsequent studies identified conserved 
CRISPR-associated (Cas) genes, which are typically located next to the repeat 
elements and encode Cas proteins (Haft et al., 2005; Jansen et al., 2002; 
Makarova et al., 2011a). More systematic analysis of CRISPR elements and 
Cas proteins lead to our current view of the CRISPR-Cas system as an adaptive 
immunity system in bacteria and archaea that uses short RNA fragments to 
destroy foreign nucleic acids (Barrangou et al., 2007; Bolotin et al., 2005; 
Brouns et al., 2008; Marraffini and Sontheimer, 2010; Mojica et al., 2005; 
Pourcel et al., 2005). 
The CRISPR defence system involves three key steps: (i) acquisition and 
integration of new targeting sequences (spacers) from invading viruses or 
plasmid DNA into the CRISPR locus, (ii) expression and processing of short 
guiding CRISPR RNAs (crRNAs) consisting of spacer-repeat units, and (iii) 
cleavage of nucleic acids (most commonly DNA) complementary to the spacer 
(Westra et al., 2012) (Figure 4). 
Three classes of CRISPR systems have been described so far (Type I, II 
and III). The most highly conserved Cas proteins, Cas1 and Cas2, are present in 
all three CRISPR basic types (Westra et al., 2012). To process the crRNAs and 
cleave target nucleotides sequences, Type I and Type III systems require 
multiple effector proteins acting as a complex. In contrast, Type II CRISPR 
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systems utilize a single effector enzyme, Cas9, to cleave double-stranded DNA 
(Makarova et al., 2011b; Westra et al., 2012) (Figure 4). 
During the adaptation stage, short pieces of DNA homologous to virus or 
plasmid sequences are integrated into the CRISPR loci (spacers, sized ~30-bp) 
(Barrangou et al., 2007). Invading DNA is recognized most probably through the 
protospacer-adjacent motif (PAM) either downstream (Type I) or upstream (Type 
II) of the protospacer (Deveau et al., 2008). New spacer sequences are 
integrated at the leader end of the CRISPR array, a process termed “polarized 
addition” (Horvath et al., 2008; Pourcel et al., 2005). Cas1 and Cas2 seem to be 
involved in spacer integration into the CRISPR locus, but the process of spacer 
integration is still not fully understood (Nunez et al., 2014; Westra et al., 2012). 
Transcription of the CRISPR array gives rise to a pre-crRNA molecule 
(Brouns et al., 2008), which is subsequently cleaved in the repeat sequence by 
an endo-ribonuclease in Type I and Type III systems (often a Cas6 homolog), 
and by RNase III and Cas9 in Type II systems (Deltcheva et al., 2011) (Figure 
4).  
A study by Charpentier and colleagues investigating the processing of 
crRNA in type II CRISPR systems elucidated a crucial component for RNA-
guided targeting of foreign nucleotides that could be bacteriophages or plasmids 
– a short trans-activating crRNA (tracrRNA). The authors could show that the 
tracrRNA acts with crRNA as a RNA hybrid, which is then used by the Cas9 
enzyme to promote the maturation of crRNAs (Deltcheva et al., 2011). Genetic 
studies further determined that Cas9 is the only enzyme required to confer 
immunity against bacteriophages and plasmids (Garneau et al., 2010), 
suggesting that a few components are essential for reconstituting the type II 
CRISPR system. Around the same time, Siksnys and coworkers demonstrated 
that components of the type II CRISPR-Cas system could be transferred across 
distant bacteria species to protect against exogenous plasmids and phage 
infection (Sapranauskas et al., 2011).  
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Figure 4. Natural Mechanisms of Microbial CRISPR Systems In Adaptive Immunity 
Following invasion of the cell by foreign genetic elements from bacteriophages or plasmids (step 1: phage 
infection), certain CRISPR-associated (Cas) enzymes acquire spacers from the exogenous protospacer 
sequences and install them into the CRISPR locus within the prokaryotic genome (step 2: spacer 
acquisition). These spacers are segregated between direct repeats that allow the CRISPR system to 
mediate self and nonself recognition. The CRISPR array is a noncoding RNA transcript that is 
enzymatically maturated through distinct pathways that are unique to each type of CRISPR system (step 3: 
crRNA biogenesis and processing).  
In types I and III CRISPR, the pre-crRNA transcript is cleaved within the repeats by CRISPR-associated 
ribonucleases, releasing multiple small crRNAs. Type III crRNA intermediates are further processed at the 
3′ end by yet-to-be-identified RNases to produce the fully mature transcript. In type II CRISPR, an 
associated trans-activating CRISPR RNA (tracrRNA) hybridizes with the direct repeats, forming an RNA 
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duplex that is cleaved and processed by endogenous RNase III and other unknown nucleases. Maturated 
crRNAs from type I and III CRISPR systems are then loaded onto effector protein complexes for target 
recognition and degradation.  
In type II systems, crRNA-tracrRNA hybrids complex with Cas9 to mediate interference. Both type I and III 
CRISPR systems use multiprotein interference modules to facilitate target recognition. In type I CRISPR, 
the Cascade complex is loaded with a crRNA molecule, constituting a catalytically inert surveillance 
complex that recognizes target DNA. The Cas3 nuclease is then recruited to the Cascade-bound R loop, 
mediating target degradation. In type III CRISPR, crRNAs associate either with Csm or Cmr complexes that 
bind and cleave DNA and RNA substrates, respectively. In contrast, the type II system requires only the 
Cas9 nuclease to degrade DNA matching its dual guide RNA consisting of a crRNA-tracrRNA hybrid. 
Figure taken with permission from (Hsu et al., 2014). Copyright © 2015 Elsevier B.V. 
 
Considering the vast attention programmable nucleases for genome 
editing obtained in late 2011 (Baker, 2012) and the importance of these tools for 
basic research as well as biomedical applications, a race to harness the 
potential of Cas9 for genome editing began. By 2012, several biochemical 
analyses showed that Cas9 is a DNA endonuclease guided by two RNAs, a 
hybrid between the activating tracrRNA and the targeting crRNA. A key study by 
Jinek et al. revealed the potential of Cas9 for eukaryotic genome editing (Jinek 
et al., 2012). The authors could reprogram Cas9 with a single chimeric RNA, so 
called guide RNA (sgRNA or gRNA), to cleave DNA (Figure 5A). The guide RNA 
can be engineered to direct Cas9 site-specific cleavage of almost any DNA 
locus, making the Cas9 RNA-guided system easy to use, “efficient, versatile, 
and programmable by changing the DNA target-binding sequence in the guide 
chimeric RNA” (Jinek et al., 2012).  
In 2013, a wave of studies demonstrated how the Cas9 system could be 
used to accomplish highly efficient genome editing in mammalian cells and 
zebrafish (Cho et al., 2013; Cong et al., 2013; Hwang et al., 2013; Mali et al., 
2013b). Since these pioneering studies, the scientific community has rapidly 
adopted the CRISPR-Cas9 technology. The fast spread of Cas9 into research 
laboratories around the world was greatly facilitated by three additional aspects: 
i) the accessibility of expression constructs for nuclear-localized Cas9 and 
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variant forms of guide RNAs through open-source plasmid distributors such as 
Addgene, ii) a number of online user forums, and iii) online software tools to 
design guide RNAs for the use with the CRISPR-Cas9 system. 
 
1.3 Shared mechanistic features of programmable nucleases 
 
One of the most harmful DNA lesions that cells encounter are DNA double 
strand breaks. Unrepaired or error-prone repaired DSBs can potentially lead to 
cell death or oncogenic mutations (Khanna and Jackson, 2001). To protect cells 
from DSBs, high fidelity repair of DNA damage evolved in every cell to maintain 
genomic integrity (Chapman et al., 2012; Moynahan and Jasin, 2010). 
Homologous directed repair (HDR) is essentially a ‘copy and paste’ mechanism, 
which uses an intact homologous segment of DNA as a template to copy and 
replace the damaged DNA across the break (Figure 1A). This mechanism is the 
most accurate form of DSB repair active in most eukaryotic cells. An alternative 
pathway besides HDR is non-homologous end joining (NHEJ), which joins DSB-
ends without regard for homology. NHEJ is an error-prone DNA repair pathway 
often resulting in small, localized deletions and/or insertions at the break that 
can cause gene disruption (Lieber, 2010).  
A common action of programmable nucleases such as ZFNs, TALENs and 
Cas9 is the generation of a DSB at a target genomic locus (Hsu et al., 2014; 
Joung and Sander, 2013; Urnov et al., 2010). Upon cleavage by programmable 
nucleases, the target locus typically undergoes one of two major pathways for 
DNA damage repair: the error-prone NHEJ or the high-fidelity HDR pathway, 
both of which can be used to achieve a desired editing outcome (Figure 1A). 
The phase of the cell cycle largely governs the choice of pathway to repair a 
DSB using NHEJ or HDR. NHEJ dominates DNA repair during G1, S and G2 
phases (Karanam et al., 2012).  
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In the absence of a repair template, DSBs are joined through NHEJ, which 
generates variable insertion/deletion (indel) mutations at the break (Lieber, 
2010). NHEJ can be harnessed to mediate gene knockouts, as indels occurring 
within a coding exon can lead to frameshift mutations and premature stop 
codons (Ran et al., 2013). Additionally, multiple DSBs can be exploited to 
facilitate larger deletions in the genome (Cong et al., 2013; Flemr et al., 2013). 
HDR is an alternative major DNA repair pathway present in most 
eukaryotic cells. HDR typically occurs at lower and more variable frequencies 
than NHEJ (Karanam et al., 2012). Nonetheless, it can be utilized to generate 
exact and defined modifications at a target locus in the presence of an 
exogenously introduced repair template (Carroll, 2011; Kim and Kim, 2014; Ran 
et al., 2013). The repair template can either be in the form of conventional 
double-stranded DNA (dsDNA) targeting donors with homology arms flanking 
the insertion sequence, or single-stranded DNA oligonucleotides (ssODNs). The 
latter provides an effective and simple method for making small edits in the 
genome, such as the introduction of single-nucleotide mutations for probing 
causal genetic variations, insertion of small DNA sequences to tag genes or 
create conditional alleles (Chen et al., 2011; Flemr and Buhler, 2015). HDR is 
active only in dividing cells, where it is restricted to S phase when DNA 
replication is highest and sister chromatids are available to serve as repair 
templates (Heyer et al., 2010; Karanam et al., 2012). HDR-mediated genome 
editing can vary widely depending on the cell cycle state, cell type, as well as 
the genomic locus and repair template. 
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1.4 Improving genome editing technologies  
 
1.4.1 Limitations of existing genome editing technologies 
Genome editing leads to permanent modifications within the genome. 
Targeting Specificity and activity are of particular concern when designing 
programmable nucleases (Kim and Kim, 2014). Other key features that need 
consideration when using DNA targeting nucleases are delivery and genome 
editing outcomes (Cox et al., 2015; Hsu et al., 2014). Here, I will examine the 
most important aspects concerning design and targeting specificity of ZFNs, 
TALENs and Cas9 nucleases. 
 
ZFNs 
Design. Compared to other programmable nucleases, the construction of 
ZFNs with high activity and high targeting specificity remains challenging. 
Methods for modular assembly of ZFNs that account for context dependence 
between neighbouring zinc-finger modules are laborious and often fail to 
produce high-quality ZFNs. In fact, off-target DNA cleavage events of self-made 
ZFNs are believed to cause cytotoxicity (Cornu et al., 2008). Alternatively, 
custom-made ZFN services (Sigma-Aldrich) use a proprietary archive of zinc-
finger modules that yields ZFNs of higher quality (Kim and Kim, 2014). However, 
the service is expensive for most academic institutions making ZFNs the least 
attractive genome editing tool. 
Targeting specificity. A general feature of FokI-domain containing 
nucleases is their modular structure, which is composed of two domains: a DNA-
binding domain and the FokI nuclease domain. Furthermore, FokI-domain 
containing nucleases must bind as pairs on the target site to cleave DNA 
(Bitinaite et al., 1998). This feature can yield high specificity and is often 
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explained making the following approximation: if DNA were a random polymer of 
four nucleotides, a 16-bp recognition sequence would be cleaved every 416 or 
4.3 x 109 base-pairs, a number that is greater than the size of the human haploid 
genome (3.2 x 109). Target sequences of ZFNs are usually 18 – 30-bp in length 
(excluding spacers) and theoretically unique in a complex genome (Figure 2B). 
Nevertheless, the unpredictable context-dependent neighbouring effects of zinc-
finger modules frequently result in poor ZFN cleavage activity and targeting 
specificity (Cornu et al., 2008; Ramirez et al., 2008). In contrast to ZFNs, 
TALENs and Cas9 are less cytotoxic, which facilitates the manipulation of single 
cells to create animals with edited genomes (Hsu et al., 2014; Kim and Kim, 
2014). 
 
TALENs 
Design. Similar to ZFNs, TALENs are FokI-domain containing nucleases 
composed of two domains: a DNA-binding domain and the FokI-nuclease 
domain. TALE-nucleases (TALENs) use a different class of DNA-binding 
domain, known as TALEs, which were discovered in plant pathogenic bacteria. 
Natural TALEs consist of an array of 34 amino-acid long repeats (Figure 3A). 
Each repeat recognizes a single DNA base-pair through the adjacent amino-acid 
residues at positions 12 and 13, the ‘repeat-variable di-residue’ (RVD). Four 
different RVD modules are most commonly used to bind the four DNA 
nucleotides and even methylated cytosine (Kim and Kim, 2014; Valton et al., 
2012). The natural occurrence of TALEs and the one-to-one match between the 
four RVDs and the four DNA bases makes it easy to design novel TALENs to 
target almost any DNA sequence. Structural and computational studies showed 
that nearly all TALE binding sites observed in nature require a thymidine at the 
5´ end of the target site (Mak et al., 2013; Moscou and Bogdanove, 2009). 
Currently, this seems to be the most important parameter in the design of 
TALENs (Reyon et al., 2012).  
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Several cloning methods have been developed for the assembly of 
custom-made TALE arrays (Briggs et al., 2012; Cermak et al., 2011; Reyon et 
al., 2012; Sanjana et al., 2012; Schmid-Burgk et al., 2013). A TALE array for 
genome engineering applications typically consists of 15 – 20 RVDs (Figure 3B). 
The construction of several arrays can be a time-consuming and laborious 
process. Therefore, improved cloning methods have been developed to 
construct large libraries of TALENs targeting genes and non-coding sequences 
in the human genome (Kim et al., 2013a; Kim et al., 2013b) allowing the 
application of TALENs in functional genomics screens. 
Targeting specificity. TALENs can be designed to target almost any given 
DNA sequence, which is a crucial advantage over ZFNs, Cas9 and other known 
Cas nucleases. Target sequences of TALEN pairs are typically 30 – 40 bp in 
length, excluding spacers. In contrast to ZFNs and Cas9, TALENs are believed 
to have less widespread off-target activity (Kim and Kim, 2014; Miller et al., 
2015). However, the principles that govern TALEN-specificity remain poorly 
understood and are currently and active area of research. A few studies 
addressing these principles used in vitro techniques or in vivo methods to 
investigate TALEN off-target activity. Both approaches have their own pros and 
cons. But, they are beginning to reveal additional factors that affect target 
specificity and cleavage activity such as design strategy, chromatin structure 
and locus accessibility (Guilinger et al., 2014; Miller et al., 2015; Veres et al., 
2014).  
 
Cas9 
Design. Streptococcus pyogenes Cas9 (SpCas9) is the most broadly used 
RNA-guided nuclease to date. SpCas9 can be directed to target DNA loci either 
with a pair of crRNA and tracrRNA (Cong et al., 2013) or with a single RNA-
hybrid guide sgRNA (Cho et al., 2013; Cong et al., 2013; Jinek et al., 2012; 
Jinek et al., 2013; Mali et al., 2013b). Researchers rapidly adopted this 
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technology because of its simple preparation and high efficiency. The only 
component of the system that needs to be designed to target a particular DNA 
locus is the crRNA or sgRNA, which contains 20-nt sequence complementarity 
to match a DNA target site (Figure 5A). Both sequences can be cloned into 
plasmids under the control of a RNA polymerase III promoter for efficient 
transcription in cells (Cong et al., 2013; Ran et al., 2013). Unlike TALENs or 
ZFNs, the Cas9 enzyme does not require de novo design and in vitro synthesis. 
Several laboratories have made plasmids encoding SpCas9 for expression in a 
variety of species and cell types available to the scientific community. In 
addition, some guide RNA design software is freely available online such as: 
http://crispr.mit.edu or http://www.e-crisp.org/E-CRISP/. In summary, these 
features represent a crucial advantage of RNA-guided nucleases like Cas9 over 
ZFNs and TALENs.  
 
 
Figure 5. Overall Structure of the Cas9-sgRNA-DNA Ternary Complex 
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(A) The Cas9 nuclease from S. pyogenes (in yellow) is targeted to genomic DNA (shown for example is the 
human EMX1 locus) by an sgRNA consisting of a 20-nt guide sequence (blue) and a scaffold (red). The 
guide sequence pairs with the DNA target (blue bar on top strand), directly upstream of a requisite 5′-NGG 
adjacent motif (PAM; pink). Cas9 mediates a DSB ∼3 bp upstream of the PAM (red triangle). Image was 
taken with permission from (Ran et al., 2013). (B) Electrostatic surface potential of Cas9. The HNH domain 
is omitted for clarity. Image taken with permission from (Nishimasu et al., 2014). 
 
Targeting specificity. A critical feature for target recognition by Cas9 and 
other RNA-guided nucleases is the PAM, which flanks the 3´end of the DNA 
target site (Figure 5A). Potential target sites lacking a PAM are unlikely to be 
interrogated for DNA cleavage by the Cas9 enzyme (Hsu et al., 2013; 
Pattanayak et al., 2013). Biochemical studies propose that sgRNA-loaded Cas9 
uses PAM recognition to identify potential target sites while scanning DNA 
(Gasiunas et al., 2012; Sternberg et al., 2014). Loading of the RNA guide 
induces large conformational changes, leading to the conversion of Cas9 from 
an inactive into a structurally activated DNA endonuclease (Jinek et al., 2014). 
Binding to a correct target sequence results in an additional structural 
rearrangement (Figure 5B). This activates both nuclease domains of Cas9 to 
engage for DNA cleavage (Jinek et al., 2014; Nishimasu et al., 2014). 
Collectively, these investigations highlight the importance of the PAM and 
sequences adjacent to this motif for target recognition and cleavage.  
In addition, the PAM sequence is specific to each Cas9 ortholog (Hsu et 
al., 2014). SpCas9 targets DNA sites flanked by 5´– NGG and with a much 
lower efficiency sites flanked by 5´– NAG (Hsu et al., 2013). The complexity of 
the PAM sequence determines the overall frequency of potential target sites in a 
given genome. For example, the 5´– NGG of SpCas9 allows it to target every 8-
bp on average within the human genome (Cong et al., 2013). Current evidence 
suggests that Cas9 technology can cause widespread off-target effects and 
genome alterations (Cho et al., 2014; Frock et al., 2015; Fu et al., 2013; Hsu et 
al., 2013; Kuscu et al., 2014; Pattanayak et al., 2013). However, these studies 
also suggest that potential off-target effects and possible genome alterations 
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following Cas9 treatment could be overcome by rational sgRNA design and 
optimal enzymatic concentration. A few studies have demonstrated that 
choosing unique target sites in the genome minimize or completely avoid off-
target effects (Cho et al., 2014; Kim et al., 2013a). Unlike ZFNs and TALENs, 
Cas9 enzyme binds its targets mostly by simple Watson-Crick base-pairing 
rules. Considering the importance of the PAM and sequences adjacent to this 
motif, these features will allow a more reliable prediction of potential off-target 
sites using sequence homology algorithms. Finally, enzymatic concentration and 
duration of Cas9 expression are likely further factors that modulate target 
specificity and require careful investigation in the future. 
 
1.4.2 Enhancing homologous recombination in genome editing 
Site-specific genetic insertions using programmable nucleases are greatly 
limited by the low rates of homologous directed repair. Besides homology 
directed repair (HDR), a second major pathway for the repair of DNA breaks is 
the error-prone NHEJ pathway. Unrepaired DSBs can result in genomic 
instability leading to apoptosis or senescence. Therefore, cells evolved a less 
accurate form of DSB repair, the NHEJ repair pathway, in which the broken DNA 
ends are processed and re-ligated without the need of a repair template. As 
discussed in the previous chapter, NHEJ is generally believed to be the 
dominant cellular repair pathway (Karanam et al., 2012).  
Researchers have designed several strategies to shift the balance from 
NHEJ to HDR and increase the frequency of recombination. In principle, DSB 
repair pathways could be manipulated either genetically or chemically to favour 
HDR over NHEJ. Genetic approaches to modulate the HDR repair machinery 
have been pioneered in plants without the involvement of programmable 
nucleases. Early studies overexpressed key recombination genes from 
Escherichia coli (RecA and RuvC) in plants without effects on gene targeting 
(Weinthal et al., 2010). More recent approaches applying protein fusions 
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consisting of site-specific TALENs fused to several recombination proteins such 
as Rad51, Ledgf, Znhit1, Nabp2 and Nbn failed to enhance targeted 
homologous recombination in mammalian cells (Flemr M., unpublished results). 
Transient inhibition of NHEJ pathway has recently been regarded as an 
alternative way to favour HDR and boost precise genetic insertions into 
mammalian genomes. A study by Kühn and colleagues published earlier this 
year demonstrated that genetic suppression of key enzymes involved in NHEJ 
such as Ku70, Ku80 or DNA ligase IV greatly stimulates the efficiency of HDR in 
mammalian cells (Chu et al., 2015). Along the same lines, chemical inhibition of 
DNA ligase IV, with the small molecule SCR7, showed increased efficiency of 
HDR-mediated genome editing in cultured cells and mice (Chu et al., 2015; 
Maruyama et al., 2015). However, chemical inhibition of NHEJ seems to be toxic 
even at low concentrations in cultured cells. Therefore, the development of more 
specific and less toxic “NHEJ inhibitors” would further extend the use of this 
approach. Since NHEJ and HDR pathways are evolutionary conserved across 
eukaryotes, it is likely that suppression of NHEJ is applicable to other model 
organisms to enhance HDR-mediated genome editing.  
 
1.4.3 Enriching nuclease activity and homologous recombination events 
Although TALEN and Cas9 technology greatly enhanced the success rate 
of genome editing, the search for genome-edited cells is time-consuming and 
requires laborious screening procedures. In addition, genome editing strongly 
depends on efficient delivery of programmable nucleases into the cell nucleus. 
Delivery of site-specific programmable nucleases can be achieved in cultured 
cells by chemical or biological transfection methods. Chemical transfection 
methods are more widely used in research laboratories because of their ease of 
use and low costs. However, transfection efficiency of these methods depends 
on several factors and varies greatly across different cell types (Kim and 
Eberwine, 2010). To further improve the technology and circumvent poor 
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delivery of nuclease encoding-plasmids into cells, systems that allow enrichment 
of genome-edited cells were required.  
The most successful strategies to enrich for genome-edited cells use 
reporter plasmids that monitor NHEJ or HDR events as a result of nuclease 
activity. Kim and colleagues developed reporter constructs for monitoring NHEJ 
and enrich for mutant cells by flow-cytometry or antibiotic selection (Kim et al., 
2011; Kim et al., 2014b; Ramakrishna et al., 2014). The first generation of these 
reporters contained the nuclease target sequence and expressed green 
fluorescent protein (GFP) only after a cut was made and the break was repaired 
by NHEJ (Kim et al., 2011). Later reporter constructs using the same strategy 
were combined with antibiotic resistance genes instead of GFP (Kim et al., 
2014b; Ramakrishna et al., 2014).  
Our laboratory recently established a similar approach to monitor HDR of 
nuclease-induced DSBs, which in turn allow the enrichment of genome-edited 
cells. Flemr and Bühler “adopted the architecture of an existing HR-dependent 
β-galactosidase reporter (Wefers et al., 2013) to create recombination reporter 
plasmids (pRR-EGFP, pRR-Puro) that contain a prematurely terminated N-
terminal part of the EGFP or puromycin coding sequence followed by a multiple 
cloning site (MCS) and a full-length enhanced GFP (EGFP) or puromycin 
resistance coding sequence, respectively, with a stop codon in place of a start 
codon" (Flemr and Buhler, 2015). Upon insertion of a nuclease target sequence 
into the MCS and co-transfection of this reporter plasmid with the respective 
nuclease-encoding constructs, the nuclease-induced DSB in the plasmid is 
anticipated to be repaired via recombination of the N-terminal part with the 
homologous portion of the full-length sequence. This results in functional EGFP 
or puromycin resistance, reporting on successful transfection, nuclease activity, 
and an effective HDR pathway (Figure 6). Finally, this approach allows the 
efficient generation of conditional knockouts and gene tagged cell lines in a 
single step. 
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Figure 6. Schematic Demonstration of TALEN-mediated pRR-EGFP Recombination 
Red lined rectangles depict TALEN recognition sites. ELD, KKR, TALENs with obligate heterodimeric FokI 
nuclease domain. Image adapted with permission from (Flemr and Buhler, 2015). 
 
1.5 Applications of genome editing technologies  
 
1.5.1 Applications in life science research 
The recent advances in genome editing technologies based on ZFNs, 
TALENs and the RNA-guided endonuclease Cas9 are enabling powerful 
applications in life science research, biotechnology and medicine. Excellent 
review articles on this topic have been published elsewhere offering a great 
resource of information for the interested reader (Cox et al., 2015; Hilton and 
Gersbach, 2015; Hsu et al., 2014; Joung and Sander, 2013; Kim and Kim, 
2014). In this chapter, I will briefly review the current and potential future 
applications of programmable nucleases in life science research and medicine.  
The ease of use of TALENs and Cas9 has enabled the rapid generation of 
cellular and animal models to study human disease (Chen et al., 2013b; Niu et 
al., 2014; Schwank et al., 2013; Wang et al., 2013; Wu et al., 2013). We 
pioneered the use of ZFNs in drug discovery by introducing a luciferase reporter 
into an endogenous gene to identify potential drug targets that activate 
transcription at that particular disease locus (Villasenor et al., 2015). This 
approach could be applied to screen drugs to treat several human monogenic 
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diseases. Other laboratories and our own group have combined genome-editing 
tools with proteomic or functional genomic approaches to map the protein-
protein, protein-DNA or protein-RNA interactions of nearly any endogenous 
protein (Dalvai et al., 2015)(Villaseñor et al., unpublished results, Tuck et al., 
unpublished results). Furthermore, the simple preparation of sgRNAs allows 
application of Cas9 in large-scale unbiased gene disruption screens (functional 
genomic screens, Figure 7F) to elucidate gene function (Shalem et al., 2014; 
Wang et al., 2014a). In contrast to RNA interference (RNAi) screens, functional 
genomics screens using Cas9 or TALENs enable the interrogation of non-coding 
parts of mammalian genomes.  
The ability to engineer ZFs, TALEs or reprogram Cas9 to bind a particular 
DNA site has unlocked several powerful applications. ZFs, TALEs and RGNs 
can be joined to a wide variety of effector domains such as nucleases, 
transcription effectors, and epigenetic modifying enzymes to carry out site-
specific modifications near their DNA binding site (Hilton and Gersbach, 2015; 
Hsu et al., 2014). Early proof-of-concept studies demonstrated the ability of ZFs 
to tether transcription activating or repressing domains to DNA and induce 
transcriptional changes at the target site (Beerli et al., 2000a; Beerli et al., 
2000b; Beerli et al., 1998). These and other studies encouraged applying similar 
strategies to modulate endogenous gene expression using TALEs or Cas9. 
Subsequent studies showed that synthetic TALEs fused to transcription 
activators or repressors could robustly modulate transcription at endogenous 
chromatin target sites (Zhang et al., 2011). Mutation of the catalytic residues of 
both nuclease domains, the HNH and RuvC-like domains, converts Cas9 to an 
inactive enzyme (dCas9), but preserves its ability to specifically bind DNA target 
sites (Jinek et al., 2012). Similar to ZFs or TALENs, dCas9 can then be fused to 
transcription activating or repressing domains to modulate transcription at the 
target locus (Gilbert et al., 2013; Konermann et al., 2013; Konermann et al., 
2015; Maeder et al., 2013; Mali et al., 2013a; Perez-Pinera et al., 2013) (Figure 
7G). Most of these approaches require tethering at multiple target sites and 
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achieve moderate changes in gene expression at target loci. Konermann and 
colleagues recently developed an elegant strategy to overcome these difficulties 
(Konermann et al., 2015). They identified two regions of the sgRNA that can be 
adapted with short RNA sequences, so called aptamers, which in turn attract an 
RNA-binding protein. The RNA-binding protein can then be fused to the 
transcription-activation domains of mammalian transcription factors. The authors 
termed this system the synergistic activation mediator (SAM), and demonstrate 
that it activates endogenous human genes more efficiently than activated by the 
dCas9-activator fusion protein (Konermann et al., 2015). Furthermore, ZFs, 
TALEs and dCas9 can be fused to chromatin modifiers, such as histone 
modifying enzymes and DNA modifying enzymes, to alter epigenetic marks near 
the target site (Hilton and Gersbach, 2015). These “designed epigenetic 
effectors” can artificially install or remove epigenetic marks at specific target loci 
and could serve as a powerful tool to probe the causal effects of epigenetic 
modifications on gene expression for instance.  
“Genomes are more than linear sequences. In vivo they exist as elaborate 
physical structures, and their functional properties are strongly determined by 
their cellular organization” (Misteli, 2007). To study the spatio-temporal 
organisation and dynamics of genomes researchers require robust methods to 
visualize DNA in living cells. Pioneering studies have developed live imaging 
techniques by fusing TALEs or dCas9 to fluorescent proteins to visualize and 
record the dynamics of single or multiple chromatin sites in mammalian cells 
(Chen et al., 2013a; Ma et al., 2015; Miyanari et al., 2013) (Figure 7I). 
Taken together, advances in genome engineering technologies enabled 
researchers to easily edit or modulate DNA sequences in a variety of organisms. 
These powerful tools will serve to systematically interrogate mammalian genome 
function and gain fundamental insights of human biology and disease.  
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Figure 7. Applications of Cas9 as a Genome Engineering Platform 
(A) The Cas9 nuclease cleaves DNA via its RuvC and HNH nuclease domains, each of which nicks a DNA 
strand to generate blunt-end DSBs. Either catalytic domain can be inactivated to generate nickase mutants 
that cause single-strand DNA breaks. (B) Two Cas9 nickase complexes with appropriately spaced target 
sites can mimic targeted DSBs via cooperative nicks, doubling the length of target recognition without 
sacrificing cleavage efficiency. (C) Expression plasmids encoding the Cas9 gene and a short sgRNA 
cassette driven by the U6 RNA polymerase III promoter can be directly transfected into cell lines of interest. 
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(D) Purified Cas9 protein and in vitro transcribed sgRNA can be microinjected into fertilized zygotes for 
rapid generation of transgenic animal models. (E) For somatic genetic modification, high-titer viral vectors 
encoding CRISPR reagents can be transduced into tissues or cells of interest. (F) Genome-scale functional 
screening can be facilitated by mass synthesis and delivery of guide RNA libraries. (G) Catalytically dead 
Cas9 (dCas9) can be converted into a general DNA-binding domain and fused to functional effectors such 
as transcriptional activators or epigenetic enzymes. The modularity of targeting and flexible choice of 
functional domains enable rapid expansion of the Cas9 toolbox. (H) Cas9 coupled to fluorescent reporters 
facilitates live imaging of DNA loci for illuminating the dynamics of genome architecture. (I) Reconstituting 
split fragments of Cas9 via chemical or optical induction of heterodimer domains, such as the cib1/cry2 
system from Arabidopsis, confers temporal control of dynamic cellular processes. Figure taken with 
permission from (Hsu et al., 2014). Copyright © 2015 Elsevier B.V. 
 
1.5.2 Applications in medicine 
 A tantalizing application for programmable nucleases is the potential to 
correct disease-causing genetic mutations in affected tissues or cells and treat 
human diseases with unmet medical need. This particular application has raised 
tremendous hope and excitement (Gaj et al., 2013; Ledford, 2015). Therapeutic 
genome editing was pioneered using ZFNs to correct disease-causing mutations 
in human cells (Chu et al., 2015; Genovese et al., 2014; Li et al., 2011; Li et al., 
2015; Perez et al., 2008; Urnov et al., 2005). But the later development of 
TALENs and CRISPR-Cas9 dramatically increased proof-of-principle studies 
demonstrating the potential of genome editing for therapeutic purposes (Bloom 
et al., 2013; Ding et al., 2014; Hu et al., 2014; Kennedy et al., 2015; Kennedy et 
al., 2014; Liang et al., 2015; Lin et al., 2014; Long et al., 2014; Mahiny et al., 
2015; Ousterout et al., 2013; Schwank et al., 2013; Wu et al., 2013; Ye et al., 
2014; Yin et al., 2014). 
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Table 1. Examples of Genome Editing to Therapeutic Models 
 
 Therapeutic genome editing involves a number of strategies including 
correction or inactivation of disease-causing mutations, introduction of protective 
mutations, addition of therapeutic transgenes and disruption of viral DNA (Cox et 
al., 2015) (Table 1). Some of these approaches have been successfully applied 
to a number of diseases at the preclinical level as well as in a phase 1 clinical 
trial. However, there are still major challenges and questions that need to be 
addressed before the technology can move to the clinic (Cox et al., 2015). The 
most important are believed to be the following:  
i) The specificity of each programmable nuclease. 
ii) The different efficiencies of DSB repair pathway. NHEJ is more active 
than HDR challenging strategies that require gene correction or gene 
insertion. 
iii) The challenge to efficiently deliver the nuclease into the cell or tissue. 
iv) The uncertainty of programmable nucleases causing cellular or 
systemic immune responses. 
 
Although the genome editing field is still in its infancy, it has the potential to 
revolutionize medicine (Ledford, 2015). Scientists have seen other promising 
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technologies such as RNAi and gene therapy that prompted great excitement, 
concern and then disappointment when major problems arose (Kim and Rossi, 
2007; Thomas et al., 2003). Therapeutic genome editing faces similar problems 
to those of gene therapy and therapeutic RNAi (Cox et al., 2015). Therefore, 
therapeutic genome editing might profit from recent advances in these fields and 
lessons learned from past difficulties. Important questions concerning safety and 
efficacy are now the focus of current investigations to translate this technology 
to the clinic.  
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1.6 Aim of this Thesis 
 
During the course of this work I applied genome editing tools in four 
different projects: 
 
Project I: Application of genome editing for drug discovery 
In the first half of my doctoral studies, I developed genome-editing 
strategies to discover drug targets for a rare genetic disease. I generated cell-
based assays using ZFNs for high-throughput genomic screens to uncover 
novel strategies to treat Friedreich’s Ataxia (FRDA). In collaboration with 
Novartis, we performed high-throughput RNAi screens and employed iPSC 
technology to generate neurons from FRDA-patient derived cells. Our innovative 
proof-of-concept study led to the identification of potential drug targets 
(Villasenor et al., 2015)(Villaseñor et al., unpublished results). 
 
Project II: Endogenous in-vivo biotinylation system for mapping 
protein networks and protein-DNA interactions of RNAi factors in 
embryonic stem cells 
In the second part of this thesis, I will explain how I combined more 
recent genome editing tools (TALENs and CRISPR/Cas9 system) with affinity 
purification approaches in mouse stem cells. I took advantage of this approach 
to study protein networks of RNAi factors keeping endogenous protein levels 
intact and to identify a potential protein variant of Argonaute-1 made by 
alternative splicing (Villaseñor et al., unpublished results). 
 
Project III: Functional analysis of Ago1 splicing isoform 
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Argonaute (Ago) proteins form the functional core of the RNA-induced 
silencing complexes that mediate RNA silencing in eukaryotes. In mammals, 
four proteins of the Ago-clade (Ago1-4) are ubiquitously expressed and bind two 
classes of small RNAs (sRNAs); microRNAs (miRNAs) and small-interfering 
RNAs (siRNAs). In this project, I will describe the discovery and functional 
characterization of a novel splice variant of mouse Ago1. 
 
Project IV: Novel insights in mammalian m6A RNA methylation 
In the last project presented in this thesis, I will describe how I used the 
above-mentioned techniques to uncover novel binding partners of the m6A 
methyltransferase complex, which are now under further investigation 
(Knuckles, Villaseñor et al., unpublished results). 
 
The results for each project will be presented in a separate chapter. 
Additionally, I will give a short introduction to the related biology. 
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2 Results 
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2.1 Project I: Application of genome editing for drug discovery 
 
2.1.1 Introduction 
 
Clinical features and pathology of Friedreich’s Ataxia 
Frataxin is a highly conserved protein that is ubiquitously expressed and 
plays a crucial role in many aspects of mitochondrial iron metabolism, 
respiratory control, and resistance to oxidative stress. Deficiency of frataxin 
causes Friedreich’s Ataxia (FRDA), an autosomal recessive degenerative 
disease that primarily affects the nervous system and the heart. FRDA is the 
most common cause of inherited recessive ataxias across Europe and several 
epidemiological studies have estimated the prevalence of FRDA as 2-3 cases 
per 100’000 people in Caucasian populations (Campuzano et al., 1996; Schulz 
et al., 2009). Unlike the small number of homozygous FRDA patients, the 
number of heterozygous mutation carriers has been estimated to be as high as 
1:60 and they are clinically normal. Intriguingly, FRDA is only found in 
individuals of European, North African, Middle Eastern, or Indian origin (Labuda 
et al., 2000). Clinical hallmarks of FRDA are progressive gait and limb ataxia, 
loss of posture and vibratory sense, leg muscle weakness, vision loss as well as 
non-neurological signs such as thickening of heart muscle (i.e. cardiomyopathy) 
and diabetes (Schulz et al., 2009). The first symptoms usually appear around 
puberty, but age of onset can vary from infancy (2-3 years) to adulthood (after 
Results published in: 
• Villaseñor R*, Miraglia L*, Romero A, Tu B, Punga T, Knuckles P, Duss S, Orth T, 
Bühler M. Genome-Engineering Tools to Establish Accurate Reporter Cell Lines That 
Enable Identification of Therapeutic Strategies to Treat Friedreich's Ataxia. J Biomol 
Screen. 2015 Jul;20(6):760-7. doi: 10.1177/1087057114568071. * equal contribution 
• Villaseñor R, Manos P, Berenshteyn F, Littlefield C, Lacoste A, Bühler M. 
Unpublished results. 
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25 years). Progressive loss of coordination and muscle weakness often result in 
the inability to walk 10-15 years after disease onset and ultimately makes the 
patient wheelchair-bound. Two-thirds of patients show cardiac symptoms, which 
further contributes to disability and premature death. Indeed, cardiomyopathy is 
the most frequent cause of death among FRDA patients (Durr et al., 1996). 
 
The GAA-triplet repeat expansion 
Friedreich’s Ataxia belongs to the human trinucleotide repeat expansion 
diseases (TREDs). Trinucleotide repeat expansion underlies at least 17 
neurological diseases, which can be generally categorized into two classes: the 
first, includes Huntington’s disease and many spinocerebellar ataxias, and is 
characterized by exonic (CAG)n repeat expansions encoding polyQ tracts. The 
second class has its repeats in non-coding sequences and is typically 
characterized by large and variable repeat expansions, which result in multiple 
tissue dysfunctions. Friedreich’s Ataxia belongs to the second class of TREDs.  
Large tracts of trinucleotides can cause disease in several ways: by 
affecting gene expression, by producing toxic RNA species, or by altering the 
function of the resultant protein. The genetic basis of the frataxin protein (FXN) 
deficiency lies in the structure of the FXN gene, which is encoded on human 
chromosome 9 (Chamberlain et al., 1988). The majority of FRDA patients (95%) 
have a pathogenic hyperexpansion of a trinucleotide GAA repeat in the first 
intron of the FXN gene resulting in reduced protein levels (Pandolfo, 2009). 
Generally, healthy individuals have up to 38 GAA repeats, whereas FRDA 
patients have approximately 70 to more than 1000 GAA triplets (Figure 8A), 
most commonly 600 – 900 GAA triplets on both alleles of the FXN gene (Durr et 
al., 1996; Montermini et al., 1997). Similar to other TREDs, the copy number of 
the GAA repeats defines the disease. Thus, the larger the number of GAA 
repeats, the earlier the onset of the disease and the quicker the decline of the 
patient. As a functional consequence of GAA repeat hyperexpansion, FRDA 
  45 
patients have a marked deficiency of FXN mRNA and thus FXN protein levels, 
thought to be due to reduced FXN gene expression (Campuzano et al., 1997; 
Campuzano et al., 1996) (Figure 8B). 
 
Figure 8. FXN Gene Structure And Consequences of GAA Triplet Repeat Expansion 
(A) Schematic view of the human FXN gene (ENSG00000165060). Exons and untranslated regions are 
depicted as blue and gray boxes, respectively. The red arrowhead indicates localization of the GAA 
repeats. (B) FXN mRNA levels (left) and FXN protein accumulation (right) in FRDA patient cell lines. The 
numbers indicate established GAA repeat numbers in two alleles in three different cell lines. Healthy 
individual cells display less than 10 GAA repeats (<10). FXN (i) and FXN (m) designate the intermediate 
and mature forms of the FXN protein, respectively. Figures shown in (B) were kindly provided by Dr. Tanel 
Punga (Uppsala, Sweden). 
 
FXN gene silencing mechanism 
Two molecular models have been proposed to explain silencing of FXN 
gene expression at the level of transcription. At first, mainly based on in vitro 
experiments, it was shown that expanded GAA repeats adopt unusual, non-B 
form DNA structures (such as DNA triplexes or “sticky DNA”) that impede the 
progress of RNA-polymerase II and thus reduce transcription (Bidichandani et 
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al., 1998; Sakamoto et al., 1999). Secondly, it was suggested that expanded 
GAA repeats induce formation of heterochromatin, which would render the FXN 
gene transcriptionally inactive (Saveliev et al., 2003).  
FXN gene silencing correlates with lysine hypoacetylation of histones H3 
and H4 and methylation of histone H3 at lysine 9 (H3K9) residues in cells with 
expanded GAA repeats (Figure 9)(Herman et al., 2006). These particular 
histone modifications are considered to be hallmark features of heterochromatin. 
Of these modifications, the methylation of H3K9 (H3K9me) is the most studied 
and best understood heterochromatic mark in various organisms. It has been 
established that H3K9 methylation is essential for recruitment of HP1 
(Heterochromatin Protein 1) family members, which in turn mediate chromatin 
condensation (Bühler and Moazed, 2007). A study in mice showed the 
involvement of the HP1 proteins in chromatin condensation around the 
expanded genomic GAA repeats. In addition, the same study demonstrated the 
repressive role of the expanded GAA repeats on a neighbouring reporter gene. 
Conclusively, it was proposed that the expanded GAA repeats silence nearby 
genes by position effect variegation (PEV) mechanism (Saveliev et al., 2003).  
Consistent with previous reports, Punga and Bühler could demonstrate 
that H3K9 methylation accumulates in the proximity of the GAA repeats in 
patient-derived cell lines (Herman et al., 2006; Punga and Buhler, 2010). It was 
also confirmed that the FXN gene is silenced on the transcriptional level. 
However, the authors could show that expanded GAA repeat tracts affect 
transcription elongation rather than initiation. Most importantly, reduction of 
H3K9 methylation by a specific drug (BIX-01294) did not enhance FXN gene 
expression (Punga and Bühler, 2010). Therefore, H3K9 methylation plays, if at 
all, a redundant role in FXN silencing and it appears that the non-B form DNA 
structure formed by the GAA repeat constitutes a major obstacle for the 
transcription machinery (Figure 9). One interesting question that remains to be 
addressed in the future is how GAA repeats trigger H3K9 methylation and what 
prevents them from spreading into the FXN promoter region. 
  47 
 
Figure 9. FXN Gene Silencing Mechanism 
Long intronic GAA repeats can induce the methylation of histone H3 at lysine 9 (H3K9me) at the FXN locus 
in FRDA cells. This epigenetic modification is a hallmark of heterochromatin and it has therefore generally 
been assumed that the FXN locus is assembled into a chromatin structure that hinders transcription. 
However, our findings suggest that H3K9me is restricted to the GAA repeat tract and that initiation of 
transcription is not affected. The long GAA repeats - and probably their adopted chromatin status - seem to 
be the major obstacle to the transcription machinery impeding transcription elongation in FRDA cells 
(Punga and Bühler, 2010). How GAA repeats and the non-B DNA form adopted by the repeats trigger 
H3K9 methylation and what prevents it from spreading into the promoter region remains unknown. 
 
2.1.2 Manuscript I / see Appendix 
As an aberrant non-B DNA conformation adopted by the long GAA 
repeats appears to constitute the major obstacle for RNA-polymerase II 
(RNAPII) in transcribing the FXN gene (Figure 9), we believe that strategic 
chemical design and high-throughput screening to identify compounds with the 
potential to promote transcription elongation through expanded GAA repeat 
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tracts should become a major focus in the quest for novel therapeutic strategies 
to treat FRDA. In addition, the regulation of the native FXN gene remains poorly 
understood. The identification of regulators of FXN gene expression would 
benefit the search for potential therapeutic targets for FRDA patients. Before this 
study, no reliable and robust system existed for cell-based drug discovery, 
hampering high-throughput screens for genes or low molecular weight (LMW) 
enhancers of frataxin expression.  
During the course of my master thesis and PhD studies, I generated 
reporter cell lines for simple detection of endogenous human FXN gene 
expression in its natural genomic context. To achieve this aim, I generated a 
reporter cell line of human origin that is compatible with high-throughput biology 
and enables accurate monitoring of endogenous FXN gene expression. I chose 
a zinc-finger nuclease (ZFN)-mediated genome-editing approach – in 2011 the 
only available genome editing tool – to tag the 3’ end of the endogenous FXN 
gene with a firefly luciferase (FL) reporter gene (Lombardo et al., 2007; Urnov et 
al., 2005). In contrast to previous work (Lufino et al., 2013; Martelli et al., 
2012a), the established HEK293T-FF2AP cell line allowed me to screen for 
modulators of FXN expression in its natural genomic context and in a high-
throughput format. The FF2AP cell line is easy to transfect and hence well 
suited for RNA interference (RNAi) or cDNA overexpression screens.  
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Figure 10. Workflow of siRNA Screen With The HEK293T-FF2AP cell line 
For details see Materials & Methods of published manuscript found in the appendix. 
 
To identify potential repressors of FXN gene expression or regulators of 
FXN protein stability, we collaborated with Loren Miraglia and Dr. Anthony Orth 
(GNF, San Diego) to run an RNAi screen targeting 4,835 human genes in the 
HEK293T-FF2AP cell line, using luciferase signal amplification as the readout 
(Figure 10). Using the HEK293T-FF2AP cell line, we performed a reconfirmation 
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screen of the top primary screen hits. In parallel, we screened positive-hit 
siRNAs for non-FXN-specific activators of luciferase activity with an HEK293 cell 
line stably expressing firefly luciferase from a CMV promoter (HEK293-pGF1-
CMV). This allowed us to filter out false-positive hits and uncover novel 
regulators of FXN gene expression (Figure 10). 
To determine if the primary hits could increase FXN gene expression also 
in cells containing expanded GAA repeats, I performed secondary hit validation 
experiments in FRDA fibroblasts using lentiviral shRNA knockdown followed by 
quantitative real-time PCR (qRT-PCR). I could identify two genes, PRKD1 and 
SBF1, whose knockdown leads to FXN gene reactivation. The roughly 1.5-fold 
increase in FXN mRNA levels after PRKD1 or SBF1 knockdown is quite modest 
and hence FXN protein increase was not reliably detectable by Western blot. 
However, this proof-of-concept study demonstrates the enormous power of 
using genome editing to easily monitor changes of endogenous FXN 
expression, but also urges us to expand our screens to genome-wide siRNA 
libraries or compound libraries to identify genes or drugs that lead to more 
drastic changes in FXN gene expression. 
 
Generation of patient-derived reporter cell line 
I set out to introduce the FL gene into a FXN allele with an expanded 
GAA tract in intron #1 with a similar strategy as described in section 2.1.2 
(Figure 11A). For this I used primary skin fibroblasts from a clinically affected 
individual (Coriell Cell Repositories; GM04078) homozygous for the GAA 
expansion (GAA541/GAA420). After immortalization of GM04078 cells with BMI1 
and hTERT (hereafter referred as FRDA4078iBT), these cells were co-
transfected with plasmids encoding the frataxin-ZFNs and Donor-2 (Figure 11A). 
Donor-2 was chosen because of its autonomous neomycin (Neo) selection 
cassette (Figure 11B). This strategy permits clonal selection in G418 containing 
medium independently of the expression status of the FXN gene. Therefore, we 
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selected single cell colonies after G418 selection and screened for correct and 
unique genomic integration events by Southern Blot analysis (Figure 11C). One 
positive clone (FRDA4078iBT-FF) was further characterized for GAA repeat 
stability and FL activity. Genomic PCR assays with primers that flank the GAA 
repeat tract (Figure 11D, bottom) revealed that repeat length in parental 
(GM04078), FRDA4078iBT, and FRDA4078iBT-FF cells remained unaffected 
(Figure 11D). Moreover, luciferase activity was observed in FRDA4078iBT-FF 
cells but not in the parental FRDA4078iBT cell line (Figure 11E). The expression 
of the endogenous FXN-FL fusion protein was absent in FRDA4078iBT-FF cells 
(data not shown). Notably, this FRDA patient-derived cell line showed a 
relatively low firefly luciferase activity, possibly reflecting the silenced state of the 
FXN locus (Figure 11E). 
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Figure 11. Generation of the FRDA4078iBT-FF Cell Line 
(A) Scheme of the ZFN-mediated genome editing strategy to tag the 3´end of the protein-coding region of 
the endogenous FXN gene with a firefly luciferase (FL) reporter gene. Each frataxin-ZFN contains the 
cleavage domain of FokI linked to an array of five zinc fingers that have been designed to specifically 
recognize sequences (black uppercase letters) flanking the cleavage site (red letters) in intron 4 of the FXN 
gene. The double-strand break induced by the frataxin-ZFN pair permits site-specific integration of a 
transgenic donor DNA fragment (Donor-1 or -2) encoding the last FXN exon fused to the open reading 
frame of firefly luciferase (V’-firefly luciferase). Both Donor constructs are flanked by regions homologous to 
the insertion site (orange) to enable homology-directed repair. To ensure correct splicing of the FXN mRNA 
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after successful genome editing, the left homology arms were designed to introduce functional branchpoint 
and 3’ splice sites (---a---ag). Donor-1 encodes puromycin N-acetyl-transferase (Puro) preceded by a 2A 
self-cleaving peptide linked to the V’-firefly luciferase fusion. Using Donor-1, puromycin resistance is only 
expected after correct integration into the FXN locus and transcription thereof. Donor-2 contains an 
autonomous neomycin (Neo) selection cassette driven by a SV40 promoter. This makes neomycin 
resistance independent of the transcriptional status of the FXN locus but might increase the rate of false-
positive integration events. The location of the GAA triplet repeat is indicated by a black arrowhead. pA, 
cleavage and polyadenylation site (B) Blow up of the ZFN-targeted integration site after successful 
integration of the Donor-2 construct. StuI restriction sites and expected DNA fragment sizes after StuI 
digestion is depicted. Probes used for Southern Blot are indicated (FXN-exon V: blue boxes; Firefly 
luciferase: yellow box). (C) Southern Blot with StuI digested genomic DNA from the cell lines indicated was 
probed with Exon V probe, stripped and re-probed with luciferase probe. Single luciferase signal confirms 
unique integration event. Exon V and luciferase signals of the expected size (T) demonstrate correct 
integration of the Donor-2 construct at the FXN locus in FRDA4078iBT-FF cells. (D) Bottom: Clinically 
affected patient is homozygous for the GAA expansion in the FXN gene with alleles of approximately 541 
and 420 repeats. PCR primers to assess GAA repeat length are depicted by red arrows. GAA repeat length 
in the cell lines indicated was assessed by genomic PCR using fwd and rev primers indicated in scheme. 
PCR product size = 457+3N base-pairs (N= number of GAA triplets). HEK293T cells serve as control (<10 
GAA triplets). GM04078, patient-derived primary fibroblasts; FRDA4078iBT, GM04078 fibroblasts 
immortalized with BMI1 and hTERT; FRDA4078iBT-FF, FRDA4078iBT cells with the edited FXN locus 
(FXN-Firefly luciferase, FF). (E) Firefly luciferase activity assayed from non-targeted FRDA4078iBT and 
FRDA4078iBT-FF cells. RLU, relative light units normalized to total protein. Error bars represent standard 
deviation. 
 
2.1.3 Use of PRKD1 chemical inhibitors in patient-derived lymphoblasts 
The RNAi screen performed in section 2.1.1 demonstrates the potential of 
our high throughput screening (HTS) system to reveal prospective drug targets 
for the development of FRDA treatments. Similar to 2-aminobenzamides that 
inhibit histone deacetylases (HDACs) (Chou et al., 2008; Herman et al., 2006; 
Rai et al., 2008) compounds with an antagonistic effect on the newly identified 
FXN repressors might be used to alleviate FXN expression in FRDA cells. To 
identify low molecular weight inhibitors of PRKD1, we searched the Novartis 
compound archive. A previous HTS campaign from the Novartis archive 
identified 2,6-naphthyridine as a dual PKC/PRKD inhibitor, which was further 
developed into a potent prototype pan-PRKD inhibitor (Figure 12A, compound 
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13c “Cpd13c”) (Meredith et al., 2010a). Compound 13c has 1000-fold selectivity 
versus PKC isoforms (Meredith et al., 2010b) and can be administered orally, 
which makes it a good candidate for drug development. As observed with 
shRNA-mediated suppression (Villasenor et al., 2015), chemical inhibition of 
PRKD1 with compound 13c in FRDA4078iBT-FF patient-derived fibroblasts 
provoked up to 5-fold elevation of luciferase activity (Figure 12B), suggesting 
that PRKD1 is a potent negative regulator of endogenous FXN expression.  
Next, I determined the effect of compound 13c on FXN mRNA and 
protein expression in FRDA4078iBT-FF cells and in patient-derived 
lymphoblasts. To this end, I treated FRDA4078iBT-FF cells with compound 13c 
for 24 hours and measured levels of mature FXN protein and FXN mRNA by 
western blot and qRT-PCR, respectively. FXN mRNA, when normalized to 
RPL13A expression, and mature FXN protein levels remained constant in 
treated versus non-treated FRDA4078iBT-FF cells (Figures 12C & 12D). 
Moreover, I tested the ability of compound 13c in restoring FXN expression in 
another patient-derived cell type with longer GAA repeat expansions. I decided 
to work with a FRDA patient-derived lymphoblastoid cell line (Coriell Cell 
Repositories), which has between 650 and 1030 GAA triplets on both FXN 
alleles (“FRDA”, GM15850). As a control, a lymphoblastoid cell line from a 
healthy sibling (“Healthy”, GM15851) of one of the FRDA patients (GM15850) 
was used. I treated both cell lines with compound 13c for 24 hours and 
measured FXN mRNA levels by qRT-PCR. Similarly to the effects observed in 
FRDA4078iBT-FF cells, FXN mRNA expression remained constant in treated 
versus non-treated healthy and FRDA cells (Figure 12E).  
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Figure 12. Chemical Inhibition of PRKD1 In Patient-derived Cells 
(A) The molecular structures of dual PKC/PRKD inhibitor and compound 13c (Cpd 13c) are depicted. (B) 
Firefly luciferase activity assayed from drug-treated FRDA4078iBT-FF cells with DMSO (control) or 
compound 13c (Cpd13c). RLU, relative light units normalized to total protein. P values were determined 
using the Student's t test in 6 biological replicates. (C) Right: Western Blot showing unchanged expression 
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of the mature FXN protein (~15 kDa) in cells treated with DMSO (control) and compound 13c. Blot was 
probed with an antibody recognizing FXN. Antibodies against Tubulin or ERK were used to control sample 
loading. Left: Ponceau staining used as loading control. Effect of compound 13c on endogenous FXN 
mRNA levels in FRDA patient derived fibroblasts (D) and lymphoblasts (E). FRDA patient-derived 
lymphoblastoid cell line has between 650/1030 GAA triplets on both FXN alleles (“FRDA”). A 
lymphoblastoid cell line from a healthy sibling (“Healthy”) with no expanded GAA repeats was used as 
control. Cells were treated with 1 µM of PRKD1 inhibitor (Cpd13c) for 24h in experiments shown in B-E. (F-
G) FRDA lymphoblasts (107 cells) were treated with 5 µM PRKD1 inhibitor (NVP-LDR869 or WA-21-JO19) 
for 48 hours. Cells treated with 5 µM of inactive compound NVP-LEG653 (inactive) serve as control. (F) 
Western blot showing FXN protein levels and PRKD1 auto-phosphorylation of drug-treated cells. (G) FXN 
mRNA levels were determined by real-time PCR, normalized to RPL13A mRNA levels and shown relative 
to the inactive compound. Data represent the average plus standard deviation of 3 biological replicates.  
 
Rational design and modification of pan-PRKD inhibitor compound 13c 
led to a more potent and specific PRKD1 inhibitor (compound WA-21-JO19; L. 
Monovich, personal communication). In addition, high throughput screening 
against recombinant PRKD1 identified 3,5-diarylpyrazole as a novel kinase 
inhibitor scaffold with moderate activity. Rational design and modification of the 
3,5-diarylpyrazole scaffold led to a more potent selective, and orally bioavailable 
PRKD1 inhibitor (compound NVP-LDR869)(Gamber et al., 2011). Next, I treated 
healthy and FRDA lymphoblasts with PRKD1 inhibitor WA-21-JO19 or NVP-
LDR869 to test their effect on FXN gene expression. Cells treated with an 
inactive compound NVP-LEG653, which is closely related chemically to WA-21-
JO19 but lacks activity on PRKD1, served as control. Only WA-21-JO19 
reduced PRKD1 auto-phosphorylation at Serine 916 (S916) in healthy and 
FRDA lymphoblasts, showing the efficacy of WA-21-JO19 in blocking PRKD1 
activity (Figure 12F). Nevertheless, mature FXN protein levels remained 
constant in FRDA lymphoblasts as measured by Western blot (Figure 12F). 
Moreover, FXN mRNA expression remained unchanged in WA-21-JO19 treated 
FRDA patient-derived lymphoblasts (Figure 12G). Intriguingly, in healthy cells, 
WA-21-JO19 increased the intermediate form of FXN protein and mRNA levels 
by roughly 50 percent (Figure 12G).  
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In summary, our hypothesis that chemical inhibition of PRKD1 restores 
FXN gene expression in FRDA cells lacks convincing evidence. However, the 
effect of PRKD1 inhibition, particularly using WA-21-JO19, could be significant in 
more disease-relevant cell types such as neurons or cardiomyocytes. To test 
this idea we set out to generate neurons from patient-derived iPSCs. 
 
 
Figure 13. Characterization of FRDA- and WT-SeV Derived HiPSCs 
(A) Immunostaining showing expression of pluripotency markers in hiPSCs derived from unaffected- (WT) 
and FRDA-patient (FRDA) fibroblasts. Scale bar represents 200 µm. (B) Quantitative real-time PCR 
analysis for expression of pluripotency genes in FRDA (FA) and WT- hiPSCs and parental fibroblasts. 
Samples were normalized to internal housekeeping genes GAPDH and presented relative to H9 hESC. 
Analysis was performed in biological and technical triplicates; error bars represent standard error. (C) 
Immunostaining showing expression of lineage-specific markers Sox17 (definitive endoderm), β-III Tubulin 
(Tuj1, neuronal, ectodermal) and alpha-actinin (mesoderm) following hiPSC differentiation. (D) FRDA- and 
WT hiPSCs have a normal karyotype and proper parental fingerprint. (E) Heat-map representation of 
pyrosequencing analysis of the OCT4 promoter in FRDA- and WT-hiPSCs compared with their respective 
parental fibroblasts. H9 hESC was included as a positive control. 
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2.1.4 Use of iPSCs to model FRDA 
We completed our drug discovery platform described above by designing 
disease-relevant cellular models, which enable the validation of primary hits and 
discovery of chemical modulators of these targets. In collaboration with Dr. 
Arnaud Lacoste´s group at NIBR (Cambridge, USA), we first reprogrammed 
dermal fibroblasts from healthy, unaffected individuals (wildtype WT, GM08399) 
and from patients affected by FRDA (FRDA, GM04078) into induced pluripotent 
stem cells (iPSCs). Sendai virus particles encoding OCT4, SOX2, KLF4, and 
cMYC (OSKM) were used to minimize the risk that random integration of 
reprogramming transgenes would affect FXN pathways. We obtained iPSCs 
from both WT and FRDA patients and all iPSC lines expressed similar 
pluripotency cell markers (Figure 13A and 13B). The iPSC lines could also 
differentiate in representatives of all three germ layers, including neurons and 
cardiomyocytes (Figures 13C), two cell types that are affected in FRDA patients. 
In addition, WT and FRDA iPSCs contained a normal karyotype and proper 
parental fingerprint compared with parental fibroblasts (Figure 13D and 13E). 
Both WT and FRDA iPSCs also formed teratomas when injected into 
mice (Figure 14). Importantly, the iPSC lines obtained from WT and FRDA 
patients exhibited a similar ability to differentiate into Pax6-expressing neural 
progenitors and β-III Tubulin-expressing neurons (Figure 15A and 15B). These 
results confirm previous reports that genetic alterations causing FRDA do not 
affect reprogramming or differentiation processes (Hick et al., 2013; Ku et al., 
2010). Finally, FRDA neuronal cells expressed lower levels of FXN mRNA and 
protein than WT neurons, (Figure 15C and 15D), indicating that the FRDA 
molecular phenotype is conserved during reprogramming.  
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Figure 14. Teratoma Formation Assay 
Representatives of all three germ layers can be identified in teratomas derived from both (A) FRDA-hiPSC 
and (B) WT-hiPSC. 
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Figure 15. Studies In FRDA-iPSC-derived Neurons Validate PRKD1 as a Druggable Target And Identify a 
Chemical Modulator of FXN Expression 
(A) Immunostaining showing expression of neuronal markers. Both WT and FRDA iPSCs can be 
differentiated into neural progenitors expressing Pax6 and neurons expressing β-III Tubulin (Tuj1). (B) 
Triplicate cell counts of three independent WT (WT1-3) and FRDA (FRDA1-3) cultures show that WT and 
FRDA iPSCs can be differentiated into Pax6-positive neural progenitors or β-III Tubulin (Tuj1)-positive 
neurons with similar efficiencies. (C-D) The FRDA molecular phenotype is conserved during 
reprogramming. (C) Quantitative real-time PCR analysis for frataxin (FXN) expression in WT versus FRDA 
neuronal cells. Samples were normalized to the internal housekeeping gene GAPDH. Analysis was 
performed in biological and technical triplicates; error bars represent standard error. (D) Western blot 
showing protein levels of frataxin (FXN) and the housekeeping protein GAPDH in WT versus FRDA 
neuronal cells. (E) Exposure of FRDA-iPSC-derived neurons to WA-21-JO19, a chemical inhibitor of 
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PRKD1, leads to an increase in FXN expression while a control compound (NVP-LEG253) has no effect. 
Neuron cultures were treated for 3 weeks with five different concentrations of PRKD1 inhibitor WA-21-
JO19, or an inactive analog of WA-21-JO19. The experiment was run in biological duplicates and no 
compound toxicity was observed at the concentrations used. FXN mRNA levels were determined by real-
time RT-PCR, normalized to RPL13A mRNA levels. *P = 0.03. 
 
Subsequently, we assessed the effect of low molecular weight inhibitors of 
PRKD1 on FXN expression in WT and FRDA neurons. We treated FRDA-iPSC-
derived neurons with either compound WA-21-JO19 or a control compound. As 
observed with shRNA-mediated suppression in FRDA fibroblasts, chemical 
inhibition of PRKD1 by WA-21-JO19 resulted in a significant increase in 
endogenous FXN gene expression in FRDA-iPSC-derived neurons (Figure 
15E). WA-21-JO19 treatment led to a 25% increase in FXN mRNA expression in 
FRDA neurons after 3 weeks of treatment. Importantly, an inhibitor against an 
unrelated protein kinase (control compound) had no significant effect on FXN 
expression in FRDA patient neurons, confirming that WA-21-JO19 activity is due 
to an inhibitory effect on PRKD1 (Figure 15E).  
In summary, these results validate PRKD1 as a modest negative regulator 
of endogenous FXN expression. They also demonstrate that PRKD1 is a 
druggable target in patient- and disease-relevant cell types such as neurons.  
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2.2 Project II: Endogenous in-vivo biotinylation system for 
mapping protein networks and protein-DNA interactions of 
RNAi factors in embryonic stem cell 
 
The RNA interference (RNAi) pathway consists of evolutionary conserved 
enzymes indispensable for gene regulation mediated via small non-coding 
RNAs (Figure 16A). MicroRNAs (miRNAs) are a class of small non-coding RNAs 
that control gene expression through regulation of messenger RNA (mRNA) 
stability and translational repression (Figure 16B). MiRNAs are genomically 
encoded in miRNA genes or introns of protein coding genes and are transcribed 
by RNA-polymerase II to primary miRNA (pri-miRNA) transcripts. A typical pri-
miRNA transcript is capped, polyadenylated and is composed of a ∼33-nt long 
stem loop with two flanking segments (Lee et al., 2002). Central to the 
production of miRNAs are members of the ribonuclease III family of double 
stranded RNA (dsRNA) processing enzymes Drosha and Dicer. Drosha carries 
out the first processing step in the nucleus in complex with other cofactors 
(microprocessor complex) for efficient and accurate processing of pri-miRNA 
(Gregory et al., 2004; Lee et al., 2003). In mammals, the main cofactor of the 
microprocessor complex is the DiGeorge syndrome critical region 8 (Dgcr8) 
protein (Denli et al., 2004; Gregory et al., 2004; Han et al., 2004; Landthaler et 
al., 2004). The first processing step of pri-miRNAs results in the formation of a 
∼70-nt long precursor or pre-miRNA. Pre-miRNAs are then exported to the 
cytoplasm to undergo a second step of processing (Figure 16A). 
Unpublished results: 
• Villaseñor R, Knuckles P, Daniel H, Burger L, Seebacher J, Bühler M. 
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Figure 16. The Mammalian RNA Interference Pathway 
(A) In animals, pri-miRNAs are transcribed by RNA-polymerase II (or, rarely, by RNA-polymerase III), 
processed in the nucleus into pre-miRNAs by the RNase III enzyme, Drosha, and then exported to the 
cytoplasm where the pre-miRNAs are converted to miRNA/miRNA∗ duplexes by a second RNase III 
enzyme, Dicer. miRNAs are then loaded into Argonaute effector protein complexes to silence target 
mRNAs. Image adapted with permission from (Matranga and Zamore, 2007) (B) Translational repression: 
the miRISC inhibits translation initiation by interfering with eIF4F-cap recognition and 40S small ribosomal 
subunit recruitment or by antagonizing 60S subunit joining and preventing 80S ribosomal complex 
formation. The miRISC might inhibit translation at post-initiation steps by inhibiting ribosome elongation. 
mRNA decay: the miRISC interacts with the CCR4–NOT and PAN2–PAN3 deadenylase complexes to 
facilitate deadenylation of the poly(A) tail (indicated by AAA(n)).  
 
Dicer, a cytoplasmic RNAse III protein of ∼216 kDa in size, mediates 
cytoplasmic processing of pre-miRNAs (Bernstein et al., 2001). This processing 
step produces a ∼22-nt long dsRNA duplex. Human DICER interacts with 
TARBP2 (TAR RNA-binding protein 2) (Chendrimada et al., 2005; Haase et al., 
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2005) and PRKRA (Protein kinase, interferon-inducible double-stranded RNA-
dependent activator) (Lee et al., 2006). Both proteins are closely related proteins 
that seemingly facilitate cleavage of pre-miRNAs (Kok et al., 2007) and are 
believed to be involved in the transfer of the mature miRNA to the downstream 
RNA Induced Silencing Complex (RISC) (Tomari et al., 2004a; Tomari et al., 
2004b). Once processed, both strands of the dsRNA intermediate are separated 
and one strand, the guide strand, is incorporated into effector protein complexes 
to recognize target mRNAs (Martinez et al., 2002) (Figure 16A and 16B).  
A key member of RISC, the main RNAi effector protein complex in 
mammals, is Argonaute (Ago). Argonaute proteins are enzymes with the ability 
to bind small non-coding RNAs and guide RISC to target mRNAs (Ketting, 2011; 
Meister, 2013). Agos belong to an evolutionary conserved protein family 
indispensable for gene regulation mediated via small non-coding RNAs (Swarts 
et al., 2014). Structural studies of Ago proteins revealed a bi-lobed architecture 
composed of four globular domains (N, PAZ, MID and PIWI) connected through 
two structured linker domains (L1 and L2). In mammals, four Ago proteins 
(Ago1-4) are ubiquitously expressed and bind primarily two classes of small 
RNAs (sRNAs), miRNAs and siRNAs. sRNA binding occurs through the 
conserved MID and PAZ domains. The PAZ domain binds the 3´end of the small 
RNA. Whereas the MID domain anchors the 5´ end of the sRNA by providing a 
binding pocket in which the 5´-terminal base engages in stacking interactions 
with a conserved tyrosine (Tyr529). In addition, several hydrogen bonds 
coordinate correct 5´-end binding (Elkayam et al., 2012; Schirle and MacRae, 
2012). The PIWI domain is responsible for the endonucleolytic activity and 
structurally resembles RNase H enzymes (Parker et al., 2004; Song et al., 2004; 
Yuan et al., 2005). In mammals, only Ago2 has endonucleolytic activity and is 
therefore the only Ago protein capable of cleaving mRNA targets (Meister et al., 
2004). The remaining Ago homologs (Ago1, Ago3, and Ago4) facilitate 
translational repression through Ago interacting proteins (Meister, 2013). 
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The incorporated guide strand in RISC directs the sequence-specific 
cleavage of complementary target mRNAs, a process termed RNA interference 
or RNAi (Fire et al., 1998; Hammond et al., 2000; Martinez et al., 2002). 
Cleavage only occurs when full complementarity between guide RNA and RNA 
target is achieved. In addition, cleavage-independent silencing mechanisms 
exist to inhibit mRNA function. This is especially important when the involved 
Ago protein has no endonucleolytic activity (as shown for Ago 1, 3, and 4), or 
when miRNAs only have restricted complementarity with their targets.  
In fact, most mammalian miRNAs do not guide cleavage of target mRNAs 
by RNAi-like mechanisms. In contrast, mammalian miRNAs predominantly 
repress gene expression on the level of translation or affect mRNA stability by 
guiding cellular decay processes, including mRNA deadenylation and decapping 
(Figure 16B). Argonautes interact with members of the GW182 protein family 
(GW proteins) to mediate post-transcriptional gene silencing via miRNAs 
(Eulalio et al., 2008b; Meister et al., 2005). Members of the GW182 protein 
family are characterized by the presence of multiple Gly-Trp (GW) repeats. 
Three paralogues exists in vertebrates, Tnrc6A/GW182 (Trinucleotide repeat-
containing gene 6A protein), Tnrc6B and Tnrc6C. GW proteins coordinate most 
downstream steps in gene silencing through recruitment of additional protein 
effector complexes to target mRNAs (Meister, 2013). Recent studies have 
revealed that GW proteins induce mRNA deadenylation by recruiting two major 
cellular deadenylase complexes, PAN2-PAN3 and CCR4-NOT (Braun et al., 
2011; Chekulaeva et al., 2009; Chekulaeva et al., 2011; Fabian et al., 2009; 
Zipprich et al., 2009). 
In mammals, core components of the RNAi pathway have extensively 
been studied over the last 15 years. Biochemical studies provided insights into 
protein networks of most members of the pathway (Chendrimada et al., 2005; 
Gregory et al., 2004; Haase et al., 2005; Hock et al., 2007; Landthaler et al., 
2008; Meister et al., 2005). Most studies made significant progress in mapping 
the mammalian RNAi protein network by combining protein affinity purification 
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with mass spectrometry (MS). However, these studies were performed in cancer 
cell lines in most of the cases using over-expression of the protein of interest. 
Ectopic expression of a protein beyond endogenous levels may result in 
artifactual protein complexes and increase nonspecific/non-physiological protein 
– protein interactions. In addition, traditional affinity purification methods are 
limited by use of antibodies against the protein of interest. The lack of specific 
antibodies against many proteins represents a significant caveat in current 
protocols. Therefore, we combined genome editing with in vivo biotinylation to 
dissect protein–protein and protein–DNA interactions of protein complexes in 
mouse embryonic stem (mES) cells keeping endogenous protein levels intact 
(Figure 17). Finally, I validated our MS-approach to map protein interaction 
networks by studying well-characterized factors of the RNAi pathway. 
 
2.2.1 Endogenous tagging of genes encoding RNAi factors 
We recently established an efficient protocol for genome editing in mES 
cells using TALENs (Flemr and Buhler, 2015). We used BirA-expressing cells 
(RosaB) as a parental cell line for endogenous gene tagging of several RNAi 
factors with the FLAG-AviTag sequence, which is a well-established tagging 
system for tandem affinity purification of protein complexes in mES cells (Kim et 
al., 2009). The FLAG-AviTag (FLAvi) tag contains the Flag epitope and a short 
peptide tag “AviTag” that serves as a substrate for in-vivo biotinylation mediated 
by the Escherichia coli biotin ligase BirA. Our genome editing approach, using 
TALENs and the CRISPR/Cas9 system, allows insertion of the FLAvi tag at the 
5’- or 3’-end of the target gene in BirA expressing mES cells (Figure 17). For this 
study, my colleague Dr. Philip Knuckles and I set out to endogenously tag the 
following RNAi factors, individually, in RosaB cells: Dicer, Dgcr8 and Ago1. 
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Figure 17. Combination of Genome Editing With In Vivo Biotinylation To Dissect Protein-Protein And 
Protein-DNA Interactions of Protein Complexes In Mouse Embryonic Stem Cells 
 
To tag the endogenous Dicer protein, I designed a pair of TALENs 
(Dicer1-TALENs) to cut at the first coding exon of the mouse Dicer1 gene in 
RosaB cells (Figure 18A & 18B). Both plasmids encoding for the Dicer1-TALENs 
were co-transfected with a recombination reporter (pRR-EGFP), and a single-
stranded oligodeoxynucleotides (ssODN) carrying the FLAvi-tag sequence. The 
homology regions against the first coding exon of Dicer1 gene in the ssODN 
serve as template for the HDR machinery to repair the cut mediated by TALENs 
(Figure 18B). Therefore, homology directed repair allows insertion of the FLAG-
AviTag into the TALEN target site. In addition, I used the pRR-EGFP 
recombination reporter, which is designed to produce an EGFP signal upon 
NHEJ repair of the Dicer1-TALENs cut, to enrich for cells with a TALEN-
modified genomic target site (see Methods). Using this approach, I obtained 9 of 
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40 positive clones (22.5%) by PCR genotyping (Figure 18C & 18E). 
Furthermore, I confirmed the expression of endogenous FLAvi-Dicer1 protein in 
three clones by Western blot (Figure 18D). Importantly, unique peptides 
matching to mouse Dicer1 protein were detected after streptavidin affinity 
purifications followed by MS analysis in two clonal cell lines (Figure 18F & 18G), 
demonstrating that our approach generates endogenously tagged FLAvi-Dicer1 
expressing cells. 
We applied a different strategy to tag endogenous mouse Dgcr8 and 
Ago1 genes. To tag the endogenous Dgcr8 or Ago1 locus, we designed a guide 
RNA (gRNA) to target the first coding exon of the mouse Ago1 gene (Figure 
19A) or the mouse Dgcr8 gene (Figure 19B), respectively. The gRNA was 
subcloned into the SpCas9-2A-mCherry plasmid (Cas9-2C, see Methods 
section). The resulting vector encoding for the gRNA and Cas9 enzyme (gR-
Cas9-2C) was co-transfected with an ssODN carrying the FLAG-AviTag 
sequence and homology regions against the first coding exon of the target gene. 
For the Dgcr8 gene tagging, 3 of 24 positive clones (12.5%) were identified by 
PCR (Figure 19C). We confirmed the expression of FLAG-AviTag-Dgcr8 protein 
in one of three tested clones by Western blot (Figure 19C). For mouse Ago1 
gene tagging, we obtained 25 of 28 positive clones (89.3%) by PCR genotyping 
(Figure 19C). Western blot analysis confirmed FLAG-AviTag-Ago1 protein 
expression in two clones (Figure 19C). Furthermore, FLAG 
immunoprecipitations followed by MS analysis confirmed the expression of 
endogenously tagged Ago1 protein (Figure 19D). 
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Figure 18. Endogenous Dicer1 Tagging With FLAG-AviTag In RosaB Cells 
(A) Illustration of mouse Dicer1 locus and TALENs target site (box). (B) Schematic overview of TALEN-
assisted integration of an ssODN carrying a FLAG-AviTag sequence downstream of the Dicer1 start codon 
(bold letters). Gray arrows indicate positions of genotyping primers. (C) PCR genotyping of FLAG-AviTag 
insertions in pRR-EGFP selected clones with a forward primer binding in the AviTag sequence and a 
primer downstream the integration site, where the expected PCR product size is 1266-bp for the allele 
containing the FLAG-AviTag sequence. (D) Western blot analysis of RosaB (FLAG-AviTag-Dicer1) clones 
with anti-streptavidin conjugate. (E) Summary statistics for Dicer1 gene tagging. (F-G) Detection of FLAG-
AviTag-Dicer1 protein in gene edited clones with streptavidin-AP followed by anti-FLAG Western blot (F) 
and mass spectrometry analysis (G). 
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Figure 19. Endogenous Ago1 and Dgcr8 Tagging With FLAG-AviTag In RosaB Cells 
(A-B) Schematic overview of Cas9-assisted integration of an ssODN carrying a FLAG-AviTag sequence 
upstream of the Ago1 and Dgcr8 start codon (bold letters), respectively. Gray arrows indicate positions of 
genotyping primers. (C) Summary statistics for Ago1 and Dgcr8 gene tagging. (D) Detection of FLAG-
AviTag-Ago1 protein in gene edited clones with streptavidin-AP followed by mass spectrometry analysis. 
 
Taken together, I established and applied a genome editing approach to 
tag endogenous Dicer1 gene in mouse ES cells. Moreover, endogenous Dicer1 
protein is efficiently enriched after streptavidin affinity purifications allowing the 
faithful identification of Dicer1 protein binding partners. Finally, the results 
obtained for Ago1 and Dgcr8 gene editing establish the Cas9-system as an 
efficient alternative method to tag endogenous genes of interest where TALENs 
are not available. 
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2.2.2 Mapping protein-protein interactions of RNAi factors in mES cells 
To test the robustness of affinity purification protocols, I performed single 
and tandem affinity purification of Dicer and Ago1 protein complexes for MS 
analysis. One-step streptavidin purification of Dicer protein complexes was 
efficient for enrichment and detection of Dicer and its known high-confidence 
interaction partner Trbp2 (Figure 18F & 18G). However, this approach also 
yielded high signal for endogenous biotinylated mitochondrial protein 
contaminants that interfere with the detection of lowly abundant interaction 
partners (data not shown). High quantities of contaminants were also observed 
in one-step FLAG immunoaffinity purifications of Dicer1 and Ago1 (data not 
shown). These observations represented a significant disadvantage of one-step 
streptavidin and FLAG immunoaffinity purifications. This prompted me to explore 
tandem affinity purification of protein complexes for accurate detection of protein 
– protein interactions (Figure 20A). This approach minimized background 
signals of contaminants in RosaB control cells and lacked detection of 
endogenously biotinylated proteins (Figure 20B). 
After optimization of the tandem affinity purification (TAP) protocol, I 
conducted TAP-MS experiments using the FLAvi-tagged Dicer, Dgcr8 and Ago1 
cells plus control cell line RosaB. To account for RNA-independent and direct 
physical interactions of Ago1, RNase A treated samples were included to MS 
analysis. Dr. Lukas Burger and I statistically analysed the MS data using the 
SAINT algorithm (Choi et al., 2011). SAINT determines a probability of 
interaction for each possible bait-prey pair. Figures 20C-E display, for each bait 
protein separately, the average fold-change between bait and control samples 
versus the SAINT probability of interaction (poi). Proteins with a probability of 
interaction score (poi-score) of at least 0.8 were defined as “potential 
interactors”. Previously reported interactors are marked in red. 
MS analysis of Dgcr8 protein complexes confirmed the high-confidence 
interaction with the second component of the microprocessor complex, Drosha 
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(Figure 20C). Moreover, SAINT analysis further confirmed a specific but weak 
interaction to Dhx9 and Srpk1 (Figure 20C). Dhx9 (DEAH box protein 9), also 
known as ATP-dependent RNA helicase A (RHA), is an RNA helicase implicated 
in a number of cellular processes involving alteration of RNA secondary 
structure (Fuller-Pace, 2006). Human DHX9 has been reported to directly 
interact with DGCR8 (Shiohama et al., 2007). In contrast, Srpk1 is a 
serine/arginine-rich protein-specific kinase that specifically phosphorylates 
splicing factors (Gonçalves 2014). Interestingly, the interaction to human 
DGCR8 has been recently revealed in IP-MS experiments of human SRPK1 
(Varjosalo et al., 2013). 
In Dicer1 purifications, all core subunits of the miRNA-loading complex 
(miRLC), which is composed of Dicer1, Ago1, Ago2 and Tarbp2, were identified 
(Figure 20D) (Gregory et al., 2005; Maniataki and Mourelatos, 2005). We also 
found other reported binding partners like Dhx9 (Robb and Rana, 2007). 
However, this interaction shows less probability in our analysis (Figure 20D). 
Finally, Ago1 co-purified all three Tnrc6 paralogs as well as Ago2 and Hspa8 
(Figure 20E). Ago1 interacts with Tnrc6 proteins (GW proteins) to mediate post-
transcriptional gene silencing (Meister, 2013). Furthermore, we detect Ago1 
binding to Heat shock 70 kDa protein 8 (Hspa8). The Hspa8/Hsp90 chaperone 
machinery mediates a conformational opening of Ago proteins, so that Ago can 
bind to stiff dsRNA, thus facilitating efficient loading of small RNAs (Iwasaki 
2010, Johnston 2010 (Iwasaki et al., 2010; Johnston et al., 2010). Importantly, 
most interactions remained constant upon RNase A treatments suggesting 
direct physical interactions of these proteins to Ago1 (Figure 20F). In agreement 
with previous results (Hock et al., 2007; Landthaler et al., 2008), a weak 
association of Ago1 to Dicer was detected (Figure 20E).  
In summary, our combined genome editing approach with tandem affinity 
purification coupled to MS analysis exemplifies a highly versatile and efficient 
method for identification of high confidence protein – protein interactions in 
mouse ES cells.  
  73 
 
Figure 20. Protein – Protein Interaction Networks of RNAi Factors In Mouse ES Cells 
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(A) Schematic of endogenous gene tagging coupled to tandem affinity purification mass-spectrometry 
(TAP-MS) analysis of protein complexes. (B) Graph showing sum of spectral counts over all samples for 
contaminant proteins. (C-E) Graphs displaying, for each bait protein separately, the average fold-change 
between bait and control samples versus the SAINT probability of interaction (poi). Previously reported 
interactors are shown as red asterisks. (F) Proteins associated with endogenously tagged Ago1 in TAP-MS 
samples, compared to RNAse-treated counterparts. All MS-data shown here was averaged from four 
biological replicates. 
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2.3 Project III: Functional analysis of Ago1 splicing isoform 
 
One of the most surprising initial findings after sequencing the human 
genome was the total number of protein encoding genes (Lander et al., 2001). 
First studies found between 20,000 and 40,000 genes in the human genome 
(International Human Genome Sequencing, 2004; Lander et al., 2001), which 
was a stunning result for scientists. It is only about double the number of genes 
in a fruit fly or worm. Eleven years after, analysis of the complete human 
genome sequence led to the identification of approximately 20,687 protein-
coding genes (Consortium, 2012), although the annotation still continues to be 
refined. 
A second mystery of life has recently been tackled with the first drafts of 
the human proteome (Kim et al., 2014a; Uhlen et al., 2015). According to these 
studies, the human body is made up of at least 17,294 different proteins. Further 
findings suggest, for instance, a core set of 10,000 to 12,000 proteins identified 
in most cell types and tissues. In addition, many tissues are characterised by the 
presence of specific proteins. In contrast to humans, a total of 7,349 proteins 
have been found in the mouse organism (Geiger et al., 2013). Today, it is 
becoming clear that there is not a direct correlation between the complexity of 
an organism and its gene and maybe even protein count. Nevertheless, it 
remains elusive how human complexity is achieved at the molecular level.  
Alternative splicing (AS) is one of the many crucial processes that 
mediate gene regulation in metazoans (Chen and Manley, 2009; Raj and 
Blencowe, 2015). During AS of precursor mRNA (pre-mRNA), different 
combinations of 5 ´ and 3 ´ splice site pairs are selected, resulting in the 
Unpublished results: 
• Villaseñor R, Flemr M, Hotz HR, Daniel H, Gut H, Seebacher J, Bühler M. 
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generation of diverse mRNA variants. In theory, AS produces multiple proteins 
from a single gene and is thought to increase the number of proteins extensively 
over the number of genes in a genome. This in turn, could be required to 
generate complexity of higher eukaryotes including humans (Blencowe, 2006). It 
is estimated that 95% of all human genes undergo AS with alternative exons 
often encoding for disordered regions important for protein-protein interactions 
(Ellis et al., 2012). Recently, it has been shown that alternative splicing remodels 
the protein-protein interaction network of alternative spliced genes (Buljan et al., 
2012; Ellis et al., 2012; Irimia et al., 2014). Rewiring the interaction network of 
protein complexes in a given tissue could possibly create further complexity in 
higher eukaryotes. 
Protein variants of RNAi factors made by alternative splicing have 
remained undiscovered. Recently, an oocyte-specific isoform of mouse Dicer1, a 
core component of the RNAi pathway essential for processing of small RNAs, 
was shown to evolved as a consequence of a specific retrotransposon insertion, 
and to be essential for oocyte function in mice (Flemr et al., 2013). This peculiar 
example prompted us to search for alternative spliced isoforms of other RNAi 
factors in mouse cells.  
 
2.3.1 Detection of mouse alternative splice variant of Ago1 (Masva1) 
Dr. Matyas Flemr discovered a novel splice variant of mouse Ago1, 
hereafter referred as Masva1, in cDNA of mouse ES cells and embryonic 
fibroblasts (NIH3T3). Sanger sequencing of Masva1 cDNA revealed that two 
alternative splicing events occur between coding exons 9 & 13 of the mouse 
Ago1 gene (Figure 21A & 21B). The first AS event causes a +1 frame shift on 
exon 10. A second AS event on exon 12 restores the original frame of Ago1 by 
shifting the frame to -1 (Figure 21B bottom). Both alternative splicing events 
result in a new stretch of 106 amino acids, which corresponds to most of the 
MID domain of Ago1 protein (amino acids 422 – 528, Figure 21C). The new 
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stretch of amino acids “replaces” the original MID domain of Ago1 and creates a 
new domain (hereafter termed novel MID domain: NMID) with probably entirely 
new structural properties (Figure 21D). However, in silico analysis done by 
Heinz Gut (FMI) suggests that NMID unlikely folds into structured domain and 
does not match to any annotated domains in structural databases (data not 
shown).  
To gain first insights into the biological function of Masva1, I set out to 
test Masva1´s ability to bind small RNAs and determine the spatio-temporal 
expression levels of Masva1 gene transcript in mice. 
 
 
Figure 21. Identification of a Mouse Alternative Splice Variant of Ago1 
(A) Scheme of mouse Ago1 locus and protein structure. Exons and untranslated regions are shown as grey 
and white boxes, respectively. The black box indicates the alternative spliced region. (B-C) Two alternative 
splicing events between exon #9 and #13 of the Ago1 gene result in a new stretch of 106 amino acids, 
which corresponds to most of the MID domain of Ago1 protein (amino acids 422 – 528). (D) This stretch of 
amino acids possibly creates a novel domain with entirely new structural properties. The crystal structure of 
HsAgo2 (Schirle and MacRae, 2012) is shown here for comparison. 
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2.3.2 Spatio-temporal expression of Masva1 transcript 
Alternative splicing of Ago1 seems only to occur in mouse. Sequence 
alignment across 37 eutherian mammals did not show evolutionary conservation 
of the 5´alternative splice site, suggesting that expression of Masva1 is 
restricted to Mus musculus (data not shown). I used two specific primer pairs 
against Masva1 or Ago1 to measure mRNA levels by SYBR-qRT-PCR. I 
measured 4 to 5 higher threshold cycles (Ct) of Masva1 in comparison to Ago1 
mRNA in mES cells and NIH3T3 cells (Figure 22A). Similarly, qRT-PCR using 
two specific taqman-probes against Masva1 or Ago1 transcript showed 3 to 6 
higher Ct values of Masva1 in comparison to Ago1 mRNA in mES cells (Figure 
22A). These results suggest that Masva1 is at least ~10-fold lower expressed 
than Ago1 in mES and NIH3T3 cells.  
 
 
Figure 22. Spatio-Temporal Expression of Masva1 Transcript 
(A-B) Quantitative real-time PCR measurement of Ago1 and Masva1 mRNA expression in ES and NIH3T3 
cells (A), as well as nine different mouse tissues (B). Computational survey of 13 published RNA-
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sequencing datasets to detect expression of Masva1 gene in several murine tissues and developmental 
stages (C-D). 
 
Next, I focused on finding out where Masva1 is most abundantly 
expressed in murine tissues to understand its physiological function. To 
determine the expression profile of Masva1 in the adult mouse, total RNA was 
isolated from six different adult mouse tissues to prepare cDNA and measure 
Masva1 and Ago1 mRNA levels. Masva1 expression failed to be detected as 
measured by qRT-PCR using two specific primer sets (Figure 22B). In contrast, 
Ago1 expression was faithfully detected in all tissues tested. 
Publicly available RNA sequencing (RNA-seq) datasets of different 
mouse tissues and developmental stages represent a rich source for evaluating 
expression of genes and finding alternative spliced transcripts. I examined 
several transcriptome-wide RNA-seq datasets (Grote et al., 2013; Seisenberger 
et al., 2012; Shen et al., 2012; Smallwood et al., 2011) to identify expression of 
the Masva1 alternative spliced exon (Figure 22B). To do this, raw data was 
downloaded, processed and mapped against the mouse genome (Figure 22C). 
Aligned reads were visualized using the UCSD genome browser 
(http://genome.ucsc.edu). My computational survey of 13 RNA-seq datasets 
failed to reveal expression of Masva1 gene in several murine tissues and 
developmental stages other than mES and NIH3T3 cells (Figure 22D). 
 
2.3.3 Sub-cellular localization of Masva1 
Ago1 is a predominantly cytoplasmic protein and has previously been 
shown to localize in cytoplasmic sites of mRNA decay known as processing-
bodies (P-bodies) (Liu et al., 2005; Sen and Blau, 2005). To determine if this 
feature is conserved in Masva1, I examined Ago1 and Masva1 sub-cellular 
distribution in NIH3T3 cells by immunofluorescence (IF) analysis.  
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Figure 23. Cellular Distribution of Masva1 In NIH3T3 Cells 
(A) Schematic of mammalian expression constructs and Western blot showing expression of tagged Ago 
fusions. (B) Image showing the cellular distribution of Ago1 and Masva1 protein in NIH3T3 cells. (C) Blow-
up of yellow box shown in image B. EGFP-Ago1 shows a predominant cytoplasmic localization. White 
arrows indicate P-bodies. (D) EGFP-Masva1 shows a diffused cellular localization with no formation of 
cytoplasmic foci. (E) Blow-up of yellow box shown in image D. DNA stained with DAPI. 
 
First, I generated plasmids encoding for tagged fusions of Ago1 and 
Masva1 (Figure 23A). Stable overexpression of exogenous 3xFLAG-EGFP-
tagged Ago1 (EGFP-Ago1) or Masva1 (EGFP-Masva1) in NIH3T3 cells was 
established (data not shown). Then, I determine the sub-cellular distribution of 
GFP-tagged Ago1 by IF analysis (Figure 23B). In most cells, Ago1 was found in 
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the cytoplasm and accumulated in cytoplasmic foci that resembled P-bodies 
(Figure 23B & 23C). In contrast, GFP-tagged Masva1 was dispersed throughout 
cytoplasm and nucleus, although the signal appeared more prominent in the 
cytoplasm when whole cell distribution was observed (Figure 23D). Interestingly, 
the formation of Masva1 cytoplasmic foci was absent in most cells visualized 
(Figure 23E). 
 
2.3.4 Profiling of Masva1 associated small RNAs 
Many small RNA classes possess specific sequence biases at the 5´- 
end. Based on structural evidence, it has become clear that the Argonaute´s 
MID domain senses the 5´-nucleotide of small RNAs. A rigid loop in the MID 
domain of human Ago2 allows specific contacts to a 5-terminal uridine or 
adenine (Elkayam et al., 2012; Schirle and MacRae, 2012; Schirle et al., 2014). 
Small RNAs with Gs or Cs at the 5´-end bind to human Ago2 with low affinities. 
Similar small-RNA-binding strategies have been found for plant proteins (Frank 
et al., 2012). Therefore, it is appealing to speculate that Masva1 would have 
different sRNA-binding properties due to its novel MID domain (NMID). 
Understanding the small RNA binding characteristics of Masva1 is crucial to 
elucidate its biological function.  
To profile Masva1-bound small RNAs, I generated NIH3T3 cell lines 
stably expressing 3xFLAG-EGFP tagged Ago1 and Masva1 proteins (see 
Section 2.3.3). Futhermore, 3xFLAG-Ago1 and 3xFLAG-Masva1 fusions were 
transiently over-expressed in NIH3T3 cells (Figure 24A). I purified total RNA 
from FLAG-immunoprecipitations (FLAG-IP) of stably or transiently expressed 
proteins and prepared libraries for small RNA sequencing (Figure 24B & 24C). 
Computational analysis of Masva1- and Ago1-bound small RNAs revealed a 
high correlation between all samples sequenced (Figure 24D). Moreover, 
Masva1 binds miRNAs (Figure 24D) and other sRNAs (data not shown). I 
observed similar sequence biases at the 5´-end of Masva1-bound miRNAs 
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compared to Ago1-associated miRNAs. In comparison to Ago1, however, 
Masva1 seemed to bind fewer miRNAs as shown by total read count, 
suggesting that Masva1 binds small RNAs with a lower efficiency than Ago1 
(Figure 24E). To assess differential binding between Masva1 and Ago1, Dr. 
Hans-Rudolf Hotz and I performed additional computational analysis. Some 
miRNAs associated to Ago1 were less efficiently bound by Masva1 (Figure 24F). 
Interestingly, a group of miRNAs was strongly reduced in Masva1 samples (Mirg 
and miR410). These miRNAs originate from a cluster of about 40 miRNAs in the 
imprinted Dlk1–Dio3 locus on mouse chromosome 12qF1. In contrast, miR330 
and miR196b preferentially associated with Masva1 (Figure 24F). 
 
Figure 24. Purification of Small RNAs Associated To Ago Proteins and Their Sequencing 
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(A) Schematic describing experimental workflow. (B-C) FLAG-immunoprecipitations of Ago-protein 
complexes. Western blot showing enrichment of Ago proteins after purification. (D) Graph showing pairwise 
correlation plot of log2 counts per million per gene of reads mapping to small RNAs. Isolated sRNAs were 
sequenced and the corresponding reads were aligned to the Mus musculus genome (GRCm38/ mm10). 
(E) miRNA expression levels were calculated and normalized using mouse miRBase 
(http://www.mirbase.org/) as a reference. Graphs showing miRNA profile of Ago1 and Masva1, 
respectively. (F) Vulcano plot showing differential binding of small RNAs to Ago1 and Masva1. Reads 
containing the word “miRNA” in their genome annotation are marked in red. 
 
2.3.5 Analysis of protein-protein interaction network of Masva1 
To gain additional insights into the biological function of Masva1 from 
another experimental angle, I purified Masva1 protein complexes to map its 
protein-protein interactions. To determine the protein interaction network of 
Masva1, the generated NIH3T3 cell line stably expressing 3xFLAG-EGFP 
tagged Masva1 was used for FLAG-IP experiments followed by MS analysis 
(Figure 25A). Importantly, IP-MS analysis was also performed from NIH3T3 cells 
stably expressing 3xFLAG-EGFP-Ago1 (Figure 25B). The results obtained in 
Ago1 IP-MS experiments served as a positive control. Interestingly, the most 
striking difference between Masva1 and Ago1 IPs was the absence of Tnrc6B-
peptides in Masva1 pull-downs (Figure 25C). Furthermore, unique peptides 
matching to other Ago proteins were not detected in both Masva1 IPs, 
suggesting that Masva1 is not able to interact with other Ago proteins. However, 
Masva1 co-purified the Hspa8/Hsp90 chaperone complex, which suggests a 
similar mechanism of small RNA loading as Ago proteins (Iwasaki et al., 2010; 
Johnston et al., 2010). In contrast, I could observe unique peptides for Ago2, 
Tnrc6B, and Hsp proteins in both Ago1 pull-down experiments (Figure 25C).  
Taken together, Masva1 protein seems to lack the ability to interact with 
other Ago proteins and more importantly with Tnrc6B. Although limitations in 
peptide detection cannot be ruled out in these experiments, the results above 
predict that Masva1 lacks the ability to mediate gene silencing through 
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recruitment of the Ccr4-Not effector complex to targeted mRNAs. This 
hypothesis remains to be tested in future experiments. 
 
Figure 25. Masva1 Interaction Partners Identified By Mass Spectrometry Analysis 
(A) Outline describing experimental workflow. (B) Coomassie stained gel showing FLAG-
immunoprecipitations of Ago-protein complexes. (C) Summary of two independent IP-MS experiments 
showing interaction partners of Masva1 in comparison to Ago1 in NIH3T3 cells. Peptide count and protein 
coverage for each identified protein in other studies are shown. Masva1 proteo-specific peptides matching 
to the NMID domain can be detected. 
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2.3.6 Proteomic analysis in Ago1 gene tagged mouse ES cells  
Expression of Masva1 mRNA was only detected in NIH3T3 mouse 
embryonic fibroblasts and mouse ES cells. Over-expression experiments in 
NIH3T3 cells demonstrate that Masva1 can be translated to a functional protein 
with the ability of binding small RNAs (Results section 2.3.4). To prove the 
existence of the endogenous Masva1 protein variant, I aimed to detect Masva1 
protein in biochemical purifications of endogenous Ago1 protein complexes by 
using mouse ES cell lines expressing endogenously tagged Ago1 generated in 
Section 2.2.1 (Figure 26A). 
 
 
Figure 26. Proteomic Search of Endogenous Masva1 Protein In Mouse ES Cells 
(A) Schematic of endogenous gene tagging coupled to tandem affinity-purification mass-spectrometry 
(TAP-MS) analysis of tagged Ago1 protein complexes. (B) Scheme of Masva1 protein showing the proteo-
specific peptides matching to the NMID domain, marked in red. (C) Western blot showing FLAG-
immunoprecipitations of Ago-protein complexes. Two endogenously tagged Ago1 cell lines were used for 
single or tandem affinity purification followed by mass-spectrometry analysis.  
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The amino acid sequence of the NMID domain in Masva1 represents the 
only difference between Masva1 and Ago1. In over-expression experiments, I 
could detect unique peptides matching to the NMID domain of Masva1 by MS 
analysis (Figure 26B). Next, I performed tandem affinity purifications in two 
endogenously tagged Ago1 cell lines and searched for unique peptides 
corresponding to Ago1 protein or to the NMID domain of Masva1 by MS analysis 
(Figure 26C). Detection of peptides exclusively matching to Masva1 failed in ten 
independent IP-MS experiments, suggesting that Masva1 protein is extremely 
low abundant in mES cells. In contrast, unique peptides corresponding to Ago1 
were found in all TAP-MS experiments.  
 
2.3.7 Summary of results 
In summary, the findings presented in chapter 2.3 suggest that Masva1 
might be expressed predominantly during early developmental stages such as 
mouse ES cells and embryonic fibroblasts. The immunofluorescence results 
indicate that Ago1 and Masva1 have different sub-cellular localization patterns 
when overexpressed in mouse fibroblasts, which may reflect differences in their 
biological function. I could show that Masva1 has the ability to bind small RNAs 
although with a much lower binding efficiency than Ago1. Furthermore, the 
NMID domain allows binding of most miRNAs found in murine fibroblasts with 
the exception of imprinted miRNAs. How structural changes in the NMID domain 
allow binding of some miRNAs but not others remains to be addressed in future 
experiments. In addition, Masva1 protein seems to lack the ability to interact with 
other Ago proteins and more importantly with Tnrc6B. Although limitations in 
peptide detection cannot be ruled out in these experiments, the results above 
predict that Masva1 lacks the ability to mediate gene silencing through 
recruitment of the Ccr4-Not effector complex to targeted mRNAs. This 
hypothesis remains to be tested in future experiments. Finally, I applied genome 
editing to tag endogenous Ago1 gene and performed TAP-MS to identify 
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endogenous Masva1 protein. However, peptides matching to the NMID domain 
of Masva1 were absent in ten independent TAP-MS experiments.  
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2.4 Project IV: Novel insights in mammalian m6A RNA 
methylation 
 
Methylation of adenosines at position N6 on RNA molecules is the most 
abundant internal modification in eukaryotic mRNA. Besides mRNA, this RNA 
modification is found on small nucleolar RNA (snoRNA), ribosomal RNA (rRNA), 
transfer RNA (tRNA) and long non-coding RNA (lncRNA), such as XIST (X-
inactive specific transcript) and MALAT1 (Dominissini et al., 2012; Meyer et al., 
2012). N6-Methyladenosine (m6A) was initially discovered in the 1970´s in 
polyadenylated RNA fractions isolated from mammalian cells (Desrosiers et al., 
1974). But the initial attention on m6A in mRNA was abandoned owing to 
concerns that m6A may have come from contamination of known sources of 
methylated RNAs (rRNAs and snoRNAs) often found in polyadenylated RNA 
isolations (Meyer and Jaffrey, 2014). After four decades of latency, the interest 
in m6A was revived by development of novel high-throughput and genome-wide 
m6A detection methods (MeRIP-seq). Two pioneering studies mapped the 
transcriptome-wide distribution of m6A methylation sites on human and murine 
transcriptomes (Dominissini et al., 2012; Meyer et al., 2012). The resulting maps 
have shown that about 25% of all mRNAs are m6A methylated and that the 
modification is enriched near the stop codons, in 3’ untranslated regions (3’ 
UTRs) and within internal long exons. Furthermore, the m6A-methylated regions 
have often a consensus sequence of RRACH (where R denotes A or G, and H 
represents A, C or U).  
Discoveries from biochemical and genetic studies further enhanced the 
interest on m6A (Bokar et al., 1997; Hongay and Orr-Weaver, 2011; Jia et al., 
Unpublished results: 
• Villaseñor R, Knuckles P, Daniel H, Burger L, Seebacher J, Bühler M. 
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2008). Recently, m6A has been linked to a plethora of physiological processes, 
ranging from obesity, synaptic signalling and cancer to circadian periods, sperm 
development, and stem cell differentiation (Fu et al., 2014). Despite important 
recent advances, the precise function of m6A and how mRNA methylation is 
regulated remain poorly understood.  
Mettl3 (Methyl-transferase-like 3) is an enzyme that promotes m6A 
methylation of RNAs (Figure 27A). Purification of the enzyme showed substrate 
specificity towards GAC and AAC sequences in single-stranded RNA (Bokar et 
al., 1994). Cloning of the human METTL3 gene revealed that it has a classic 
SAM-binding methyltransferase domain, which is consistent with its function 
(Bokar et al., 1997). Additionally, homologues in plants (MTA), Saccharomyces 
cerevisiae (inducer of meiosis 4; Ime4) and Drosophila melanogaster (Ime4) 
have also been identified (Clancy et al., 2002; Hongay and Orr-Weaver, 2011). 
Genetic ablation of Mettl3 results in early embryonic lethality in mice and 
impaired oogenesis in flies (Geula et al., 2015; Hongay and Orr-Weaver, 2011). 
Biochemical studies on human METTL3 revealed interactions to another 
N6-methyltransferase, known as METTL14 (Methyl-transferase-like 14) in 
mammals (Figure 27). In addition to METTL14, Wilms tumour 1-associated 
protein (WTAP) was found to associate to the human METTL3-METTL14 
complex (Liu et al., 2014; Ping et al., 2014; Wang et al., 2014c). Previously, 
human WTAP has been shown to interact with RNA binding proteins in the 
nucleus and bind nuclear lncRNAs. Another recent study expanded the 
interaction network of the METTL3-METTL14 complex. Schwartz and 
colleagues previously found the protein VIRILIZER to interact with METTL14 in 
human cells. Knockdown experiments of VIRILIZER showed that it is required in 
human cells for cellular mRNA methylation (Schwartz et al., 2014). Interestingly, 
knockdown of human WTAP lowered global m6A levels and decreased the 
amount of RNA bound to METTL3, suggesting that WTAP may recruit the 
METTL3-METTL14 enzymatic complex to substrate RNAs (Liu et al., 2014; Ping 
et al., 2014; Schwartz et al., 2014). 
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Figure 27. The m6A Pathway and Its Cellular Functions 
(A) N6-methyladenosine methylation and demethylation reactions. Methyltransferase complex containing 
METTL3, METTL14, and WTAP catalyzes m6A methylation, whereas FTO and ALKBH5, the 
demethylases, catalyze oxidative demethylation of m6A. (B) Domain structures of writer, eraser, and 
reader/effector proteins in human. METTL3, METTL14, and WTAP are components of the 
methyltransferase complex. METTL3 and METTL4 have a SAM-binding domain required for m6A 
methylation, whereas WTAP contains no characteristic domain. Eraser proteins, FTO and ALKBH5 
demethylases, have an AlkB domain in common. Compared to ALKBH5, FTO has an additional C-terminal 
domain. YTHDF1,2,3 containing a YTH RNA-binding domain are effector proteins. The P/Q/N-rich domain 
is known to be important for the localization of YTHDF2 to P body (Fu et al., 2014). (C) Proposed model of 
the cellular function of m6A on mRNA. Reversible methylation/demethylation is thought to occur in nuclear 
speckles where the enzymes are concentrated. Methylation may affect the export and splicing of mRNAs in 
the nucleus. Exported methylated mRNAs are recognized by YTHDF2 in the cytoplasm and then localize to 
P bodies, where mRNA decay factors are enriched. Image taken with permission from (Lee et al., 2014). 
Copyright © 2015 Elsevier B.V. 
 
m6A is likely to have a role in mediating RNA-protein interactions. In 
principle, methylation of adenosine could either block or induce RNA-protein 
interactions (Figure 27C). To date, several m6A-binding proteins have been 
identified from mammalian cellular extracts using RNA pull-down approaches, 
which are followed by mass spectrometry (Dominissini et al., 2012; Schwartz et 
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al., 2014; Wang et al., 2014c). These include the mammalian proteins YTH 
domain‐containing family 1 (YTHDF1), YTHDF2, YTHDF3, YTHDC1 and 
YTHDC2 each of which contains an YTH RNA‐binding domain (Figure 27B).  
To date, only two cytoplasmic m6A readers have been characterized in 
human cells – namely YTHDF1 and YTHDF2. He and co-workers showed that 
the cytoplasmic YTHDF1 protein promotes the translation of m6A methylated 
mRNAs in human cells (Wang et al., 2015). Transcriptome-wide protein-RNA 
interaction mapping indicated that around 5,000 mRNA are targets of YTHDF1. 
Ribosome profiling revealed a significant decrease in the translation efficiency of 
YTHDF1 targets following YTHDF1 knockdown or the reduction of m6A levels. 
Furthermore, YTHDF1 associates with translation initiation factors and subunits 
of the ribosome. Therefore, it is believed that YTHDF1-dependent translation 
could be promoted by delivering mRNAs to the translation machinery and by 
enhancing translation initiation (Wang et al., 2015).  
Both YTHDF1 and YTHDF2 locate in the cytoplasm. YTHDF1 and 
YTHDF2 seem to share about 50% common target transcripts. However, it has 
been previously reported that m6A reader protein YTHDF2 decreases the 
stability of its m6A-modified target mRNAs (Wang et al., 2014b), which seems to 
contradict the findings about the translation-promotion role of m6A. A possible 
explanation for this conundrum suggests the following: YTHDF1 and YTHDF2 
could have differences in timing of their binding to common RNA targets. 
Support for this hypothesis showed that YTHDF1 binds to m6A methylated 
mRNA transcripts earlier than YTHDF2, which would be consistent with the 
expectation that translation of most of these mRNAs should occur before 
degradation under normal growth conditions (Wang et al., 2015). 
Recently m6A has been identified as a novel regulator of miRNA 
processing. Human METTL3 mediates methylation of pri-miRNAs, seemingly 
facilitating their recognition and processing by the microprocessor complex 
(Alarcon et al., 2015). To study the link between N6-adenosinemethylation and 
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miRNA biogenesis, and more importantly how METTL3 binds its substrates, we 
endogenously tagged Mettl3 using CRISPR/Cas9 technology in mouse ES cells. 
By TAP-MS I found novel protein interaction partners. We currently are 
characterizing the function of these interaction partners by measuring the effect 
their depletion has on Mettl3 binding to chromatin and enzymatic activity. 
 
2.4.1 Mapping protein-protein interactions of Mettl3 in mouse ES cells 
To study the protein interaction network of Mettl3, Dr. Philip Knuckles and 
I set out to endogenously tag Mettl3 in RosaB (BirA-expressing) mouse ES cells. 
To tag the endogenous Mettl3 gene, we designed a gRNAs to target the first 
coding exon of the mouse Mettl3 gene (Figure 28A). A vector encoding for the 
Mettl3-gRNA and Cas9 enzyme (gR-Cas9-2C) was co-transfected with an 
ssODN carrying the FLAG-AviTag sequence and homology regions against the 
first coding exon of Mettl3 gene. We obtained 15 of 96 positive clones (15.6% 
efficiency) by PCR genotyping analysis. Moreover, we confirmed the expression 
of FLAvi-Mettl3 protein in six out of eight tested clones by western blot (Figure 
28B).  
Next, I conducted tandem affinity purification of Mettl3 protein complexes 
using two cell lines expressing endogenously tagged FLAvi-Mettl3. The same 
tandem affinity purification was done in non-tagged RosaB cells that served as 
control samples. RNase A treated samples were included to the MS analysis to 
account for RNA-dependent and RNA-independent direct physical interactions 
of Mettl3. All TAP-samples were subjected to MS analysis and the obtained data 
was statistically analysed using the SAINT algorithm (as previously described in 
Section 2.2.2).  
  93 
 
Figure 28. Protein-Protein Interaction Network of Mettl3 In Mouse ES Cells 
(A) Schematic overview of Cas9-assisted integration of an ssODN carrying a FLAG-AviTag sequence 
downstream of the Mettl3 start codon (bold letters). (B) Summary statistics for Cas9-assisted Mettl3 gene 
tagging. (C) Graphs displaying the average fold-change between Mettl3-IP and control samples versus the 
SAINT probability of interaction (poi). Previously reported interactors are shown as red asterisks. Blue 
asterisks denote RNA-binding proteins previously identified by Horiuchi et al. (Horiuchi et al., 2013). (F) 
Proteins associated with endogenously tagged Mettl3 in TAP-MS samples, compared to RNAse-treated 
counterparts. All MS-data shown here was averaged from four biological replicates. 
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Previously identified partners of Mettl3, namely Mettl14, Wtap and 
Virilizer (alias KIAA1429), were found among the proteins with the highest 
enrichment and probability of interaction in all TAP purifications (Figure 28C). In 
addition to these interactors, we identified novel binding partners of the Mettl3-
Mettl14 complex that were not detected in previous MS-experiments using 
overexpression of Mettl3. SAINT analysis revealed a high-probability interaction 
to the chaperone proteins Hspa5, Hspa8 and Hspa9. These interactions seem 
highly specific to Mettl3, as we do not observe similar interactions to other bait 
proteins (Figure R11). Our analysis further revealed high-confidence interactions 
of Mettl3 with other RNA-binding proteins and splicing factors. Among those 
interactions, I observed the strongest log2 fold-change (2.2) and a probability of 
interaction score of ~0.9 for Zinc finger CCCH domain-containing protein 13 
(Zc3h13) – a poorly characterized CCCH-type zinc finger protein in eukaryotes 
with the potential to bind RNA transcripts. Interestingly, another RNA-binding 
protein known to bind RNA through its conserved RNA recognition motifs (RRM) 
domains, called Rbm15 (RNA binding motif 15), shows a strong enrichment and 
high poi-score in all TAP-MS experiments. In contrast, other observed 
interactions had lower poi-scores and enrichments over control samples, 
suggesting that these factors are weak or indirect interactors of the Mettl3-
Mettl14 complex (Figure 28C). Most of the weak Mettl3-interacting proteins are 
RNA-binding proteins, which participate in the control of pre-mRNA splicing. 
These results are noteworthy because they could provide further evidence for 
the hypothesis that m6A is set co-transcriptionally on nascent mRNAs, which I 
will further discuss chapter 3.4. 
In addition, I treated Mettl3-TAP samples with RNase A to account for 
RNA-dependent and RNA-independent direct physical interactions of Mettl3. 
Most high-probability interactions remained constant upon RNase A treatment, 
suggesting direct physical interactions of these proteins to Mettl3 (Figure 28D).  
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Figure 29. The Mouse N6-Methyladenosine Transferase Complex Consists of a Highly Stable Mettl3-
Mettl14 Complex 
Heatmap showing enrichment of the most highly detected proteins in all samples that show at least 2-fold 
enrichment in the 150-mM NaCl condition. Most interactions detected at 150-mM NaCl are lost under more 
stringent affinity purification conditions (350 – 500-mM NaCl). 
 
To test the strength of the identified interactions, I performed TAP-MS of 
Mettl3 protein complexes under increasing salt concentrations (150, 350 and 
500-mM NaCl). The parental cell line, which lacks expression of endogenous 
tagged proteins, was treated under exact same conditions as the Mettl3-TAP 
samples. We calculated the enrichments over TAP-MS control samples using 
the spectral counts for each detected protein after MS-analysis. The heatmap 
shown in Figure 29 displays the enrichment of the most highly detected proteins 
in all samples that show at least 2-fold enrichment in the 150-mM salt condition. 
Most of the observed interactions in Figure 28D are lost under more stringent 
affinity purification conditions (Figure 29). Remarkably, the Mettl3 to Mettl14 
interaction resisted all three salt concentrations, suggesting that Mettl3 acts 
primarily in a complex with Mettl14 in vivo and might function synergistically. 
Other previously reported components of the Mettl3-Mettl14 complex such as 
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Wtap and Virilizer are lost under high salt concentrations (350 and 500-mM 
NaCl). Surprisingly, Hspa8 is the only interaction partner besides Mettl14, which 
seems to remain bound to Mettl3 under high stringency conditions (Figure 29). 
The biological meaning of the strong Mettl3-Hspa8 interaction awaits further 
investigation. 
Taken together, we applied genome editing to tag endogenous Mettl3 
gene and identify novel protein binding partners of the Mettl3-Mettl14 protein 
complex. Our combined genome editing approach with tandem affinity 
purification coupled to MS analysis led to the discovery of high-confidence and 
novel protein binding partners of the m6A methyltransferase complex such as 
chaperone proteins Hspa5, Hspa8 and Hspa9 and the RNA-binding proteins 
Zc3h13 and Rbm15. In current follow-up experiments, we are assessing the 
biological significance of these findings. 
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3 Discussion & 
Conclusion 
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Recent advances in genome editing technologies are having a remarkable 
impact in the life sciences. During the course of my doctoral studies I 
experienced the development of more advanced genome editing tools such as 
TALENs and the CRISPR/Cas9 system. The first project presented in this 
doctoral thesis applied ZFN technology – at that time the only available tool for 
genome editing. However, this technology has severe limitations compared to 
more recent programmable nucleases (see Introduction). Therefore, I switched 
from ZFNs to TALENs and Cas9. These technologies were successfully applied 
in subsequent projects presented in this thesis, which are now becoming 
standard molecular techniques in biology research. Here, I will discuss the 
results and open questions for each project in a separate chapter. 
 
3.1 Project I: Application of genome editing for drug discovery 
 
In recent years, a significant body of literature has proposed that in theory, 
genome-editing technologies, cellular reprogramming, and high-throughput 
biology each have the potential to revolutionize biomedicine and pharmaceutical 
pipelines. This study establishes that these emerging biotechnologies can be 
effectively combined to perform as proposed, exemplifying a new paradigm for 
drug discovery. 
 
3.1.1 Genome-engineering tools to establish accurate reporter cell lines 
that enable identification of therapeutic strategies to treat 
Friedreich’s Ataxia. 
 
 Since the expanded GAA repeats in FRDA reside in the first intron of the 
FXN gene and thus do not alter the amino acid sequence of the protein, gene 
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reactivation would be of therapeutic benefit. Efforts to find small molecules that 
reverse FXN gene silencing are thus of medical importance. Several studies 
have demonstrated that benzamide-based histone deacetylase inhibitors 
(HDACi) and synthetic PPAR-γ agonist (e.g. A-PAF) have the ability to 
moderately increase FXN protein levels in non-affected and FRDA patient-
derived cells as well as in FRDA mouse models (Chou et al., 2008; Herman et 
al., 2006; Marmolino et al., 2009; Rai et al., 2008). However, it is not clear how 
this compounds act on FXN gene expression.  
One important application for HEK293T-FF2AP cell line is its use in high-
throughput genomic screens for the discovery of drug targets that activate FXN 
gene expression or stabilize FXN protein turnover. The HEK293T-FF2AP cell 
line established in this study is the first luciferase reporter-based cellular model, 
which allows an accurate and effortless assessment of endogenous frataxin 
gene regulation and is compatible with high-throughput biology. HEK293T-
FF2AP cells are easy to transfect and can be expanded to a very large scale at 
a relatively low cost. Thus, this system should be compatible with the technical 
and financial constraints of most academic and industrial screening platforms.  
Using the HEK293T-FF2AP cell line in a pilot high-throughput genomic 
screen, we uncovered novel negative regulators of FXN expression, 
demonstrating the importance of monitoring gene expression from the 
endogenous FXN locus. Our results showing that FXN expression can be 
increased even in the presence of an expanded repeat tract also demonstrate 
that screening for general regulators of FXN transcription, irrespective of GAA 
repeat length, is an appropriate strategy. Thus, our approach opens up new 
opportunities for target discovery and we anticipate that high-throughput 
screening of genome-wide siRNA or cDNA libraries will reveal additional 
potential drug targets in the near future.  
Furthermore, the genome engineering tools designed in this study will 
serve as a powerful resource to the FRDA community. The ZFNs and donor 
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constructs developed in this study will enable others to knock in any given 
sequence tag into the FXN locus in many different cell types, facilitating the 
dissection of molecular pathways involved in FRDA. 
 
Generation of patient-derived reporter cell line 
High-throughput screening for FXN gene activators or low molecular 
weight compounds has so far met with limited success because current cellular 
models may not accurately assess endogenous FXN gene regulation under 
disease conditions. To facilitate the identification of molecules that enhance FXN 
gene expression and therefore could alleviate FXN deficiency, the cause behind 
FRDA, cell lines that fully reflect the in vivo disease situation are essential tools 
for drug discovery. Although FXN knockout mice and cell lines are important 
tools for understanding the role of frataxin in cell physiology and disease 
etiology and progression (Martelli et al., 2012a), these resources are not 
appropriate for discovery of FXN gene activators. For that purpose, several 
groups have developed reporter cell lines harbouring a reporter gene separated 
by an artificial intron containing extended GAA repeat tracts to mimic the genetic 
defect observed in FRDA (Puccio, 2009). Another group recently developed a 
HeLa-based reporter cell line with a randomly integrated BAC containing the 
human FXN locus and 350-nt long GAA repeats (Lufino et al., 2013). Because 
the FXN-FL fusion is expressed from BAC clones, this system does not monitor 
FXN expression in its native chromosomal context. Consequently, none of these 
cell lines fully recapitulate the molecular defects of an endogenous, silenced 
FXN gene. Therefore, we set out to develop a FRDA patient-derived reporter 
cell line that entirely reflects the complexity of the repressed FXN gene in the in 
vivo disease scenario in FRDA.  
My efforts lead to the generation of the FRDA4078iBT-FF cell line. Several 
lines of evidence indicated the suitability of this cell line for basic research and 
HTS applications. In contrast to the HEK293T-FF2AP cell line, where other 
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integrations of the reporter gene were observed, only a single specific 
integration at the FXN gene locus was detected by southern hybridizations. 
Furthermore, the FRDA4078iBT-FF line contains extended GAA repeats tracts 
on both alleles. More importantly, the cells show stable luciferase activity that 
responds to treatments of one specific chemical inhibitor of PRKD1. However, 
more experiments performed to further validate the FRDA4078iBT-FF cell line 
failed to detect the low abundant FXN-FL fusion protein (data not shown). 
Treatment of these cells with PRKD1 chemical inhibitor compound 13c led to a 
5-fold increase of luciferase activity that failed to translate to a similar increase 
of FXN protein.  
In conclusion, I believe the FRDA4078iBT-FF cell line is erroneous and 
caution is needed if these cells are employed in future experiments. Moreover, 
the FXN-ZFNs used in this study were less efficient in FRDA patient-derived 
fibroblasts preventing FXN gene editing in those cells. Therefore, modern 
genome editing tools like TALENs and CRISPR/Cas9 might offer additional 
possibilities to edit the FXN locus in FRDA patient-derived cells with expanded 
GAA repeats. As shown in later projects, TALENs or the CRISPR/Cas9 system 
combined with recombination reporters can be used to efficiently edit mouse 
gene loci. I am confident that a similar approach can be applied in human 
primary cells, iPSCs or stem cells to edit disease loci such as the human FXN 
gene. 
 
Use of PRKD1 chemical inhibitors in patient-derived lymphoblasts 
To assess the effect of PRKD1 chemical inhibition in reactivation of FXN 
expression, we tested several low molecular weight inhibitors of PRKD1 in 
patient-derived cells. FXN mRNA and protein levels remained constant after 
24h-treatments using compound 13c in FRDA fibroblasts (GAA541/GAA420) and 
FRDA lymphoblasts (GAA1030/GAA650). Similarly, WA-21-JO19 failed to 
reactivate FXN expression in FRDA lymphoblasts after 48h treatment. 
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Remarkably, I noticed a modest increase in FXN mRNA and FXN intermediate 
protein expression after 48h WA-21-JO19-treatment of lymphoblasts derived 
from healthy individuals. However, these results still need further verification to 
evaluate their statistical significance.  
What could be the mechanisms of action for PRKD1 inhibitors? PRKD1 
belongs to the serine/threonine protein kinase D family, which consists of three 
isoforms playing a role in growth factor signalling and in stress-induced 
signalling (Steinberg, 2012). In cardiac myocytes, PRKD1 phosphorylates 
HDAC5 resulting in nuclear export of HDAC5 and de-repression of downstream 
target genes. HDAC5 suppresses stress-dependent remodelling of the heart via 
association with the myocyte enhancer factor 2 (MEF2) transcription factor 
(Fielitz et al., 2008). MEF2 gene transcription in the myocyte, in turn, alters 
myocyte growth, contraction, calcium handling, metabolism and promotes 
cardiac hypertrophy (Kim et al., 2008). 
In other cells, the MEF2 family of transcription factors are bound to their 
target promoters and repressed by a variety of HDACs (Potthoff and Olson, 
2007). Other transcription factors might be repressed by HDACs similarly to 
MEF2 in cardiac cells. It remains to be tested if PRKD1 inhibition might lead to 
MEF2-dependent transcription of frataxin. In addition, several studies have 
demonstrated that benzamide-based HDAC inhibitors promote moderate 
increase of FXN protein levels in non-affected and FRDA patient-derived cells 
as well as in FRDA mouse models (Chou et al., 2008; Herman et al., 2006; Rai 
et al., 2008). However, it is not clear how these compounds act on FXN gene 
expression. A possible mechanism of action for benzamide-based HDACi could 
be the activation of MEF2-dependent transcription leading to increased FXN 
expression. Alternatively, other transcription factors repressed by HDACs might 
be involved in FXN transcription. Therefore, the identification of regulators of 
FXN gene expression would benefit the search for potential therapeutic targets 
for FRDA patients. The established HEK293T-FF2AP cell line also enables high-
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throughput screening of cDNA libraries to decipher the transcriptional regulatory 
network of FXN gene expression. 
 
Use of iPSCs to model FRDA 
In section 2.1.4, I described the use of human iPSCs to model FRDA and 
the testing of a PRKD1 inhibitor in FRDA neurons. The outcome of this work is 
two-fold: we found that PRKD1 is a druggable target in the patient- and disease-
relevant cell type, and we found 2,6-naphthyridines as candidate compounds for 
drug development to treat FRDA. Importantly, WA-21-JO19 treatment led to a 
25% increase in FXN mRNA expression in FRDA neurons after 3 weeks of 
treatment. Therefore, I speculate that the effect of PRKD1 chemical inhibition 
might be dependent on GAA repeat length and duration of treatment. It remains 
to be verified if a 25% increase in FXN expression is therapeutically sufficient for 
at least a subpopulation of FRDA patients as some FRDA patients exhibit FXN 
levels only 20-30% lower than asymptomatic carriers (Martelli et al., 2012b; 
Miranda et al., 2002). In addition, neuron viability was not affected by exposure 
to WA-21-JO19, even at 10 µM. Therefore, it may be possible to increase WA-
21-JO19 efficacy or the efficacy of its structure-activity relationship (SAR) 
derivatives by increasing treatment duration and/or compound concentration. 
Oral availability, high PRKD1 selectivity, and low toxicity thus make WA-21-
JO19 an attractive candidate for drug development.  
In conclusion, this multifaceted approach, developed collaboratively by 
academic and industrial research teams, allowed us to identify a means to 
counteract a disease-causing phenotype in a patient-derived cellular context, 
highlighting the potential of this discovery paradigm. 
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3.2 Project II: Endogenous in-vivo biotinylation system for 
mapping protein networks and protein-DNA interactions of 
RNAi factors in embryonic stem cells 
 
We have recently developed reagents and protocols for in vitro genome 
engineering such as endogenous gene tagging in mouse ES cells (Flemr and 
Buhler, 2015). Additionally, we established Cas9-constructs and protocols for 
efficient editing of gene loci where TALENs are not available (Knuckles, 
Villaseñor et al., unpublished). This study establishes that endogenous gene 
tagging and in vivo biotinylation can be successfully combined to map the 
protein interaction network of virtually any protein of interest. This method 
exemplifies a new paradigm for mass-spectrometry based proteomics of protein 
complexes. Unlike traditional affinity purification approaches to study protein-
protein interactions, the technique presented here allows detection of most 
physical interactions for a bait protein. Importantly, this approach circumvents 
the need for specific antibodies against the protein of interest, retains 
endogenous expression levels of the gene of interest, and allows reverse 
genetic experiments in isogenic mouse ES cells. In addition, the relatively small 
size of the FLAG-AviTag is likely to lack interference with the native function of 
the target protein. However, some proteins lose functionality when tags are 
fused to them, representing a foremost disadvantage of this approach. 
Therefore, tagging of endogenous proteins requires additional downstream 
analysis such as functional testing of the generated fusions using biochemical 
methods and/or genomic approaches. 
To assess the competence of our method to map protein-protein 
interactions, we established several mouse ES cell lines expressing 
endogenously tagged RNAi factors. Both gene-tagging approaches using 
TALENs or the CRISPR/Cas9 system showed similar efficiencies (Figures 18 & 
19). It remains to be investigated why just a few and not all positive clones 
  105 
identified by PCR genotyping express tagged proteins. A possible explanation is 
the efficiency and accuracy of the underlying mechanism to repair a DSB using 
an ssODN as a template. Microhomology-mediated end-joining (MMEJ) is an 
additional DSB repair mechanism active in G1 that uses microhomologous 
sequences (5–25 bp) for error-prone end-joining (McVey and Lee, 2008). 
Depending on the cell cycle stage where cells are targeted for genome editing, 
repair of induced DSBs might be achieved using the error-prone MMEJ 
pathway.  
The combined genome editing approach with tandem affinity purification 
coupled to MS analysis yielded high confidence bait-prey interactions for all 
tagged RNAi factors. I could identify most of the previously reported protein-
binding partners of Dgcr8, Dicer1 and Ago1 regardless of their predominant 
cellular localization (Figure 20). For all three bait purifications, I observe novel 
interaction partners with a probability of interaction score greater than 0.8. 
However, the novel interactors are mostly ribosomal proteins, which are difficult 
to reconcile with a function in the canonical miRNA biogenesis pathway. Further 
validation experiments are needed to assess the functional role of these 
interactors in the miRNA pathway. 
Interestingly, our analysis failed to detect a known interaction partner of 
Ago1 in all TAP purifications, the Moloney leukemia virus 10 protein (Mov10). 
Much of the existing literature describes Mov10 as a cytoplasmic protein that 
associates with Ago complexes in P-bodies (Chendrimada et al., 2007; Meister 
et al., 2005). A recent proteomics study confirmed the inability of human MOV10 
to interact with AGO1 (Gregersen et al., 2014). Instead, AGO2 seems to be a 
direct binding partner of MOV10, suggesting additional functions of AGO2 in 
other pathways. This and my results suggest that Ago proteins can have 
differential binding partners. To provide evidence for this hypothesis TAP-MS 
experiments of Ago2 would be needed. Finally, my results indicate that Ago1s 
main function is miRNA-mediated gene silencing in mammals. This function 
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would be consistent with the role of Ago1 in Drosophila showing an astonishing 
evolutionary conservation across animal kingdoms (Figure 30).  
 
Figure 30. Phylogenetic Analysis of a Representative Set of 177 Eukaryotic Agos 
1, Trypanosoma Ago family; 2, WAGO family. Ago sequence alignment and uncollapsed phylogenetic tree 
are in found in (Swarts et al., 2014). Picture adapted from (Swarts et al., 2014). Copyright © 2014, Rights 
managed by Nature Publishing Group. 
In summary, the methodology presented in this chapter is highly 
reproducible and versatile, making it ideal to study interaction networks of 
almost any protein in mouse ES cells. 
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3.3 Project III: Functional analysis of Ago1 splicing isoform 
 
Alternative splicing (AS) has the potential to remodel the protein interaction 
network of alternative spliced genes (Ellis et al., 2012; Irimia et al., 2014). Until 
now, alternative spliced variants of RNAi genes have remained undiscovered. In 
this project, we discovered an alternative spliced variant of the mouse Ago1 
gene, which we termed Masva1. Masva1 protein acquired through two AS 
events a novel domain (NMID) that replaces the MID domain of Ago1. Masva1 
transcript appears to be specific for Mus musculus, since the alternative splice 
sites and amino acid sequence of NMID are not evolutionary conserved. 
To assess the biological relevance of Masva1, I first determined its spatio-
temporal expression in different mouse organs and cells. My results described in 
section 2.3 showed that Masva1 mRNA is only expressed in mouse ES and 
NIH3T3 cells, suggesting that Masva1 is predominantly expressed during early 
murine development. Additionally, Masva1 is ~10-fold less abundant than Ago1 
in these cells. However, I cannot rule out the expression of Masva1 in other 
mouse tissues that were not tested – possibly at higher levels than Ago1. 
Therefore, it will be crucial for future follow-up experiments to determine the 
exact spatio-temporal expression of Masva1 in other mouse tissues and 
developmental stages. 
The MID domain of Ago proteins is crucial for binding the 5´-end of small 
RNAs (Meister, 2013). Surprisingly, Masva1 is able to bind small RNAs through 
its NMID domain. Masva1 showed similar sequence preferences at the 5´-end of 
its bound miRNAs in comparison to Ago1-associated miRNAs. Modelling of the 
5´-binding pocket of both proteins (Heinz Gut, FMI) partly explains why Masva1 
retained the ability to specifically bind miRNAs (Figure 31). A conserved tyrosine 
residue (Tyr529) is important to stabilize the binding of the first base of the small 
RNA (Elkayam et al., 2012; Schirle and MacRae, 2012). Although Masva1 lacks 
this particular tyrosine residue, it seems to replace it by a glutamine residue 
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(Gln540) to bind the first base of small RNAs. Therefore, it is reasonable to 
speculate that NMID domain of Masva1 folds into a structured domain partly 
resembling the three-dimensional fold of Argonaute MID domains. 
Moreover, results from small RNA profiling experiments suggest that 
Masva1 binds small RNAs less efficient than Ago1 (Figure 16E). This qualitative 
observation could partially be explained by the replacement of the aromatic 
Tyr529 to the non-aromatic Gln540 residue. Gln540 could in theory stabilize the 
first base-pair of the sRNA via hydrophobic interactions and/or hydrogen bond 
formation. However, this effect would be less efficient than stabilization via 
electrostatic interactions between aromatic residues (Figure 31). Lastly, it is 
more likely that the unstructured parts of the NMID domain have a negative 
effect on the overall fold of Masva1 leading to reduced sRNA binding 
efficiencies. 
 
Figure 31. Detailed View Onto The 5´Binding Site of Human Ago2 In Complex With Mir-20a 
The crystal structure of human Ago2 [(Elkayam et al., 2012), PDB ID 4F3T ] is displayed as grey cartoon 
model with selected residues involved in miRNA binding and the first five nucleotides on the 5’ side of 
microRNA-20a shown as sticks (grey, atom colors). A homology model of the Masva1 is superimposed and 
displayed in cyan with selected residues predicted to interact with miRNA as sticks in cyan (atom colors). 
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In contrast to Ago1, Masva1 lacks the ability to localize to cytoplasmic P-
bodies (section 2.3.3). In addition, Tnrc6B was absent in Masva1 affinity 
purifications, suggesting that Masva1 lost the ability to interact with GW proteins 
(section 2.3.5). As discussed above, Masva1 binds small RNAs in a similar 
fashion as Ago1. These results raise the question whether Masva1 is able to 
mediate gene silencing through recruitment of effector complexes to target 
transcripts. The Ccr4-Not complex is recruited to target mRNAs through its 
interaction with GW proteins. The absence of Tnrc6B and possibly other Tnrc6 
proteins in Masva1 complexes, suggests that Masva1 lacks the ability to recruit 
deadenylase complexes to target mRNAs. Moreover, Masva1 showed a diffused 
cellular localization without accumulation in cytoplasmic foci. But, the formation 
of P-bodies seems to be a consequence, rather than the cause, of miRNA-
mediated gene silencing (Eulalio et al., 2008a). Therefore, I assume that 
Masva1 is not involved in miRNA-mediated gene silencing mechanisms. This 
assumption could be tested in tethering experiments of Masva1 to reporter 
mRNAs. 
The discovery of Masva1 opens up the exciting possibility to remodel the 
interaction network of Ago1 to gain additional functions. In the following 
paragraph, I will briefly describe four aspects to consider if somebody continues 
this line of research. First, Masva1 mRNA quantities are almost below detection 
levels in mouse ES and NIH3T3 cells. Bioinformatics search across several 
RNA-seq datasets from different mouse tissues and developmental stages could 
not reveal expression of Masva1. Second, Masva1 protein is below detection in 
mouse ES cells. Third, AS leading to the generation of Masva1 seems to be 
restricted to Mus musculus, raising concerns about its general biological 
significance. Fourth, the functional redundancy between Argonaute proteins 
further complicates functional studies of individual members. The biological role 
of mammalian Ago1 still remains unclear, since genetic ablation of the Ago1 
gene in vivo and in cellulo does not lead to striking observable phenotypes. 
Therefore, it is questionable to what extent genetic ablation studies of Masva1 
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might provide clear insights into its biological role. However, some findings 
presented in this project are intriguing and deserve further attention. I believe 
that future efforts should be put primarily in identifying the tissue or biological 
scenario (e.g. disease) where Masva1 is most highly expressed to understand 
its function. 
What could be the biological function of Masva1, if any, in the cell? 
Masva1 could possibly act as a storage protein to protect miRNAs and other 
sRNAs from degradation. To function as proposed, Masva1 protein levels could 
be lower than the protein levels of endogenous Argonaute proteins. This 
hypothesis also foresees a mechanism of miRNA exchange between Masva1 
and Ago proteins, which could be facilitated by heat-shock proteins. Additionally, 
signalling pathways and tissue distribution might control the abundance of 
Masva1 in mice. Future experiments should focus on finding the place and time 
of endogenous Masva1 protein expression as well as unbiased approaches to 
uncover its biological role. 
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3.4 Project IV: Novel insights in mammalian m6A RNA 
methylation 
 
In this project, I performed TAP-MS analysis of endogenous Mettl3 
complexes purified from murine ES cells. Previously identified partners of Mettl3, 
namely Mettl14, Wtap and Virilizer, were found among the proteins with the 
highest enrichment and probability of interaction in all TAP-MS experiments. 
More importantly, our proteomic approach allowed us to uncover novel 
interaction partners of Mettl3 that are now under further investigation. In this 
chapter, I will discuss how the identified Mettl3 binding partners could contribute 
to mammalian N6-adenosine methylation of RNA transcripts. 
Heat shock proteins are commonly observed contaminants in affinity 
purification experiments presumably because of the presence of unfolded 
polypeptides during the purification procedure (Gingras et al., 2007). Heat shock 
proteins perform chaperone function by stabilizing new proteins to ensure 
correct folding or by helping to refold proteins that were damaged during cell 
stress (Saibil, 2013). I could observe a significant interaction of Hspa5, Hspa8 
and Hspa9 with Mettl3, suggesting a role for chaperone proteins in stabilizing 
the Mettl3-Mettl14 complex. What could be the function for protein chaperones 
in the m6A RNA-methylation pathway? Although caution is required in the 
interpretation of these findings, chaperones play important roles in other 
pathways. In the RNAi pathway for example, the Hspa8/Hsp90 complex 
facilitates the binding of “unloaded” Argonaute proteins to duplex miRNAs 
(Iwasaki et al., 2010; Johnston et al., 2010). Since empty Ago proteins are 
actively destroyed, chaperones are thought to protect unloaded Argonautes from 
degradation (Martinez and Gregory, 2013). It might be possible that similar 
functions for chaperones operate in m6A pathway. For instance, chaperone 
proteins might help stabilize the interaction of the Mettl3-Mettl14 complex to 
other proteins. This might be required to control the enzymatic activity of both 
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methytransferases and protect the complex from degradation. In vitro 
methylation assays of RNA substrates in the presence and absence of 
chaperone proteins could provide important insights to understand the role of 
chaperones in m6A methylation. 
The RNA binding factors identified as Mettl3 interactors could be involved 
in recruitment of the methyltransferase complex to certain RRACH sites on 
mRNAs. In fact, why and how the Mettl3-Mettl14 complex methylates certain 
mRNAs and not others remains elusive. Most m6A sites are located in the 
vicinity of the stop codon. Additionally, a subset of mRNAs contains m6A 
residues in their 5ʹ-untranslated regions (Dominissini et al., 2012; Meyer et al., 
2012). Analysis of the MeRIP-seq generated peaks using motif-discovery 
algorithms identified the enrichment of RRACH consensus motifs within these 
peaks. However, the majority of RRACH sites are not methylated in mammalian 
mRNAs, which begs the question of how asymmetric distribution of m6A sites is 
achieved.  
Mettl3 and Mettl14 proteins lack obvious RNA-binding domains (Figure 
27B). Therefore, it remains unclear how both enzymes specifically recognize 
their substrates. Recent studies have pointed towards Wtap as the RNA-binding 
component of the methyltransferase complex (Ping et al., 2014; Schwartz et al., 
2014). Schwartz and colleagues recently demonstrated that Wtap is crucial for 
the methylation around the stop codon of certain mRNAs (Schwartz et al., 
2014). However, Wtap also lacks RNA-binding domains, suggesting that other 
Mettl3 interaction partners achieve binding to mRNA targets. Another recent 
study identified Rbm15, Zc3h13, Hakai and Virilizer as binding partners of 
human WTAP (Horiuchi et al., 2013). These proteins seem to form a complex 
that is required for cell cycle and alternative splicing regulation. But, the authors 
could not provide further mechanistic insights into this potential complex, and 
more importantly, link their findings to the m6A methylation pathway. In this 
project, I was able to show that Mettl3 specifically interacts with nuclear RNA 
binding proteins such as Zc3h13, Rbm15 and Hakai (Figure 28). Therefore it is 
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tempting to speculate that these RNA binding proteins might function as 
“recruiters” of the Mettl3-Mettl14 complex to target nascent mRNAs in the cell 
nucleus (Figure 32). In addition, Wtap might act as a scaffold protein to anchor 
Mettl3 recruiters. In the next paragraphs, I will briefly discuss about potential 
functions for Zc3h13, Rbm15 and Hakai, which are currently the subject of 
further investigations in our group. 
 
 
Figure 32. Speculative Model For Co-Transcriptional Methylation of Nascent RNAs 
(A) Schematic representation of the Mettl3-Mettl14 N6-methyladenosine transferase complex (yellow). The 
biological role of Hspa8 (gray) is not clear. (B) Scheme showing the multi-protein Wtap complex consisting 
of Wtap, Virilizer and the RNA-binding proteins Hakai, Rbm15 and Zc3h13. (C) Cartoon showing a 
speculative model for the co-transcriptional methylation of nascent RNAs by the Mettl3-Mettl14 complex. 
m6A methylation site (red star) on RRACH consensus sequence (where R denotes A or G, and H 
represents A, C or U). 
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Zc3h13 is a poorly characterized and evolutionary conserved CCCH-type 
zinc-finger protein. Proteins of the CCCH-type zinc-finger family have the ability 
to bind single-stranded RNA through their zinc-finger domains. The 
Trypanosoma brucei Zc3h13 protein has been reported to play various roles in 
RNA metabolism (Ouna et al., 2012). In addition, a recent genome-wide 
association study identified the Zc3h13 gene as a schizophrenia risk locus 
(Oldmeadow et al., 2014). We are currently testing whether genetic ablation of 
Zc3h13 affects recruitment of Mettl3 to target transcripts and reduces m6A 
levels on mRNAs. Additionally, transcriptome-wide protein-RNA association 
mapping will be crucial to determine which transcripts Zc3h13 binds. This might 
enhance our understanding of how the Mettl3-Mettl14 complex targets only 
certain mRNAs in mammals. 
Rbm15 is a member of the Split ends (Spen) protein family of 
transcriptional repressors originally discovered in Drosophila melanogaster in 
the late 1990s. Every family member contains three predicted RNA recognition 
motifs (RRMs) in the N-terminal region of the protein and a conserved Spen 
paralog and ortholog C-terminal domain (SPOC). Repression of transcription by 
Spen proteins can occur through interactions with other repressors, by 
recruitment of proteins involved in histone deacetylation, or through 
sequestration of transcriptional activators. The human Spen family proteins 
Sharp, Rbm15/Ott1, and Rbm15B/Ott3 share the structural domain architecture 
but show distinct functional properties. The SPOC domain of the human 
homolog of the fly Spen protein, named SHARP (SMRT/HDAC1 associated 
repressor protein), has been shown to mediate the interaction with the silencing 
mediator for retinoid and thyroid-hormone repressor protein (SMRT/NCoR) as 
well as with the histone deacetylase HDAC1 (Ariyoshi and Schwabe, 2003; 
Mikami et al., 2014; Shi et al., 2001). In contrast, the SPOC domain of Rbm15, a 
primarily nuclear protein, has been reported to interact with the general mRNA 
export factor Nxf1 (Lindtner et al., 2006). Similarly to Rbm15, Rbm15B/Ott3 
binds Nxf1 via its C-terminal region and shares with Rbm15 the association with 
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the splicing factor compartment and the nuclear envelope as well as the binding 
to other export factors such as Aly/REF (Uranishi et al., 2009). Nevertheless, 
genetic ablation of Rbm15 in mice results in embryonic lethality, indicating that 
Ott3 cannot compensate for the Rbm15 loss, which supports the notion that 
these proteins, in addition to sharing similar activities, likely have distinct 
biological roles (Raffel et al., 2007; Uranishi et al., 2009). 
Rbm15 was recently identified in a genetic screen as a factor involved in 
Xist-mediated gene silencing. Interestingly, the same study also identified 
additional proteins such as Wtap and Virilizer, which interact with the Mettl3-
Mettl14 complex. Additionally, a recent proteomic study by Guttmann and 
colleagues identified Rbm15 as the second most abundant Xist-interacting 
protein (McHugh et al., 2015). This study shows direct evidence that Rbm15 
binds lncRNAs such as Xist and Malat1, which are known to be m6A methylated 
(Dominissini et al., 2012).  
What is the role of Rbm15 in the m6A methyltransferase complex? The 
proteomic study by Guttmann and colleagues identified Sharp as the major Xist-
interacting protein (McHugh et al., 2015). Sharp knockdown leads to de-
repression of genes silenced by Xist, suggesting that Sharp recruits repressor 
complexes to promote Xist-mediated gene silencing. In contrast, knockdown of 
Rbm15 did not reactivate genes silenced by Xist (McHugh et al., 2015). A 
possible explanation for this observation could be that Rbm15 is not involved in 
the recruitment of repressor complexes to Xist target loci. Alternatively, Rbm15 
could recruit the Mettl3-Mettl14 complex to Xist and possibly other transcripts. 
Binding to RNA might be achieved through the three predicted RNA recognition 
motifs (RRMs) in the N-terminus of Rbm15. mRNA binding might occur in a 
sequence specific manner and/or through recognition of secondary structures. 
The C-terminal SPOC domain might serve as an interaction surface to recruit 
the Mettl3-Mettl14 complex to certain mRNAs. Transcriptome-wide protein-RNA 
interaction mapping will be essential to assess which transcripts Rbm15 binds 
and whether these substrates are shared with Zc3h13. 
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What is then the function of m6A methylation of nuclear transcripts? The 
m6A mark could have a role in mediating RNA-protein interactions. Apart from 
this purpose, m6A could also affect the local secondary structure of mRNAs. 
Chang and colleagues lately reported a biochemical approach that allows a 
global view of RNA secondary structures in living cells. Using this method they 
could show that m6A impacts RNA structure, favouring the transition from paired 
to unpaired RNA (Spitale et al., 2015). It remains to be tested if deletion of m6A 
sites affects the secondary structure of methylated transcripts like Xist and 
whether this has an impact on their function, localization or stability. 
The E3 ubiquitin-protein ligase Hakai (Hakai, which means “destruction” 
in Japanese) also known as Casitas B-lineage lymphoma-transforming 
sequence-like protein 1 (Cbll1) is an enzyme that in humans is encoded by the 
CBLL1 gene. Hakai was originally discovered as a RING finger domain-
containing E3 ubiquitin-ligase targeting the E-cadherin complex, a major 
component of adherens junctions (Pece and Gutkind, 2002). Hakai binds to the 
cytoplasmic domain of E-cadherin and mediates its ubiquitination, endocytosis 
and lysosomal degradation by the proteasome. Hakai contains RING, zinc-finger 
and proline-rich domains, and interacts with E-cadherin in a tyrosine 
phosphorylation-dependent manner (Fujita et al., 2002).  
In search of downstream effectors of Hakai that function independently of 
binding to E-cadherin, PSF (polypyrimidine tract-binding protein-associated 
splicing factor) was identified as a novel Hakai-interacting protein (Figueroa et 
al., 2009). PSF is a nuclear protein implicated in transcription, DNA binding, 
unwinding, and repair, as well as pre-mRNA splicing and RNA editing. PSF co-
localizes with Hakai in the nucleus (Figueroa et al., 2009). Another recent study 
identified Wtap as a Hakai-interaction partner in human cancer cells (Horiuchi et 
al., 2013). Hakai co-localizes with Wtap in the nucleus, raising the possibility that 
Hakai could play a role in nuclear RNA processing through its association with 
PSF or Wtap.  
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What could be the function of Hakai in the nucleus? The crystal structure 
of Hakai revealed that it forms an atypical, zinc‐coordinated homodimer by 
utilizing residues from the phosphotyrosine‐binding domain of two Hakai 
monomers. Hakai dimerization allows the formation of a phosphotyrosine-
binding pocket that recognizes specific phosphorylated tyrosines and flanking 
acidic amino acids of Src kinase substrates (Mukherjee et al., 2012). 
Interestingly, Hakai purification experiments revealed a strong interaction to 
Wtap. The use of a Hakai mutant lacking a small part of the RING finger domain 
(amino-acids 125-133), which is probably required to form a functional 
phosphotyrosine-binding pocket, abolished interaction with all Hakai binding 
partners including Wtap (Horiuchi et al., 2013). Thus, it is appealing to speculate 
that Hakai binds to Wtap in a tyrosine phosphorylation-dependent manner and 
mediates ubiquitination of Wtap.  
Could Wtap be a Src substrate and be phosphorylated upon Src 
signalling? Src, and related Src family kinases, are involved in numerous 
functions and signalling pathways. Recently, two proteomic studies identified 
nuclear RNA binding proteins as bona fide Src kinase substrates (Ferrando et 
al., 2012; Sirvent et al., 2012). However, components of the Mettl3-Mettl14 
complex were not identified as Src substrates. But, the data suggests that Src 
over-expression might have a profound effect on mRNA splicing and stability in 
vivo. In conclusion, the role of Hakai in the nuclear m6A-transferase complex 
remains elusive. 
Although m6A is generally believed as a posttranscriptional modification, 
the actual timing and localization of its deposition on RNA transcripts is not clear 
(Fu et al., 2014; Meyer and Jaffrey, 2014). mRNA processing events like 
capping, splicing, cleavage and poly-adenylation occur primarily co-
transcriptionally and because m6A modifications were found within introns as 
well as exons (Dominissini et al., 2012), it is likely that the Mettl3-Mettl14 
complex methylates nascent RNAs co-transcriptionally. Consistent with this idea 
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are three additional lines of evidence:  
 
i) Primary miRNA transcripts and lncRNAs are m6A-methylated 
(Alarcon et al., 2015; Dominissini et al., 2012; Meyer et al., 2012) 
ii) Mettl3 co-precipitates components of the splicing machinery and 
other nuclear proteins (results presented in this doctoral thesis).  
iii) Mettl3 localizes to nucleus and associates with chromatin. 
Genome wide Mettl3 is enriched at genes known to be m6A-
methylated as well as at miRNAs containing loci suggesting the 
mark is installed co-transcriptionally (results obtained by P. 
Knuckles during the writing process of this doctoral thesis). 
 
We currently are characterizing the function of the novel interaction 
partners by measuring the effect their depletion has on Mettl3 binding to 
chromatin and activity. Finally, the results obtained from these experiments will 
shed light into the mechanisms of Mettl3 recruitment to target RNAs. 
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4 Methods 
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4.1 Methods Project I 
 
See experimental procedures in the published manuscript found in the 
appendix. Methods not covered in the manuscript are found here. 
 
Cell culture 
Dermal fibroblasts from patients affected by Friedreich’s Ataxia (FRDA, 
GM04078) and transformed B-lymphocytes from FRDA-affected (GM15850) and 
unaffected individuals (GM15851) were obtained from Coriell Cell Repositories 
(Camden, N.J.). H9 hESCs were obtained from WiCell (Madison, Wis.). 
GM04078 cells were immortalized by lentiviral delivery of BMI1 and hTERT as 
described previously (Villasenor et al., 2015), resulting in the cell line FRDA-
4078iBT. GM04078 and FRDA-4078iBT human dermal fibroblasts (HDF) were 
maintained in MEM-α (Life Technologies, Grand Island, N.Y.) media containing 
20% heat-inactivated FBS (Geminibio, West Sacramento, Calif.) and 1X L-
glutamine (Life Technologies) or in Minimal Essential Medium Eagle (Sigma, St. 
Luis, Mo.) supplemented with 10% FCS (Sigma) and 2mM L-glutamine at 37°C 
in 5% CO2. Transformed B-lymphocytes were propagated in RPMI1640 medium 
supplemented with 15% FCS and 2mM L-glutamine at 37°C in 5% CO2. 
HEK293T cells were cultured in Dulbecco´s Modified Eagle Medium (DMEM) 
supplemented with 10% FCS (Sigma), 100 U ml-1 penicillin, 100 µg ml-1 
streptomycin and 2 mM L-glutamine at 37°C in 5% CO2. Human induced 
pluripotent stem cells (hiPSC) and human embryonic stem cells (hESC) were 
maintained in mTeSR (Stem Cell Technologies, B.C., Canada) on Growth-
Factor-Reduced Matrigel (BD, San Jose, Calif.) culture conditions and were 
passaged every 4-6 days using dispase (Stem Cell Technologies). Karyotype 
and fingerprint analyses were performed by Cell Line Genetics (Madison, Wis.). 
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Genome editing 
 Plasmids encoding FXN-ZFN-L, FXN-ZFN-R, and donor constructs 
(sequences available as supplementary material) were co-transfected into 
FRDA-4078iBT human dermal fibroblasts by Amaxa Nucleofection (Lonza). In 
brief, cells were passaged 2-3 days before nucleofection. Prior to nucleofection, 
cells were trypsinized and counted. 1-2 x 106 viable cells were then centrifuged, 
and the supernatant was removed completely. Cells were re-suspended in 100 
µl Nucleofector Solution R, mixed with three non-linearized plasmids (two ZFN 
encoding plasmids + Donor 1 or Donor 2) in a 1:10 ZFN / Donor molar ratio in 
10 µl nuclease-free water, and nucleofected using program X-01 (Amaxa, Kit-R). 
Following nucleofection, sterile plastic pipettes were used to transfer the cells to 
warm MEM media in 10 cm tissue culture dishes that were already prepared 
with MEM media. After transfer, cells were cultured in standard conditions for 3 
days prior selection with puromycin or G418 (neomycin). After 1-2 weeks of drug 
selection colonies start to form. Single puromycin-resistant or G418-resistant 
clones were picked and expanded for further analysis. Sequences of plasmids 
used in this study are provided as text files. Following clonal isolation and 
expansion, individual clones were screened by southern blotting and by 
luciferase assays.  
Southern blotting 
Southern hybridizations were performed using the Digoxigenin-system 
(DIG, Roche) for chemiluminescent detection of DNA samples. Genomic DNA 
was extracted from parental and gene edited cells (FRDA-4078iBT and FRDA-
4078iBT cells) using the QIAGEN DNeasy Blood & Tissue Kit (QIAGEN, 69504). 
10 µg of extracted genomic DNA were incubated with StuI at 37°C for 16 h. DNA 
was concentrated after digestion by standard ethanol precipitation followed by 
resuspension in 20 µl TE-buffer. Digested DNA was separated on a 0.7% 
agarose gel overnight (~16h) at 20 V. After complete separation of DNA 
fragments, DNA was denatured by gently shaking the gel in denaturing solution 
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(2x 15min). Gel was neutralized by gently shaking in neutralization solution (2x 
15min). DNA was transferred to a nylon membrane (Roche) by capillary action 
using absorbent paper to soak transfer solution (20x SSC) through the gel and 
the membrane (for a detailed description of the protocol see reference 
(Southern, 2006)). After over-night transfer procedure, DNA was cross-linked to 
the membrane by exposure to short-wavelength ultraviolet light. The dry 
membrane was pre-hybridize in 20 ml DIG Easy Hyb solution (Roche, 
11796895001) in hybridization bottles for 1-2 h at 42°C. The purified DIG-
labeled DNA probe, prepared by PCR with DIG-labeled dNTPs (Roche, 
11835289910) was diluted in 10 ml DIG Easy Hyb solution to a final 
concentration of 25 ng/ml and denatured by heating 68°C for 10 minutes just 
before use (probe solution can be re-used several times). The pre-hybridization 
solution was replaced by the freshly denatured probe solution. Hybridization was 
performed over-night at 42°C in a roller oven. After hybridization, probe solution 
was removed and membrane was washed twice in 2x wash solution at room 
temperature. Before proceeding with chemiluminescent DIG detection, 
membrane was washed twice for 15 minutes each at 68°C in pre-warmed 0.5x 
wash solution. Next, membrane was washed for 5 min in 50 ml washing buffer 
by gentle shaking. The membrane was incubated then for 30 min in 50 ml 
blocking buffer with gentle shaking. The blocking buffer was replaced by 20 ml 
fresh blocking buffer containing 1 µl of anti-DIG-AP conjugate (1:20000; Roche, 
11093274910). The membrane was washed 3 times for 15 minutes each in 
washing buffer at RT. Then the membrane was equilibrated for 2 min in 20 ml of 
AP-buffer, before incubation with chemiluminescence substrate CDP-Star 
(Roche, 11685627001) diluted 1:100 in AP-buffer for 5 minutes. The membrane 
was exposed to an X-ray film for 20 minutes. To strip for re-hybridization, the 
membrane was washed twice for 10 minutes in 0.2N NaOH 0.1%SDS at 37-
42°C and then briefly washed again in 2x SSC. The dry membrane can be 
stored at 4°C. 
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Solutions  Components 
Denaturation solution 0.4N NaOH, 0.6M NaCl 
Neutralization solution 0.5M Tris-HCl pH 7.5, 1.5M NaCl 
20x SSC 3M NaCl, 0,3M Na-Citrate, pH 7 
(autoclave) 
DIG Easy Hyb make from Hyb Granules (Roche, 
11796895001) 
2x wash solution 2x SSC, 0.1% SDS 
0.5x wash solution 0.5x SSC, 0.1% SDS 
MS-buffer 100mM maleic acid, 150mM NaCl; pH 7.5 
adjusted with NaOH 
Washing buffer MS-buffer + 0.3% Tween-20 
Blocking buffer MS-buffer with 1% (w/v) Roche blocking 
reagent (11096176001) and autoclave 
AP-buffer 100mM Tris-HCl pH 9.5, 100mM NaCl 
 
Table 2. Solutions And Buffers For Southern Blotting 
 
Luciferase assays 
FRDA-4078iBT human dermal fibroblasts were washed with PBS and 
trypsinized before preparation of cell lysates. The trypzined cells were washed 
at least twice with PBS to remove residual trypsin. Cell pellets were re-
suspended in 100 µl of 1x passive lysis buffer (PLB, Promega Dual-Luciferase 
Reporter Assay System E1910) supplemented with 1x cOmplete Protease 
Inhibitor Cocktail (Roche) and cell lysates were transferred to Eppendorf tubes. 
Tubes were incubated at 25°C for 15 min and rocked several at 1000 rpm to 
ensure complete lysis. Cell lysates were centrifuged at maximum speed in an 
Eppendorf microcentrifuge for 10 min at 4°C. Luciferase measurements were 
performed with 10 µl of lysate supernatants in triplicate. All measurements were 
performed on a Centro LB 960 luminometer (Berthold Technologies, Germany). 
Bradford assays were carried out to determine total protein concentration, which 
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was used for normalization. Cell lysate can be stored at minus 80°C for later 
use. 
Immunoflorescent staining 
hiPSCs were seeded on a matrigel-coated black-clear bottom imaging 
plate (BD). Two days after plating, cells were washed once with PBS and fixed 
in 4% formaldehyde (USB Corp, Cleveland, Ohio) for 20 min. Cells were 
permeabilized and incubated for 30 min in blocking buffer containing 3% Donkey 
Serum (Jackson Labs, Bar Harbor, Maine) and 0.1% Triton (Sigma) in PBS. 
Cells were stained with primary antibodies Oct4/Nanog (Abcam, Cambridge, 
Mass./Santa Cruz Biotech, Santa Cruz, Calif.) and dye-conjugated antibodies 
SSEA-4 and Tra-1-81/1-60 (BD) overnight at 4˚C in blocking buffer. Cells were 
washed in 1% Tween (Sigma) in PBS and stained with secondary antibodies for 
1 h at room temperature. Images were captured using a Zeiss Confocal 
Microscope (Thornwood, N.Y.). 
Pyrosequencing 
Cells were collected and outsourced to EpigenDX (Worcester, Mass.). 
Pyrosequencing analysis was performed according to standard procedures with 
primers that were developed for the CpG sites at positions (-50; +96) from the 
start codon of OCT4 (Assay ID: ADS510) gene. 
Real-time RT-PCR 
For quantitative RT-PCR (qRT-PCR) experiments, total RNA was 
extracted from FRDA-4078iBT, and transformed B-lymphocytes cells with the 
Absolutely RNA Microprep Kit (Stratagene). A 1-µg aliquot of total RNA was 
reverse transcribed with AffinityScript enzyme (Stratagene) using random oligo 
dT primers according to the manufacturer’s instructions. qRT-PCR was 
performed on a CFX96 Real-Time PCR System (Bio-Rad) using the 
SsoAdvanced SYBR Green Supermix (Bio-Rad, #172-5264). Relative RNA 
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levels were calculated from CT values according to the ΔCT method and 
normalized to RPL13A mRNA levels. Primer sequences are provided in Table 3.  
Reprogrammed cells were washed once and total RNA isolated using 
TRIzol (Life Technologies). After chloroform extraction, RNA was purified using 
a RNeasy Plus Kit (Qiagen, Germantown, Md.). RNA purity and concentration 
were verified using an Aligent 2100 Bioanalyzer (Santa Clara, Calif.). In a two-
step procedure, 1.5 µg of total RNA input was first used to synthesize cDNA with 
random primers with a High-Capacity cDNA Reverse Transcription Kit (Life 
Technologies) according to the manufacturer’s instructions. Q-PCR analysis was 
performed on a ViiA-7 Real Time PCR System (Life Technologies) using Fast 
Advanced SYBR Green PCR master mix (Life Technologies). PCR conditions 
were as follows: 95˚C – 5 min; (60˚C – 30 s; x 40 cycles); 74˚C – 10 min. 
Sendai virus reprogramming and isolation 
Sendai virus (SeV) particles encoding OCT4, SOX2, KLF4 and cMYC 
(OSKM) were purchased from Life Technologies and SeV-reprogramming was 
performed as follows: patient and unaffected HDFs were seeded on Matrigel-
coated 24-well plates at a density of 25-50 x 103 per well. Cells were transduced 
with SeV particles encoding the 4-factors (MOI; O=10, SKM=7.5) overnight in 
fibroblast media containing 10 µg/ml polybrene (Sigma). The medium was 
changed to mTeSR 3 days post-infection. On days 5 or 6, cells were dissociated 
using accutase (Life Technologies) and plated onto Matrigel-coated 35-mm 
dishes seeded with mitomycin-C-treated human neonatal fibroblast feeders 
(GlobalStem, Rockville, Md.). Emerging hiPSC colonies were observed 20-30 
days post-infection, selected and transferred to matrigel and mTeSR culture 
conditions. 
Tri-layer differentiation and teratoma formation 
Endoderm: Accutase was used for cell dissociation to single cells, which 
were then plated on matrigel in mTeSR with rock-inhibitor Y27632 (Calbiochem, 
Darmstadt, Germany) at a density of 100 x 103 per cm2. Three days post-plating, 
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the medium was changed to RPMI containing 0.5% FBS (Thermo, Waltham, 
Mass.) and 100 ng/ml Activin A (R&D, Minneapolis, Minn.). Cells were washed 
once, replenished with fresh media daily, fixed on day 5-6, and stained with 
Sox17 (Abcam) for analysis.  
Mesoderm: hiPSC/hESC cultures were grown to confluence. Using 
dispase (Stem Cell Technologies), cells were collected and plated into non-
adherent 6-well culture dishes for embryoid body (EB) formation in media 
containing BMP4, G-CSF (R&D) and hSCF, hFlt3, and IL-3/6 (Peprotech, Rocky 
Hill, N.J.). Media were changed every 3 days. Cells were collected or re-plated 
on MG-coated 96-well plates for fixation at day 18 and then stained with α-
Actinin (Abcam) for analysis. 
Ectoderm and neural derivatives: Undifferentiated hESC/hiPSC cultures 
were first exposed to dual inhibition of SMAD signaling, which has been shown 
to convert hESC to neural progenitors (Chambers et al., 2009). For neuronal 
differentiation, neural progenitors were expanded in DMEM/F-12 with B27 and 
N2 supplements (Gibco), 10 ng/ml human epidermal growth factor (hEGF) and 
10 ng/ml human basic fibroblast growth factor (hbFGF) (Gibco). Neural 
progenitors were finally differentiated into neurons in neurobasal medium 
(Gibco) supplemented with B27, 10 ng/ml human neurotrophin-3 (hNT-3) (R & 
D), and 10 ng/ml human brain-derived neurotrophic factor (hBDNF) (R & D) for 
at least 4 weeks. Antibodies against Pax6 (DSHB) and β-III Tubulin (Tuj1, 
Covance) were used to identify neural progenitors and neurons, respectively. In 
order to quantify the efficiency of differentiation into Pax6-expressing neural 
progenitors, immunostained cultures were generated and the percentage of 
Pax6-positive and DAPI-positive cells determined in 10 randomly selected 
microscopic fields. In order to quantify the efficiency of differentiation into β-III 
Tubulin-expressing neurons, a similar approach was used with cultures 
previously treated with cytosine-1-β-D-arabinofuranoside to prevent the 
expansion of neural progenitors.  
Teratoma formation was outsourced to Applied Stem Cells (Menlo Park, 
Calif.). 
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Western blotting 
Proteins were extracted for 30 min on ice, the lysates were centrifuged at 
16,000 × g for 20 min at 4°C, and protein concentration in the supernatant was 
determined using the Bio-Rad protein assay. For western blotting, 20 µg of 
protein were resolved on SDS-PAGE. Alternatively, frataxin protein samples 
were separated on NuPAGE-Novex Bis-Tris 4-12% gradient gels (Invitrogen) in 
MES buffer at 200 V for 40 min. Semi-dry transfer on polyvinylidene fluoride 
(PVDF) membrane was performed at 15 V for 15 min, then immediately shifted 
to 25 V for 20 min. The membranes were blocked for 30 min 1% non-fat dry milk 
in TBS-0.05% Tween 20 (TBST), and stained with primary antibodies at 4°C 
overnight. The primary antibodies used for western blotting were mouse anti-
FXN (1:500; Life Technologies, clone 18A5DB1), mouse anti-FLAG (1:2,000; 
Sigma clone M2), rabbit-anti-PRKD1-S916 (1:1,000; Cell Signaling Technology, 
Antibody #2051), and rat-anti-tubulin (1:5,000; Abcam clone YL1/2). Signal was 
detected with corresponding HRP-conjugated secondary antibodies and 
Immobilon Western Chemiluminiscent HRP Substrate (Millipore). For 
streptavidin staining, membranes were blocked after transfer in 2% BSA in 
TBST and incubated with streptavidin-HRP (1:25,000, Sigma) for 30 min at room 
temperature, followed by signal development as above.  
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Table 3. qRT-PCR and PCR Primers Used In Project I 
  
Table 3. qRT-PCR and PCR primers used in project I
qRT-PCR primers
Transcript Forward Reverse
FXN ACAAGCAGACGCCAAACAAGCA ACCCAGTTTTTCCCAGTCCAGTCA
PRKD1 ACGTCCGCGAGATGGCTTGC TCACTGGCCGCTTTCACCAGC
RPL13A CTGCCCTTCCTCCATTGTT CTTTCAAGCAACTTCGGGAG
OCT4 CCTCACTTCACTGCACTGTA CAGGTTTTCTTTCCCTAGCT  
NANOG TGAACCTCAGCTACAAACAG  TGGTGGTAGGAAGAGTAAG  
SOX2 CCCAGCAGACTTCACATGT  CCTCCCATTTCCCTCGTTTT  
KLF4 GATGAACTGACCAGGCACTA GTGGGTCATATCCACTGTCT 
GDF3 AAATGTTTGTGTTGCGGTCA   TCTGGCACAGGTGTCTTCAG 
REX1 TCGCTGAGCTGAAACAAATG CCCTTCTTGAAGGTTTACAC  
DPPA4 GGAGCCGCCTGCCCTGGAAAATTC TTTTTCCTGATATTCTATTCCCAT 
UTF1 CCGTCGCTGAACACCGCCCTGCTG CGCGCTGCCCAGAATGAAGCCCAC  
SeV GGATCACTAGGTGATATCGAGC ACCAGACAAGAGTTTAAGAGATATGTA 
SeV-OCT4  CCCGAAAGAGAAAGCGAACCAG AATGTATCGAAGGTGCTCAA 
SeV-SOX2 ATGCACCGCTACGACGTGAGCGC AATGTATCGAAGGTGCTCAA 
SeV-KLF4 TTCCTGCATGCCAGAGGAGCCC AATGTATCGAAGGTGCTCAA 
SeV-cMyc  TAACTGACTAGCAGGCTTGTCG TCCACATACAGTCCTGGATGATGATG 
GAPDH CCTTCATTGACCTCAACTAC GGAAGGCCATGCCAGTGAGC 
B-Actin TGAAGTGTGACGTGGACATC GGAGGAGCAATGATCTTGAT 
PCR primers
Transcript Forward Reverse
GAA repeats GGGATTGGTTGCCAGTGCTTAAAAGTTAGGATCTAAGGACCATCATGGCCACACTTGCC
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4.2 Methods Project II 
 
Cell Culture And Transfection 
Mouse embryonic fibroblast cell line NIH3T3 from was obtained from 
ATCC (clone CRL-1658). NIH3T3 cells were cultured in Dulbecco´s Modified 
Eagle Medium (DMEM) supplemented with 10% FBS (Sigma), 100 U ml-1 
penicillin, 100 µg ml-1 streptomycin and 2 mM L-glutamine at 37°C in 5% CO2. 
Purified plasmids were transfected into murine NIH3T3 cells and treated with 
blasticidin 48 hr post-trasfection for selection. All transfections were carried out 
using Lipofectamine 3000 reagent (Invitro- gen) at 3 ml/1 mg DNA ratio in 
OptiMEM medium (Invitrogen). 
Mammalian Expression Vector Cloning 
To construct mammalian expression vectors, parental plasmid pEF1a-
Blasticidin (pEF1a_B) was a gift from Dr. Matyas Flemr. A gBLOCK encoding for 
the 3xFLAG-AviTag sequence was cloned into the HindIII site of pEF1a_B. 
Integrated DNA Technologies synthesized the gBLOCK as linear dsDNA and its 
sequence is listed in Table 3. The resulting plasmid pEF1a-3xFLAG-AviTag was 
cut with XbaI to introduce mouse Ago1, Masva1, EGFP-Ago1, and EGFP-
Masva1 coding sequences by In-Fusion cloning (In-Fusion HD Cloning Plus Kit, 
Clontech Laboratories). All primers used for In-Fusion cloning are listed in Table 
4. Plasmids containing coding sequences were obtained from MF. All plasmids 
were verified by sequencing. 
Fluorescence Microscopy 
Living cells expressing EGFP-Ago1 fusions were imaged in FlouroBrite 
DMEM medium (Invitrogen) on an Olympus iX-53 inverted micro- scope using 
the Olympus U-FGFP filter cube. 
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Argonaute Immunoprecipitation  
Immunoprecipitation of FLAG-Ago1 and FLAG-Masva1 was performed as 
described previously (de la Mata 2015) with Anti-FLAG M2 magnetic beads 
(Sigma, M8823). Briefly, beads were washed twice with TBS buffer (50 mM Tris 
HCl, 150 mM NaCl, pH 7.4). For each IP, two 15-cm plates with cells grown to 
80-90% confluency were used. Cells were washed once with cold PBS, pelleted 
and lyzed in 500 µl of lysis buffer [50 mM Tris–HCl pH 7.5, 150mM NaCl, 1% 
(v/v) TRITON X-100, 1 mM EDTA, containing protease inhibitors (cOmplete, 
EDTA-free Protease Inhibitor Cocktail, Roche) and RNAse inhibitor (Invitrogen)]. 
The lysates were incubated 30 min on ice, cleared by centrifugation at 16,000g 
for 10 min at 4°C and mixed with the washed beads. After 2 h of rotation at 4°C, 
the beads were washed three times with TBS buffer. As a control for the IPs, 
parental NIH3T3 cells were used. FLAG-Ago expression and 
immunoprecipitation efficiency were determined by western blot. RNA was 
extracted by adding Trizol reagent (Invitrogen) directly on the beads or FLAG-
peptide elutions. 
Generation Of Small RNA Libraries For High-Throughput Sequencing 
RNA purity and concentration were verified using an Aligent 2100 
Bioanalyzer (Santa Clara, Calif.). ~17–30 nt small RNAs were PAGE purified. 
ALL small RNA libraries were prepared using Illumina TruSeq Small RNA kits 
(Cat # RS‐200‐0024).  
Small RNA Data Analysis 
Individual reads were assigned to their sample based on the first four 
nucleotides containing the barcode. The 3′ adaptor was removed by aligning it to 
the read allowing one or two mismatches in prefix alignments of at least seven 
or ten bases, respectively. Low-complexity reads were filtered out based on their 
dinucleotide entropy (removing <1% of the reads). All reads that were shorter 
than 14 nucleotides were removed. Alignments to the Mus musculus genome 
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(GRCm38/ mm10) were performed using the FMI galaxy pipeline. miRNA 
expression levels were calculated and normalized using mouse miRBase 
(http://www.mirbase.org/) as a reference. 
Homology Modeling 
The amino acid sequence of the M. musculus Masva1 was submitted to 
the HHPRED server for homology detection and structure prediction (Soding et 
al., 2005). The structure of H. sapiens Ago2 in complex with miR-20a (PDB ID 
4F3T) was among the top hits of similar structures yielding a very high score 
(Score=1647, E-value=7.2e-182, 75% sequence identity). The HHPRED 
alignment between HsAgo2 and Masva1 was then sent to the HHPRED 
MODELLER pipeline for homology modelling of the mouse protein using the 
human Ago2 structure as template. Structural figures were prepared using 
PyMOL (www.pymol.org).  
 
Table 4. qRT-PCR Primers and Taqman Probes Used In Project II 
  
Table 4. qRT-PCR primers and taqman probes used in project II
qRT-PCR primers and Taqman probes
Transcript Forward Reverse
Ago1 p1 AGCCGCCTGATGAAGAATG TTGGTTGGGCGTAGCAAT
Ago1 p2 ATTTGGAATCAAAGTGAAGGATGAC TCCCATTGTAGAACTGTTTCCC
Masva1 p1 AGCCGCCTGATGAAGAATG CCAGGTGAGCCTCAGTAGA
Masva1 p2 TAGCTACAACCTGGATCCCTAC GGTTCTAGGGATAGGCAGAGG
Taqman Ago1 probe1 5HEX/TGGCAATGA/ZEN/GAGGGTTGACTTTGAGG/3IABkFQ
Ago1 probe1 primers GCCTGTGTATGATGGAAAGAAGA GCC ACT TGA TGG AGA CCT TAA A
Taqman Ago1 probe2 5HEX/AGTATGGCG/ZEN/GCCGGAACCG/3IABkFQ
Ago1 probe2 primers AGGATGACATGACGGAGGT TCCCATTGTAGAACTGTTTCCC
Taqman Masva1 probe1 56-FAM/CAGTATGGC/ZEN/GGCCGGGCTC/3IABkFQ
Masva1 probe1 primers TTTGGAATCAAAGTGAAGGATGAC GCAATGGCCCGGTTCTA
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4.3 Methods Projects III-IV 
 
Similar methods were used for projects II – IV. Therefore, those methods 
are covered together in this section. 
 
TALEN Assembly 
TALENs were assembled using the Golden Gate TALEN cloning kit 
(Cermak et al., 2011) (Addgene 1000000024) and previously described acceptor 
vectors SV40-ELD and SV40-KKR carrying obligate heterodimeric FokI 
nuclease domains (Flemr et al., 2013). 
The following repeat variable diresidues were assembled for individual TALENs: 
Dicer-Nterm_left_ELD (targeted sequence GCTTTGCAGCCCCTCAGCAT) 
NN HD NG NG NG NN HD NI NN HD HD HD HD NG HD NI NN HD NI NG 
Dicer-Nterm_right_KKR (targeted sequence GAGGAAGCAGGGGTCAT) 
NN NI NN NN NI NI NN HD NI NN NN NN NN NG HD NI NG 
SpCas9-2A-mCherry Cloning 
To generate the SpCas9-2A-mCherry construct, we mutated the BbsI 
recognition site on pX330-U6-Chimeric_BB-CBh-hSpCas9 doing mutagenesis 
with In-Fusion® HD Cloning Plus Kit (Clontech Laboratories). pX330-U6-
Chimeric_BB-CBh-hSpCas9 was a gift from Feng Zhang (Addgene plasmid # 
42230). To perform mutagenesis with In-Fusion, PCR primers were designed so 
that they have a 15 bp overlap with each other at their 5' ends and incorporate 
a BsaI recognition site. pX330-U6-Chimeric_BB-CBh-hSpCas9 was PCR 
amplified (CloneAmpTM HiFi PCR Premix, Clontech Laboratories) using the 
forward primer  CGGAGACCGAGGTCT CTGTTTTAGAGCTAGAAATAGCAAG 
and the reverse primer AGACCTCGGTCTCCG 
GTGTTTCGTCCTTTCCACAAGATA following the manufacturer´s instructions 
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(In-Fusion Mutagenesis Protocol). The amplicon was treated with the In-Fusion 
HD enzyme premix and transformed into DH5alpha competent cells. The 
resulting intermediate plasmid was digested with EcoRI and the full mCherry 
coding sequence was then PCR amplified using the forward primers 
GCCGGCCAGGCAAAAAAGAAAAAGctcgagATGgtgagcaagggcgagg and the 
reverse primer 
GATCAGCGAGCTCTAGGAATTtatcgattaCTTGTACAGCTCGTCCATG, and 
integrated using In-Fusion cloning kit resulting in a Cas9-XhoI-mCherry fusion 
plasmid. The 2A self cleavage peptide was obtained by annealing two primers: 
tcgagGGCAGCGGAGAgggcagaggaagtcttctaacatgcggtgacgtggaggagaatcccggcc 
& tcgaggccgggattctcctccacgtcaccgcatgttagaagacttcctctgcccTCTCCGCTGCCc, 
and then cloned into the XhoI site to obtain pX330-U6-Chimeric_BsaI-CBh-
hSpCas9-2A-mCherry, termed SpCas9-2A-mCherry for convenience.  
To clone individual Cas9-sgRNA sequences into SpCas9-2A-mCherry 
plasmid, the corresponding oligos (listed in Table 3) were annealed in annealing 
buffer (10 mM Tris-HCl [pH 7.5], 0.1 M NaCl, 1 mM EDTA) and cloned into BsaI 
cut SpCas9-2A-mCherry.  
Recombination Reporter Cloning 
Cloning of pRR-EGFP recombination reporter has been previously 
described (Flemr and Buhler, 2015). To clone individual TALEN-recognition and 
Cas9-recognisition sequences into pRR-EGFP recombination reporter, the 
corresponding oligos (listed in Table 3) were annealed in annealing buffer (10 
mM Tris-HCl [pH 7.5], 0.1 M NaCl, 1 mM EDTA) and cloned into SacI/AatII cut 
pRR-EGFP. 
Cell Culture and Transfection 
Mouse embryonic stem cells were cultured on gelatin-coated dishes in 
mES medium (DMEM (Gibco 21969-035), supplemented with 15% fetal bovine 
serum (Biosera), 1 x non-essential amino acids (Gibco), 1 mM sodium pyruvate 
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(Gibco), 2 mM L-glutamine (Gibco), 0.1 mM 2-mercaptoethanol (Sigma), 50 
mg/ml penicillin, 80 mg/ml streptomycin and home-made LIF conditioned 
medium) at 37°C in 5% CO2. 
For endogenous gene tagging using TALENs, Rosa26:BirA-V5-
expressing cells (RosaB; (Flemr and Buhler, 2015)) were transfected with 400 
ng of each TALEN, 200 ng pRR-EGFP-Target_site, and 1 mg Target_Gene-
FLAG-AViTag ssODN. The ssODNs were synthesized as Ultramers by 
Integrated DNA Technologies and their sequences are listed in Table 5.  
For endogenous gene tagging using SpCas9-2A-mCherry, Rosa26:BirA-
V5-expressing cells (RosaB) were transfected with 500 ng of SpCas9-sgRNA-
2A-mCherry, 500 ng pRR-EGFP-Target_site, and 1 mg Target_Gene-FLAG-
AViTag ssODN. The ssODNs were synthesized as Ultramers by Integrated DNA 
Technologies and their sequences are listed in Table 5.  
All transfections were carried out using Lipofectamine 3000 reagent 
(Invitro- gen) at 3 ml/1 mg DNA ratio in OptiMEM medium (Invitrogen).  
Cell Sorting 
Gene edited cells were trypsinized 48-72 hr post-transfection, re-
suspended in PBS, and filtered through a 45-µm filter. EGFP-positive cells were 
sorted on a BD FACSAria III cell sorter (Becton Dickinson) using a 488-nm laser 
and a 530/30-nm filter. mCherry-positive cells were sorted using a 561-nm laser 
and a 610/20nm filter. EGFP/mCherry-positive and EGFP cells were collected 
as single cells into gelatin-coated 96-well plates containing pre-warmed mES 
medium for clonal expansion. 
ES Cell Clone Selection and PCR Genotyping 
Sorted EGFP-positive cells transfected with pRR-EGFP were sorted as 
single cells into gelatin-coated, mES medium containing 96-well plates for clonal 
expansion. After 7 days of culture, individual clones were picked and expanded 
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in 96-well plates for 2 more days. Cells were then washed with PBS and lysed 
directly in 96-well plates with 20 ml lysis buffer (10 mM Tris-HCl [pH 8.0], 0.5 
mM EDTA, 0.5% Triton X-100, and 0.5 mg/ml Proteinase K) for 2 hr at 55°C in a 
humidified box. Proteinase K was inactivated by incubating the lysates at 95°C 
for 10 min and 0.5 ml of the lysate was directly used for PCR. Genotyping was 
done in a single 35 cycle run in 6-µl reactions using QIAGEN Fast Cycling PCR 
Kit (QFC). FLAG-AviTag integrations into targeted genes were screened with 
universal primers FLAvi_F or FLAvi_R binding on the integration and a locus 
specific primer binding 0.5 - 1 kb distant of the target site. The region spanning 
FLAG-AviTag integrations was amplified with locus specific primers yielding 
PCR amplicons of ~ 500 bp. Primer sequences are listed in Table 5.  
Tandem Affinity Purification Of Protein Complexes 
A detailed bench protocol can be found in the appendix.  
Mass Spectrometry Data 
 Data can be found in the attached SD card. 
 
 
Table 5. Guide RNAs and ssODNs Used In Project III & IV 
  
Table 4. guide RNAs and ssODN used in project III & IV
guide RNAs
Target Gene ID guide RNA (forward primer) guide RNA (reverse primer)
Ago1 ENSMUSG00000041530 caccgTGTCCTCCGCACGGGTATAT aaacATATACCCGTGCGGAGGACAc
Dgcr8 ENSMUSG00000022718 caccgAGTCTTAACTGCTCATAATA aaacTATTATGAGCAGTTAAGACTc
Mettl3 ENSMUSG00000022160 caccgGAGCTAGGATGTCGGACACG aaacCGTGTCCGACATCCTAGCTCc
ssODN
Target sequence
Ago1 cctcagtctcccggccgcctgtcctccgcacgggtatatgtcCCACCATGGACTACAAAGACGATGACGATAAAGGTGATGGGTCCGGCCTGAACGACATCTTCGAGGCTCAGAAAATCGAATGGCACGAAGGCGCGCCGAGCTCGAGGGAAGCGGGACCCTCGGGAGCAGgtaagggccctcggggactgg
Dgcr8 ATGTAAGGTGGTTTAAAACTCTGGTCTTTTAAAGTAGTCTTAACTGCTCCCACCATGGACTACAAAGACGATGACGATAAAGGTGATGGGTCCGGCCTGAACGACATCTTCGAGGCTCAGAAAATCGAATGGCACGAAGGCGCGCCGAGCTCGAGGGAGACATATGAGAGTCCCTCTCCTCTCCCGCGTGAGCCCGCAG
Mettl3 GCTAGTCCGCCGCGCCTGATTCGAGCCGAGTCCGCGCTGGGAGCCACCATGGACTACAAAGACGATGACGATAAAGGTGATGGGTCCGGCCTGAACGACATCTTCGAGGCTCAGAAAATCGAATGGCACGAAGGCGCGCCGAGCTCGAGGTCGGACACGTGGAGCTCTATCCAGGCCCATAAGAAACAGCTGGACTCGCT
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Introduction
Friedreich’s ataxia (FRDA) is an autosomal recessive dis-
ease resulting from repression of the iron-binding protein 
frataxin (FXN).1 Reduced FXN expression results from an 
expansion of a trinucleotide repeat in the first intron of the 
frataxin gene2 and provokes a spectrum of neuropathologi-
cal defects in patients with FRDA. FRDA is the most com-
mon recessively inherited ataxia disorder across Europe, 
and several epidemiological studies have estimated the 
prevalence of FRDA as two to three cases per 100,000 peo-
ple in Caucasian populations.2–4 Despite years of research, 
FXN gene regulation remains poorly understood, and treat-
ment options for FRDA are limited.
Therapeutics that reactivate frataxin expression are 
expected to be beneficial to FRDA patients.5 The long non-
coding GAA triplet repeats found in intron 1 of the FXN gene 
in FRDA patients impede transcription elongation. Therefore, 
overcoming this blockade and reactivating FXN expression 
is an attractive therapeutic strategy. In addition, approaches 
that enhance transcription rates or increase FXN protein or 
messenger RNA (mRNA) stability could also correct the 
FXN protein deficiency in patients with FRDA.6–8
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Genome-Engineering Tools to Establish 
Accurate Reporter Cell Lines That Enable 
Identification of Therapeutic Strategies to 
Treat Friedreich´s Ataxia
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Abstract
Friedreich’s ataxia is a neurodegenerative disease caused by deficiency of the mitochondrial protein frataxin. This deficiency 
results from expansion of a trinucleotide repeat in the first intron of the frataxin gene. Because this repeat expansion 
resides in an intron and hence does not alter the amino acid sequence of the frataxin protein, gene reactivation could 
be of therapeutic benefit. High-throughput screening for frataxin activators has so far met with limited success because 
current cellular models may not accurately assess endogenous frataxin gene regulation. Here we report the design and 
validation of genome-engineering tools that enable the generation of human cell lines that express the frataxin gene fused 
to a luciferase reporter gene from its endogenous locus. Performing a pilot high-throughput genomic screen in a newly 
established reporter cell line, we uncovered novel negative regulators of frataxin expression. Rational design of small-
molecule inhibitors of the identified frataxin repressors and/or high-throughput screening of large siRNA or compound 
libraries with our system may yield treatments for Friedreich’s ataxia.
Keywords
Friedreich’s ataxia (FRDA), triplet repeat expansion disorder (TRED), frataxin (FXN) gene, high-throughput screening 
(HTS), zinc-finger nuclease, genome engineering, drug discovery, PRKD1, SBF1
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Cell-based assays are essential for the identification of 
druggable regulators of FXN gene expression and low 
molecular weight compounds that alleviate FXN deficiency. 
Previous attempts at developing high-throughput screening 
(HTS)–friendly assays have used artificial intronic sequences 
with extended GAA tracts or cell lines containing FXN reporter 
gene fusions randomly integrated into the genome.9–14 A poten-
tial drawback of these systems is that they do not assess the 
activity of the endogenous FXN gene in the native chromo-
somal context. This may limit the identification of modulators 
of FXN expression, because the endogenous chromatin 
structure and/or nuclear organization of the human genome 
are major determinants of FXN gene activity.15–18 Thus, 
more advanced reporter systems that enable the monitoring 
of gene expression from the endogenous FXN locus are 
desirable.
Here we report the use of genome-engineering tools to 
establish a novel drug discovery system that combines genet-
ically accurate reporter systems and high-throughput biology 
to identify novel therapeutics for Friedreich’s ataxia. We used 
zinc-finger nucleases (ZFNs) to generate a cellular model in 
which a luciferase reporter gene is introduced into the endog-
enous FXN locus. Using this system in a high-throughput 
genomic screen, we discovered novel repressors of FXN 
gene expression. Using our system in future drug discovery 
efforts may finally yield treatments for FRDA.
Materials and Methods
Cell Culture
Dermal fibroblasts from patients affected by FRDA 
(GM04078) were obtained from Coriell Cell Repositories 
(Camden, NJ). GM04078 cells were immortalized by lenti-
viral delivery of BMI1 and hTERT as described previ-
ously,19 resulting in the cell line FRDA-4078iBT. GM04078 
and FRDA-4078iBT were maintained in Eagle’s minimal 
essential medium (Sigma, St. Louis, MO) supplemented 
with 10% non–heat-inactivated fetal bovine serum (FBS; 
Sigma) and 1× L-glutamine (Life Technologies, Carlsbad, 
CA) at 37 °C in 5% CO2. HEK293T cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% heat-inactivated FBS (Sigma), 100 U/
mL−1 penicillin, 100 µg/mL−1 streptomycin, and 1× 
L-glutamine (Life Technologies) at 37 °C in 5% CO2.
Genome Editing
Plasmids encoding FXN-ZFN-L, FXN-ZFN-R, and donor 
constructs (sequences available as supplementary material) 
were cotransfected into HEK293T cells with the polyethyl-
enimine (PEI) transfection method. Briefly, exponentially 
growing cells were trypsinized and seeded in a 10-mm tis-
sue culture dish 1 day before transfection. A solution 
containing 60 µL of 1 mg/mL PEI and 15 µg DNA (two 
ZFN plasmids + donor 1) in a 1:5 molar ratio (ZFNs/donor) 
was prepared in 1 mL of sterile DMEM lacking serum. The 
solution was briefly vortexed and left for 15 min at room 
temperature before pipetting dropwise to adherent HEK293 
cells. Cells were cultured under standard conditions for 2 to 
3 days, followed by culturing the cells in the presence of 
puromycin-containing growth media for 2 weeks. Single 
puromycin-resistant clones were picked and expanded for 
further analysis. Sequences of plasmids used in this study 
are provided as text files.
Luciferase Assays
Luciferase assays were performed with the Promega 
(Madison, WI) Dual-Luciferase Reporter Assay system 
according to the manufacturer’s protocol. Briefly, lysis buf-
fer was added directly to confluent cell monolayers. Culture 
dishes were incubated at 25 °C for 15 min and rocked sev-
eral times to ensure complete lysis. Cell lysates were centri-
fuged at maximum speed in an Eppendorf microcentrifuge 
for 10 min at 4 °C. Luciferase measurements were per-
formed with lysate supernatants in duplicate. All measure-
ments were performed on a Centro LB 960 luminometer 
(Berthold Technologies, Bad Wildbad, Germany). Bradford 
assays were carried out to determine total protein concen-
tration, which was used for normalization.
Real-Time RT-PCR
For quantitative reverse transcriptase PCR (qRT-PCR) 
experiments, total RNA was extracted from GM04078, 
FRDA-4078iBT, and HEK293T-FF2AP cell lines with the 
Absolutely RNA Microprep Kit (Stratagene, La Jolla, CA). 
A 1-µg aliquot of total RNA was reverse transcribed with an 
AffinityScript enzyme (Stratagene) using the oligo(dT) 
primer according to the manufacturer’s instructions. qRT-
PCR was performed on a CFX96 Real-Time PCR System 
(Bio-Rad, Hercules, CA) using the SsoAdvanced SYBR 
Green Supermix (#172-5264; Bio-Rad). Relative RNA lev-
els were calculated from CT values according to the ∆CT 
method and normalized to GAPDH mRNA levels. Primer 
sequences are provided in Supplemental Table S3.
RNA Interference Screen
A synthetic small interfering RNA (siRNA) library target-
ing the druggable genome (4835 genes with 9670 constructs 
or two constructs per gene) was screened in a duplicate 384-
well plate format with two gene-targeting siRNAs per well 
to identify genes that upregulate frataxin-luciferase fusion 
expression. The library was reverse transfected into the 
HEK293T-FF2AP reporter cell line via high-throughput 
transfection20,21 using a fully integrated genomic robotic 
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system (GNF Systems, San Diego, CA). Each plate con-
tained transfection controls targeting cell viability (AllStars 
Cell Death; Qiagen, Valencia, CA), as well as a nontarget-
ing (AllStars Negative Control; Qiagen) and a frataxin-tar-
geting siRNA (Frataxin-12; Qiagen). Data from each plate 
were normalized to the plate mean and processed for fold 
activity. Duplicate readings for each well were geometri-
cally averaged to generate a single activity score. A nonlin-
ear transformation was applied to remove plate variation.22 
Putative hit wells were rescreened as single siRNAs per 
well for validation. In addition to the first-round hit siR-
NAs, all siRNA constructs targeting genes of interest from 
other available libraries (Qiagen; Integrated DNA Technologies, 
Coralville, IA) were included in the validation screen. An 
additional 96 nontargeting controls were spotted into each 
384-well plate of the validation assay (Qiagen). Data analy-
sis included evaluation of individual and multiple-well 
RNA interference (RNAi) activities for each gene 
(Redundant siRNA Activity Analysis).22
Short Hairpin RNA Delivery
Short hairpin RNA (shRNA) constructs were delivered to 
FRDA-4078iBT cells by lentiviral transduction. Lentivirus 
was produced by calcium phosphate transfection of 
HEK293T cells.23 All infections were performed at a multi-
plicity of infection of approximately 30 viral particles per 
cell. Cells were harvested 6 days after transduction for total 
RNA isolation. Lipofection was used to deliver shRNA con-
structs into HEK293T-FF2AP cells; ~200 cells per mm2 
were seeded 1 day before transfection. Cells were trans-
fected with plasmids using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s protocol. 
shRNA sequences are provided in Supplemental Table S3.
Western Blotting
Protein samples were separated on NuPAGE-Novex Bis-Tris 
4% to 12% gradient gels (Invitrogen) in MES buffer at 200 V 
for 40 min. Transfer to Immobilon-P PVDF membrane 
(Millipore, Billerica, MA) was performed at 25 V (constant) 
for 45 min in Towbin transfer buffer with 5% methanol and 
0.05% sodium dodecyl sulfate (SDS). The membranes were 
blocked in 5% nonfat dry milk in tris buffered saline with 
0.1% Tween-20 (TBST) for at least 30 min at room tempera-
ture and subsequently washed once in TBST for 5 to 10 min. 
The membranes were incubated with the anti-FXN antibody 
(1:1000, SKU 456300; Invitrogen) in 5% nonfat dry milk in 
TBST overnight at 4 °C. Membranes were washed in TBST 
and incubated with secondary antibody (anti–mouse horse-
radish peroxidase [HRP], 1:10,000) in 5% nonfat dry milk in 
TBST for 45 to 60 min at room temperature. Blots were devel-
oped with Immobilon Western HRP Substrate (Millipore).
Results and Discussion
We aimed at generating genome-editing tools that will 
enable the FRDA research community to knock in any 
given sequence tag into the FXN locus in different cell 
types. To this end, we chose a ZFN-mediated genome- 
editing approach to tag the 3′ end of the protein-coding 
region of the endogenous FXN gene with a firefly luciferase 
(FL) reporter gene.24,25 To induce a double-strand break 
approximately 1 kb downstream of the 5′ splice site in the 
last intron of the FXN gene, we designed a pair of ZFNs 
that bind to the FXN locus uniquely (Fig. 1A). For homolo-
gous recombination, we created a transgenic donor DNA 
fragment encoding the last FXN exon fused to the open 
reading frame of FL (Fig. 1A). To allow clonal selection 
after targeted insertion, we created donor constructs encod-
ing either puromycin N-acetyl-transferase (Puro) preceded 
by 2A self-cleaving peptide linked to the FXN-FL fusion 
(donor 1) or an autonomous neomycin (Neo) selection cas-
sette (donor 2). The left homology arm of the donor con-
structs was designed to introduce a functional branchpoint 
and 3′ splice sites to favor efficient splicing between exon 4 
and inserted exon 5 (Fig. 1A).
To provide proof of concept that the ZFN approach is 
working and to establish a novel reporter cell line that is 
suitable for high-throughput genomic screening, we used 
the ZFN system to introduce the luciferase reporter gene 
into the FXN locus of human embryonic kidney (HEK) 
293T cells. This cell line was selected because it can be 
expanded to a very large scale at a relatively low cost. As a 
consequence, our FXN reporter system should be compati-
ble with the technical and financial constraints of most aca-
demic and industrial screening platforms. We cotransfected 
human HEK 293T cells with expression plasmids encoding 
the two frataxin-ZFNs (ZFN-L and ZFN-R) and a plasmid 
encoding donor 1 (Fig. 1A), which confers puromycin 
resistance only after correct integration, proper pre-mRNA 
splicing, and translation of the FXN-FL-2A-PURO (FF2AP) 
fusion protein (Fig. 1B). At 2 to 3 weeks posttransfection, 
puromycin-resistant colonies were isolated and subjected to 
Western blot analysis. This revealed specific expression of 
a 75-kDa FXN-FL fusion protein in puromycin-resistant 
cells (hereafter referred to as HEK293T-FF2AP; Fig. 1C). 
We also observed a FXN fusion protein of higher molecular 
weight than the mature FXN-FL fusion protein, demonstrat-
ing efficient cotranslational self-cleavage of the 2A peptide, 
release of the Puro protein, and mitochondrial processing of 
the FXN-FL fusion protein. Importantly, we detected firefly 
luciferase activity in lysates from HEK293T-FF2AP but not 
from parental HEK293T cells (Fig. 1D), an activity that 
could be abrogated upon expression of an shRNA targeting 
exon 2 of the FXN mRNA (Fig. 1E). Thus, we concluded 
that the firefly luciferase activity in HEK293T-FF2AP cells 
came solely from the targeted integration at the FXN locus 
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and, thus, reliably reports expression of the FXN gene from 
its endogenous location.
In contrast to previous work,5 the HEK293T-FF2AP cell 
line allowed us to screen for modulators of FXN expression 
in its natural genomic context and in an HTS format. This 
cell line is easy to transfect and hence well suited for RNAi 
or complementary DNA (cDNA) overexpression screens. 
Therefore, to identify potential repressors of FXN expres-
sion, we performed an RNAi screen targeting 4835 human 
genes in the HEK293T-FF2AP cell line, using luciferase 
signal amplification as the readout (Fig. 2A). Two unique 
siRNAs were assayed in a pooled format (two siRNAs per 
well) at 72 h posttransfection (Fig. 2B). Due to the pooled 
construct format, we chose a baseline of 1.6-fold luciferase 
activation over the mean as a cutoff to capture phenotypes 
generated from wells in which only one siRNA may be 
active. Maximal luciferase expression was 5.1-fold over 
baseline (targeting hypothetical gene 1000292277), with an 
additional five siRNAs scoring between 4- and 5-fold. 
Minimal expressions were obtained with siRNAs targeting 
Qiagen AllStars Cell Death control (0.06-fold) and frataxin 
(0.09-fold), indicating that the siRNA transfection was suc-
cessful and that the relationship between frataxin and lucif-
erase expression was intact. In subsequent validation 
screens, positive hit siRNAs were spotted in an arrayed well 
format of one siRNA per well and screened in duplicate 
under identical conditions. Using the HEK293T-FF2AP cell 
line, we performed a reconfirmation screen of the primary 
screen hits (Fig. 2C). In parallel, we screened positive hit 
siRNAs for non-FXN-specific activators of luciferase activ-
ity with an HEK 293T cell line stably expressing firefly 
luciferase from a cytomegalovirus (CMV) promoter 
(HEK293-pGF1-CMV) (Fig. 2D). This allowed for thor-
ough analysis of independent constructs via redundant 
siRNA analysis (RSA),22 which enriched for genes where 
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Figure 1. Generation of the HEK293T-FF2AP cell line. (A) 
Scheme of the zinc-finger nuclease (ZFN)–mediated genome-
editing strategy to tag the 3c end of the protein-coding region of 
the endogenous frataxin (FXN) gene with a firefly luciferase (FL) 
reporter gene. Each frataxin-ZFN contains the cleavage domain 
of FokI linked to an array of five zinc fingers that have been 
designed to specifically recognize sequences (black uppercase 
letters) flanking the cleavage site (red letters) in intron 4 of the 
FXN gene. The double-strand break induced by the frataxin-ZFN 
pair permits site-specific integration of a transgenic donor DNA 
fragment (donor 1 or 2) encoding the last FXN exon fused to 
the open reading frame of firefly luciferase (Vc-firefly luciferase). 
Both donor constructs are flanked by regions homologous to 
the insertion site (orange) to enable homology-directed repair. 
To ensure correct splicing of the FXN messenger RNA (mRNA) 
after successful genome editing, the left homology arms were 
designed to introduce functional branchpoint and 3c splice sites 
(—a—ag). Donor 1 encodes puromycin N-acetyl-transferase 
(Puro) preceded by a 2A self-cleaving peptide linked to the 
Vc-firefly luciferase fusion. Using donor 1, puromycin resistance is 
expected only after correct integration into the FXN locus and 
transcription thereof. Donor 2 contains an autonomous neomycin 
(Neo) selection cassette driven by a SV40 promoter. This makes 
neomycin resistance independent of the transcriptional status 
of the FXN locus but might increase the rate of false-positive 
integration events. The location of the GAA triplet repeat is 
indicated by a black arrowhead. pA, cleavage and polyadenylation 
site. (B) Schematic representation of the FXN locus after 
successful genomic insertion of donor 1. Cotranslational self-
cleavage of the 2A peptide sequence releases the FXN-FL fusion 
protein and the puromycin N-acetyl-transferase, which confers 
resistance against puromycin. (C) Western blot showing specific 
expression of the FXN-FL fusion protein (~75 kDa) in HEK293T-
FF2AP cells. The blot was probed with an antibody recognizing 
FXN. Intermediate (i) and mature (m) forms of FXN-FL and 
endogenous FXN protein expressed from nontagged alleles are 
indicated. (D) Firefly luciferase activity assayed from nontargeted 
HEK293T and HEK293T-FF2AP cells. RLU, relative light units. 
(E) RNA interference (RNAi) experiment demonstrating that 
firefly luciferase activity reliably reflects FXN expression in 
HEK293T-FF2AP cells. Cells were transfected with a nontargeting 
short hairpin RNA (shRNA) (shRenilla) and shRNAs targeting 
either FXN or firefly mRNA (red bars). Firefly luciferase signals 
were normalized to total protein and shown relative to the 
nontargeting control. Error bars represent the standard deviation.
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Figure 2. Small interfering RNA (siRNA) screen with the HEK293T-FF2AP cell line uncovers novel negative regulators of frataxin 
(FXN) expression. (A) Scheme of the workflow of the RNA interference (RNAi) screen. For details, see Materials and Methods. 
(B) Primary high-throughput screening (HTS) of the Qiagen (Valencia, CA) V1 Druggome siRNA library was performed in duplicate. 
Screening data are represented as fold activation in a scatterplot of one set of normalized plates (data, blue squares). Each plate 
contains the same control wells (cell death control siRNAs, antifrataxin siRNAs, nontargeting control siRNAs, and empty wells).  
(C) A reconfirmation screen of the top 87 hits from the primary screen, including additional targeting as well as nontargeting control 
siRNAs, was run in duplicate. Results are plotted as normalized replicate values. Activators are at or near the top of the diagonal, 
while inhibitors such as antifrataxin, antiluciferase, and the cell death siRNA controls are found at the bottom of the diagonal. 
Reproducibility can be evaluated on the same plot by identifying data points and their position compared with the diagonal. Those 
points off to the left or bottom from the diagonal indicate disparate values between the replicates. A ranked list of hits after redundant 
siRNA analysis (RSA) is provided in Supplemental Table S1. Individual siRNAs targeting the genes PRKD1 and SBF1, which rank 
as number 1 and 3 after RSA analysis, respectively, are indicated. (D) Filter screen for nonspecific activators of luciferase activity. 
An HEK293T cell line stably expressing luciferase from a cytomegalovirus (CMV) promoter (HEK293-pGF1-CMV) was transfected 
in duplicate with siRNAs covering the top 87 hits from the primary screen. Results were normalized to the plate median and then 
subjected to RSA analysis. A ranked list of hits after RSA is provided in Supplemental Table S2. LogP values for genes from the 
CMV luciferase cell line were plotted against LogP values for the same genes from the HEK293T-FF2AP reporter line to identify 
outliers (the lower the negative score, the more confidence there is in the gene being associated with the observed phenotype). 
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two or more independent siRNAs elevated the FXN-
luciferase protein levels specifically (Fig. 3A). Complete 
ranked lists of hits after RSA are provided in the supple-
mental material (Suppl. Tables S1 and S2).
The FXN alleles in the HEK293T-FF2AP cell line used in 
our primary RNAi screen do not contain pathogenic GAA 
triplet repeat expansions. The main reason why we designed 
our screening cell line that way was because high-throughput 
biology requires large amounts of cells, and FXN deficiency 
could prevent cell expansion. Moreover, the readily available 
FRDA patient-derived B lymphoblasts turned out to be diffi-
cult to use for genome engineering and are not really well 
suited for high-throughput RNAi screening approaches. We 
also encountered poor cutting efficiency/homologous recom-
bination in immortalized FRDA patient-derived fibroblasts 
that we have generated (FRDA-4078iBT), preventing us 
from establishing a luciferase reporter cell line that would 
allow direct monitoring of FXN expression from an expanded 
GAA allele. Therefore, we performed secondary hit valida-
tion experiments in the FRDA-4078iBT fibroblasts by quan-
titative real-time RT-PCR to determine whether our primary 
hits could increase FXN gene expression also in cells that 
contain an expanded repeat tract. Expression analysis 
revealed that four of the top five candidate genes (Fig. 3A) 
are also expressed in FRDA fibroblasts (PRKD1, CDK12, 
SBF1, and CDK13) (data not shown). To knock down these 
genes, we designed lentiviral shRNA constructs and deliv-
ered them into fibroblasts by lentiviral transduction. mRNA 
levels of all expressed candidate genes were reduced signifi-
cantly upon shRNA expression (Fig. 3B,C and data not 
shown). Depletion of the cell cycle–related kinases CDK12 
and CDK13 resulted in strong proliferation defects and were 
omitted from further analysis (data not shown). Even though 
knockdown efficiencies for PRKD1 or SBF1 were never 
higher than 60%, we consistently observed a significant 
increase in FXN mRNA levels (Fig. 2B,C). These results 
confirmed that reducing the levels of the serine/threonine-
protein kinase PRKD1 or the putative pseudophosphatase 
SBF1 results in increased FXN expression even in the pres-
ence of an expanded repeat tract. Thus, monitoring gene 
expression from the endogenous FXN locus irrespective of 
expanded GAA repeats opens up new opportunities for target 
discovery and the dissection of molecular pathways involved 
in FRDA. We note that the roughly 1.5-fold increase in FXN 
mRNA levels after PRKD1 or SBF1 knockdown is quite 
modest and was hence not reliably detectable by Western 
blot. This demonstrates the enormous power of using the 
highly sensitive luciferase approach to monitor changes in 
FXN expression but also urges us to expand our screens to 
genome-wide siRNA libraries to identify hits that lead to 
more drastic changes in FXN expression.
In recent years, a significant body of literature has pro-
posed that genome-engineering technologies and high-
throughput biology each have the potential to revolutionize 
biomedicine and pharmaceutical pipelines. This study 
establishes that these emerging biotechnologies can be 
effectively combined to perform as proposed, exemplifying 
a new paradigm for drug discovery. The HEK293T-FF2AP 
cell line established in this study is the first luciferase 
reporter–based cellular model, which allows an accurate 
and effortless assessment of endogenous frataxin gene reg-
ulation and is compatible with high-throughput biology. 
HEK293T-FF2AP cells are easy to transfect and can be 
expanded to a very large scale at a relatively low cost. Thus, 
this system should be compatible with the technical and 
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Figure 3. Validation of top five genes in Friedreich’s ataxia 
(FRDA) patient-derived fibroblasts. (A) List of top five genes 
obtained after reconfirmation screens and redundant small 
interfering RNA analysis (RSA) analysis. RSA ranking in 
cytomegalovirus (CMV)–luc and frataxin (FXN)–luc screens 
is shown. Genes marked in bold are expressed in FRDA 
patient-derived fibroblasts and lymphoblasts (data not shown). 
The complete lists are available as supplementary tables. 
(B) Short hairpin RNA (shRNA)–mediated knockdown of 
PRKD1 messenger RNA (mRNA) in FRDA patient-derived 
fibroblasts (4078iBT cells). Fibroblasts were transduced with a 
lentiviral vector encoding an shRNA targeting PRKD1 mRNA. 
PRKD1 (left panel) and FXN (right panel) mRNA levels were 
determined by quantitative real-time reverse transcriptase PCR 
(RT-PCR). PRKD1 and FXN mRNA levels are shown relative 
to the nonsilencing shRNA control. Mean values normalized to 
GAPDH are shown (n = 4 different transduction experiments). 
Error bars represent SEM. (C) shRNA-mediated knockdown of 
SBF1 mRNA in FRDA patient-derived fibroblasts (4078iBT cells). 
Fibroblasts were transduced with a lentiviral vector encoding an 
shRNA targeting SBF1 mRNA. SBF1 (left panel) and FXN (right 
panel) mRNA levels were determined by quantitative real-time 
RT-PCR. SBF1 and FXN mRNA levels are shown relative to 
the nonsilencing shRNA control. Mean values normalized to 
GAPDH are shown (n = 5 different transduction experiments). 
Error bars represent SEM.
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financial constraints of most academic and industrial 
screening platforms.
Using the HEK293T-FF2AP cell line in a pilot high-
throughput genomic screen, we uncovered novel negative 
regulators of FXN expression, demonstrating the impor-
tance of monitoring gene expression from the endogenous 
FXN locus. Our results showing that FXN expression can 
be increased even in the presence of an expanded repeat 
tract also demonstrate that screening for general regulators 
of FXN transcription, irrespective of GAA repeat length, is 
an appropriate strategy. Thus, our approach opens up new 
opportunities for target discovery, and we anticipate that 
HTS of genome-wide siRNA libraries will reveal additional 
potential drug targets in the near future.
Finally, the genome-engineering tools designed in this 
study will serve as a powerful resource to the FRDA com-
munity. The ZNFs and donor constructs developed in this 
study will enable others to knock in any given sequence tag 
into the FXN locus in many different cell types, facilitating 
the dissection of molecular pathways involved in FRDA. 
Notably, our donor constructs can also be used in combina-
tion with the more recently introduced CRISPR/Cas9 tech-
nology, which may work more effectively in patient-derived 
cell lines than the ZNFs that we have used in this study.
In conclusion, we have developed new tools that will 
serve the FRDA research community as a valuable resource 
for future mechanistic studies and the identification of new 
therapeutic strategies for a so far untreatable disease.
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"#$%&'5 5,,(+-,* %.'(7550+ 1$99,( (45/70-*7(5 6(4),(+5*57 (-7 (/
"#$%&', 5,,(+-,* %.'(7550+ 1$99,( /4+7*+5(*/7 6(4),(+5*57 5,+ (/
"#$%&') 5,,(+-,* %.'(7550+ 1$99,( /4+)-75)(+( 6(4),(+5*57 5-- (/
"#$%&'- 5,,(+-,* %.'(7550+ 1$99,( /4+),70,5), 6(4),(+5*57 5-7 (/
"#$%&'( *,,+0,50 %.'//*(70 <B(*: (40(++)/)7 6(45,,/*--(, )/ ((
"#$%&'* *,,+0,50 %.'//*(70 <B(*: (45**070*,* 6(45,,/*--(, ()0 ((
"#$%&'5 *,,+0,50 %.'//*(70 <B(*: (4*-,*(7*+* 6(45,,/*--(, (7- ((
"#$%&', *,,+0,50 %.'//*(70 <B(*: (4*50,+(0() 6(45,,/*--(, */- ((
"#$%&') *,,+0,50 %.'//*(70 <B(*: (4/+(+-)+0+ 6(45,,/*--(, *70 ((
"#$%&'- *,,+0,50 %.'//*(70 <B(*: (4/,5)/0+,* 6(45,,/*--(, 5(5 ((
"#$%&'0 *,,+0,50 %.'//*(70 <B(*: /4-)-(/7),7 6(45,,/*--(, )(5 ((
"#$%&'( (5,*,,)7, %.'//,77, 1C%8 (470)0+--) 6(4*7+00,(5* 5/ (*
"#$%&'* (5,*,,)7, %.'//,77, 1C%8 (40)-*0*5-7 6(4*7+00,(5* ,- (*
"#$%&'5 (5,*,,)7, %.'//,77, 1C%8 (45(/7()+)- 6(4*7+00,(5* (-0 (*
"#$%&', (5,*,,)7, %.'//,77, 1C%8 /4)00)**+0* 6(4*7+00,(5* ))( (*
"#$%&') **((5-7*, %.'//-57) D%;*(( *4),()*,,5) 6(4*)*+,5(,7 - (5
"#$%&'- **((5-7*, %.'//-57) D%;*(( (47)-555+++ 6(4*)*+,5(,7 5( (5
"#$%&'0 **((5-7*, %.'//-57) D%;*(( (4*-0/)/*,- 6(4*)*+,5(,7 (7, (5
"#$%&'7 **((5-7*, %.'//-57) D%;*(( (4(0))-7/0) 6(4*)*+,5(,7 *5) (5
"#$%&'+ **((5-7*, %.'//-57) D%;*(( /4)/))7,+*) 6(4*)*+,5(,7 )7) (5
"#$%&'( (,775+50) %.'(57,++ 1>>1*: (4)-+5(7+-7 6(4()70-0*(7 7* (,
"#$%&'* (,775+50) %.'(57,++ 1>>1*: (455(-(0)) 6(4()70-0*(7 (), (,
"#$%&'5 (,775+50) %.'(57,++ 1>>1*: (4(+,)7+(*0 6(4()70-0*(7 *** (,
"#$%&', (,775+50) %.'(57,++ 1>>1*: /4++77,(/07 6(4()70-0*(7 5,( (,
"#$%&') */+)0,5** %.'///-(, 8%@; (4-*//0(50, 6(4(,5,757-) -) ()
"#$%&'- */+)0,5** %.'///-(, 8%@; (4,,/0,/0( 6(4(,5,757-) ((0 ()
"#$%&'0 */+)0,5** %.'///-(, 8%@; (4(7775-7* 6(4(,5,757-) **- ()
"#$%&'7 */+)0,5** %.'///-(, 8%@; /4++*0/7)0- 6(4(,5,757-) 5,, ()
"#$%&'( 575*0-5+ %.'//(55, 8@9= (45*/0()-)0 6(4(5)75075* (-/ (-
"#$%&'* 575*0-5+ %.'//(55, 8@9= (4*++(0*07* 6(4(5)75075* (0, (-
"#$%&'5 575*0-5+ %.'//(55, 8@9= (4(0,0+-,*) 6(4(5)75075* *50 (-
"#$%&', 575*0-5+ %.'//(55, 8@9= (4(-7+7**-7 6(4(5)75075* *,5 (-
"#$%&') 575*0-5+ %.'//(55, 8@9= (4/-(777,+ 6(4(5)75075* 5/5 (-
"#$%&'- 575*0-5+ %.'//(55, 8@9= /4)5*+7(7*5 6(4(5)75075* )0* (-
"#$%&'( *5)(/*77 %.'()*57- 9E11* (4+-))(/77* 6(4(555-+()- *- (0
"#$%&'* *5)(/*77 %.'()*57- 9E11* (4+)0/7*-7- 6(4(555-+()- *0 (0
"#$%&'5 *5)(/*77 %.'()*57- 9E11* (4/7/+*(5-, 6(4(555-+()- *+5 (0
"#$%&', *5)(/*77 %.'()*57- 9E11* /4+7+*7*/-+ 6(4(555-+()- 5,- (0
"#$%&') 5//(+5/5/ %.'//57(/ @%;9;(/ (4-05/07)*+ 6(4/)))0*5*+ )0 (7
"#$%&'- 5//(+5/5/ %.'//57(/ @%;9;(/ (4)705*7,(5 6(4/)))0*5*+ 0) (7
"#$%&'0 5//(+5/5/ %.'//57(/ @%;9;(/ (4)*75+70 6(4/)))0*5*+ +5 (7
"#$%&'7 5//(+5/5/ %.'//57(/ @%;9;(/ (4/(*)/,55( 6(4/)))0*5*+ 5*+ (7
"#$%&'+ 5//(+5/5/ %.'//57(/ @%;9;(/ /470+**+*)5 6(4/)))0*5*+ ,/( (7
"#$%&'(/ 5//(+5/5/ %.'//57(/ @%;9;(/ /407-0/*5(5 6(4/)))0*5*+ ,,5 (7
"#$%&'( -*,*/77) %.'//(/(,0+- 33$* (47(-))/(/0 6(4/),77/50) 5) (+
"#$%&'* -*,*/77) %.'//(/(,0+- 33$* (4*)+((05+( 6(4/),77/50) (+/ (+
"#$%&'5 -*,*/77) %.'//(/(,0+- 33$* (4(*5)()*0, 6(4/),77/50) *-0 (+
"#$%&', -*,*/77) %.'//(/(,0+- 33$* (4/)-5/*(5 6(4/),77/50) 5/, (+
"#$%&') -*,*/77) %.'//(/(,0+- 33$* (4/(0+)(/*+ 6(4/),77/50) 5*, (+
"#$%&'- -*,*/77) %.'//(/(,0+- 33$* /4+))()7/7+ 6(4/),77/50) 5-0 (+
"#$%&'0 -*,*/77) %.'//(/(,0+- 33$* /470/(*0(-( 6(4/),77/50) ,/, (+
"#$%&'7 -*,*/77) %.'//(/(,0+- 33$* /47,+,(),,0 6(4/),77/50) ,(* (+
"#$%&'+ -*,*/77) %.'//(/(,0+- 33$* /40+-77+,,- 6(4/),77/50) ,5- (+
"#$%&'(/ -*,*/77) %.'//(/(,0+- 33$* /4-5+0,/0(( 6(4/),77/50) )*( (+
"#$%&'( (),0)+*,- %.'(++/,- @F11 (4)0,))55*0 6(4/)/-,75/+ 0+ */
"#$%&'* (),0)+*,- %.'(++/,- @F11 (4*,755)-)0 6(4/)/-,75/+ (+) */
"#$%&'5 (),0)+*,- %.'(++/,- @F11 (4*5+*-/50( 6(4/)/-,75/+ */, */
"#$%&', (),0)+*,- %.'(++/,- @F11 /4)75-557-, 6(4/)/-,75/+ ))/ */
"#$%&'( ()0*--555 %.'//55** @CB1( (47,7(+*+,5 6/4++)(555,0 5* *(
"#$%&'* ()0*--555 %.'//55** @CB1( (4)/,+0((-5 6/4++)(555,0 ++ *(
"#$%&'5 ()0*--555 %.'//55** @CB1( (4,5)7)5/0- 6/4++)(555,0 (*/ *(
"#$%&', ()0*--555 %.'//55** @CB1( /4+)07,,,)0 6/4++)(555,0 5-) *(
"#$%&') ()0*--555 %.'//55** @CB1( /475(,-)-,) 6/4++)(555,0 ,*/ *(
"#$%&'( *7+),0-** %.'/(,)-) =$(&( (4557+*(*-* 6/4+0,/,5*+* ()* **
"#$%&'* *7+),0-** %.'/(,)-) =$(&( (45(*5*+,57 6/4+0,/,5*+* (-- **
"#$%&'5 *7+),0-** %.'/(,)-) =$(&( (4(/,/(,/+5 6/4+0,/,5*+* *7/ **
"#$%&', *7+),0-** %.'/(,)-) =$(&( (4/**05,-*+ 6/4+0,/,5*+* 5*/ **
"#$%&') *7+),0-** %.'/(,)-) =$(&( /475-),+-7 6/4+0,/,5*+* ,(0 **
"#$%&'- *7+),0-** %.'/(,)-) =$(&( /40)*750)00 6/4+0,/,5*+* ,)0 **
"#$%&'( ))0)//5/ %.'/(,070 3%&G8- *4*-755-/7, 6/4+)+/+*-** (* *5
"#$%&'* ))0)//5/ %.'/(,070 3%&G8- (4+0,,*+700 6/4+)+/+*-** *) *5
"#$%&'5 ))0)//5/ %.'/(,070 3%&G8- (45+7+-0))0 6/4+)+/+*-** (5( *5
"#$%&', ))0)//5/ %.'/(,070 3%&G8- (4(77---77, 6/4+)+/+*-** **7 *5
"#$%&') ))0)//5/ %.'/(,070 3%&G8- /4-*++)(*++ 6/4+)+/+*-** )*7 *5
"#$%&'- ))0)//5/ %.'/(,070 3%&G8- /4,+-00-7)( 6/4+)+/+*-** )+5 *5
"#$%&'( )(0/**,( %.'//(//,/*5 3H$25 (40/+,,,7/, 6/4+5/),0*/7 )5 *,
"#$%&'* )(0/**,( %.'//(//,/*5 3H$25 (4)//-*+,0) 6/4+5/),0*/7 (/, *,
"#$%&'5 )(0/**,( %.'//(//,/*5 3H$25 (45/(,+)++0 6/4+5/),0*/7 (05 *,
"#$%&', )(0/**,( %.'//(//,/*5 3H$25 (4(-7/--)7+ 6/4+5/),0*/7 *,, *,
"#$%&') )(0/**,( %.'//(//,/*5 3H$25 (4/(0-),5)- 6/4+5/),0*/7 5*) *,
"#$%&'- )(0/**,( %.'//(//,/*5 3H$25 /4+0+)0-+7) 6/4+5/),0*/7 5)* *,
"#$%&'0 )(0/**,( %.'//(//,/*5 3H$25 /4+*/+,5-/5 6/4+5/),0*/7 507 *,
"#$%&'7 )(0/**,( %.'//(//,/*5 3H$25 /4+(+)7,+- 6/4+5/),0*/7 50+ *,
"#$%&'+ )(0/**,( %.'//(//,/*5 3H$25 /4-*-),05/+ 6/4+5/),0*/7 )5* *,
"#$%&'(/ )(0/**,( %.'//(//,/*5 3H$25 /4-**0(,7() 6/4+5/),0*/7 )5- *,
"#$%&'( +5//,/7/ %.'//--** 1B2* (40))7/0,+0 6/4+(/75)7-- ,0 *)
"#$%&'* +5//,/7/ %.'//--** 1B2* (4-0/0(++)+ 6/4+(/75)7-- )7 *)
"#$%&'5 +5//,/7/ %.'//--** 1B2* (4,((00055+ 6/4+(/75)7-- (*0 *)
"#$%&', +5//,/7/ %.'//--** 1B2* (4(+*+,7(05 6/4+(/75)7-- **) *)
"#$%&') +5//,/7/ %.'//--** 1B2* (4(5(7,755) 6/4+(/75)7-- *-( *)
"#$%&'- +5//,/7/ %.'//--** 1B2* (4(/-*0/,07 6/4+(/75)7-- *0+ *)
"#$%&'0 +5//,/7/ %.'//--** 1B2* /40(,))0,0 6/4+(/75)7-- ,75 *)
"#$%&'7 +5//,/7/ %.'//--** 1B2* /4)*()*/*0) 6/4+(/75)7-- )07 *)
"#$%&'+ +5//,/7/ %.'//--** 1B2* /4)/5-+5*0* 6/4+(/75)7-- )+/ *)
"#$%&'( )(,-,++/ A.'*+((,( .&9@, (4)-()//(,+ 6/4+/+7,-+5( 7) *-
"#$%&'* )(,-,++/ A.'*+((,( .&9@, (4,)-+0()77 6/4+/+7,-+5( ((, *-
"#$%&'5 )(,-,++/ A.'*+((,( .&9@, (45,+700/7) 6/4+/+7,-+5( (,7 *-
"#$%&', )(,-,++/ A.'*+((,( .&9@, (4*,((7-0*- 6/4+/+7,-+5( */* *-
"#$%&') )(,-,++/ A.'*+((,( .&9@, (4()/,0++7) 6/4+/+7,-+5( *), *-
"#$%&'- )(,-,++/ A.'*+((,( .&9@, (4/,,/-+07) 6/4+/+7,-+5( 5(* *-
"#$%&'0 )(,-,++/ A.'*+((,( .&9@, /4+/0()0*07 6/4+/+7,-+5( 577 *-
"#$%&'7 )(,-,++/ A.'*+((,( .&9@, /47)(((0+/* 6/4+/+7,-+5( ,/+ *-
"#$%&'+ )(,-,++/ A.'*+((,( .&9@, /40-,0,+*0+ 6/4+/+7,-+5( ,)5 *-
"#$%&'(/ )(,-,++/ A.'*+((,( .&9@, /4-/,(,*)-) 6/4+/+7,-+5( ),/ *-
"#$%&'( ,),5+5-5 %.'//,,57 F1?&, *4(*,5/,5)5 6/477))(/)(7 (7 *0
"#$%&'* ,),5+5-5 %.'//,,57 F1?&, (4)-7,0+(*) 6/477))(/)(7 75 *0
"#$%&'5 ,),5+5-5 %.'//,,57 F1?&, (45-+-0(*) 6/477))(/)(7 (,* *0
"#$%&', ,),5+5-5 %.'//,,57 F1?&, (4*))(,)0** 6/477))(/)(7 (+( *0
"#$%&') ,),5+5-5 %.'//,,57 F1?&, (4(7/0++-/( 6/477))(/)(7 *5* *0
"#$%&'- ,),5+5-5 %.'//,,57 F1?&, (4(,/7-+-(0 6/477))(/)(7 *)7 *0
"#$%&'0 ,),5+5-5 %.'//,,57 F1?&, (4/,(+75,+ 6/477))(/)(7 5(, *0
"#$%&'7 ,),5+5-5 %.'//,,57 F1?&, /4)0/,*,)(7 6/477))(/)(7 ))5 *0
"#$%&'+ ,),5+5-5 %.'//,,57 F1?&, /4)/50,(+*, 6/477))(/)(7 )7+ *0
"#$%&'(/ ,),5+5-5 %.'//,,57 F1?&, /4,/+(575*, 6/477))(/)(7 -5, *0
"#$%&'( 70/7/7(* %.'()**0( B=%$;( *4+7,,/+07( 6/4775(+55/+ 5 *7
"#$%&'* 70/7/7(* %.'()**0( B=%$;( (4-/*770+(* 6/4775(+55/+ 0* *7
"#$%&'5 70/7/7(* %.'()**0( B=%$;( /4-0(+0/((7 6/4775(+55/+ )/) *7
"#$%&', 70/7/7(* %.'()**0( B=%$;( /4--/5*(*,* 6/4775(+55/+ )(( *7
"#$%&') 70/7/7(* %.'()**0( B=%$;( /4,*,*7-+/- 6/4775(+55/+ -*- *7
"#$%&'- 70/7/7(* %.'()**0( B=%$;( /450(*/7-(7 6/4775(+55/+ -,, *7
"#$%&'( -*+)5(57 %.'/*/+-0 %8=&) *4,(0/),,-+ 6/477/,(/,,0 0 *+
"#$%&'* -*+)5(57 %.'/*/+-0 %8=&) (4))+)(5- 6/477/,(/,,0 7- *+
"#$%&'5 -*+)5(57 %.'/*/+-0 %8=&) (4,50*(770) 6/477/,(/,,0 ((+ *+
"#$%&', -*+)5(57 %.'/*/+-0 %8=&) /477**0,5,* 6/477/,(/,,0 ,// *+
"#$%&'( )(,-7-5, A.'*/7),) :.1$(& (4)-*-/,0(- 6/475+57+)+5 7, 5/
"#$%&'* )(,-7-5, A.'*/7),) :.1$(& (450)5-0/7) 6/475+57+)+5 (50 5/
"#$%&'5 )(,-7-5, A.'*/7),) :.1$(& (45(*77(,*) 6/475+57+)+5 (-, 5/
"#$%&', )(,-7-5, A.'*/7),) :.1$(& (4*-77(+0)5 6/475+57+)+5 (75 5/
"#$%&') )(,-7-5, A.'*/7),) :.1$(& /4+5(,+77-7 6/475+57+)+5 50* 5/
"#$%&'- )(,-7-5, A.'*/7),) :.1$(& /470***0-() 6/475+57+)+5 ,/5 5/
"#$%&'0 )(,-7-5, A.'*/7),) :.1$(& /47,*//),/7 6/475+57+)+5 ,() 5/
"#$%&'7 )(,-7-5, A.'*/7),) :.1$(& /407+75*7 6/475+57+)+5 ,,/ 5/
"#$%&'+ )(,-7-5, A.'*/7),) :.1$(& /40,,7+/-/0 6/475+57+)+5 ,-5 5/
"#$%&'(/ )(,-7-5, A.'*/7),) :.1$(& /4,5**5+*0, 6/475+57+)+5 -*( 5/
"#$%&'( 5,),,(0), %.'//,-5) .&12&125 (4-*5)+5-0* 6/47*))+*(0, -, 5(
"#$%&'* 5,),,(0), %.'//,-5) .&12&125 (4)/(/+7),, 6/47*))+*(0, (/* 5(
"#$%&'5 5,),,(0), %.'//,-5) .&12&125 (4,()00(+-* 6/47*))+*(0, (*, 5(
"#$%&', 5,),,(0), %.'//,-5) .&12&125 (4(0+*//()* 6/47*))+*(0, *5, 5(
"#$%&') 5,),,(0), %.'//,-5) .&12&125 (4/*/55+()( 6/47*))+*(0, 5*( 5(
"#$%&'- 5,),,(0), %.'//,-5) .&12&125 /47((77-)/* 6/47*))+*(0, ,*7 5(
"#$%&'0 5,),,(0), %.'//,-5) .&12&125 /40+0,*7-5 6/47*))+*(0, ,5) 5(
"#$%&'7 5,),,(0), %.'//,-5) .&12&125 /40-05+5-*( 6/47*))+*(0, ,,+ 5(
"#$%&'+ 5,),,(0), %.'//,-5) .&12&125 /40,/*))*0) 6/47*))+*(0, ,-) 5(
"#$%&'(/ 5,),,(0), %.'//,-5) .&12&125 /4,*(50*5,5 6/47*))+*(0, -*7 5(
"#$%&'( ((,)*/-(, %.'//(+), 33$( (4,-/-,*+*7 6/40++-*(+-0 ((* 5*
"#$%&'* ((,)*/-(, %.'//(+), 33$( (4,/75/)55 6/40++-*(+-0 (*+ 5*
"#$%&'5 ((,)*/-(, %.'//(+), 33$( (4/,/(,,*+- 6/40++-*(+-0 5() 5*
"#$%&', ((,)*/-(, %.'//(+), 33$( (4/5)/+/5(5 6/40++-*(+-0 5(0 5*
"#$%&') ((,)*/-(, %.'//(+), 33$( /4+7)++),- 6/40++-*(+-0 5,0 5*
"#$%&'- ((,)*/-(, %.'//(+), 33$( /4+0//,)070 6/40++-*(+-0 5)7 5*
"#$%&'0 ((,)*/-(, %.'//(+), 33$( /4+(7,*7)** 6/40++-*(+-0 57/ 5*
"#$%&'7 ((,)*/-(, %.'//(+), 33$( /47+5/)+7-( 6/40++-*(+-0 5+) 5*
"#$%&'+ ((,)*/-(, %.'//(+), 33$( /4)+/-()/*, 6/40++-*(+-0 ),- 5*
"#$%&'(/ ((,)*/-(, %.'//(+), 33$( /4*750-)-0 6/40++-*(+-0 -)+ 5*
"#$%&'( (//+(5(+) %.'()*+++ 9@F&1* (4()775(, 6/4070**5,5( *,+ 55
"#$%&'* (//+(5(+) %.'()*+++ 9@F&1* (4/+/)/-,), 6/4070**5,5( *77 55
"#$%&'5 (//+(5(+) %.'()*+++ 9@F&1* (4/0)(/-/7* 6/4070**5,5( *+7 55
"#$%&', (//+(5(+) %.'()*+++ 9@F&1* /47(()(*)77 6/4070**5,5( ,*+ 55
"#$%&') (//+(5(+) %.'()*+++ 9@F&1* /40,--7)5+) 6/4070**5,5( ,-* 55
"#$%&'( ((/5,+0+7 %.'//0(0/ @F92* (4)(,+*75*5 6/4007/-))) +0 5,
"#$%&'* ((/5,+0+7 %.'//0(0/ @F92* (4505/7)(,7 6/4007/-))) (57 5,
"#$%&'5 ((/5,+0+7 %.'//0(0/ @F92* (455)/,,7*- 6/4007/-))) ()5 5,
"#$%&', ((/5,+0+7 %.'//0(0/ @F92* (4*//*,7077 6/4007/-))) **/ 5,
"#$%&') ((/5,+0+7 %.'//0(0/ @F92* (4/0)*,,)-) 6/4007/-))) *+0 5,
"#$%&'- ((/5,+0+7 %.'//0(0/ @F92* /4++(5)(+0) 6/4007/-))) 5,) 5,
"#$%&'0 ((/5,+0+7 %.'//0(0/ @F92* /47-(57*()7 6/4007/-))) ,/0 5,
"#$%&'7 ((/5,+0+7 %.'//0(0/ @F92* /47(+()5*(- 6/4007/-))) ,*) 5,
"#$%&'+ ((/5,+0+7 %.'//0(0/ @F92* /405*(+0)(( 6/4007/-))) ,0* 5,
"#$%&'(/ ((/5,+0+7 %.'//0(0/ @F92* /4)/*,(,/-) 6/4007/-))) )+( 5,
"#$%&'( 5/(55-(,+ %.'//(/-) @%;$9;(& (45+05,07), 6/400/(/*7(+ (5* 5)
"#$%&'* 5/(55-(,+ %.'//(/-) @%;$9;(& (4(70(*+,-7 6/400/(/*7(+ **+ 5)
"#$%&'5 5/(55-(,+ %.'//(/-) @%;$9;(& (4()5(//707 6/400/(/*7(+ *)5 5)
"#$%&', 5/(55-(,+ %.'//(/-) @%;$9;(& /477-/(5,00 6/400/(/*7(+ 5++ 5)
"#$%&') 5/(55-(,+ %.'//(/-) @%;$9;(& /47/+5,)(+, 6/400/(/*7(+ ,5/ 5)
"#$%&'- 5/(55-(,+ %.'//(/-) @%;$9;(& /4-+7/)//+) 6/400/(/*7(+ ,+, 5)
"#$%&'( ,0/07*5, %.'//(,+) E;$&* (4),0)00--+ 6/40-0+,*5++ 7+ 5-
"#$%&'* ,0/07*5, %.'//(,+) E;$&* (450*5*-((( 6/40-0+,*5++ (5+ 5-
"#$%&'5 ,0/07*5, %.'//(,+) E;$&* (4(,-+5+07+ 6/40-0+,*5++ *)- 5-
"#$%&', ,0/07*5, %.'//(,+) E;$&* (4((0))7/7) 6/40-0+,*5++ *-7 5-
"#$%&') ,0/07*5, %.'//(,+) E;$&* /4+)/0)(+,+ 6/40-0+,*5++ 5-+ 5-
"#$%&'- ,0/07*5, %.'//(,+) E;$&* /4)/)7*,0+5 6/40-0+,*5++ )7, 5-
"#$%&'( +7+7-,,+ %.'/**/,7 89%2(E( /4+7))-5-*- 6/40),(-)+(* 5,7 50
"#$%&'* +7+7-,,+ %.'/**/,7 89%2(E( /47)(5,///7 6/40),(-)+(* ,/7 50
"#$%&'5 +7+7-,,+ %.'/**/,7 89%2(E( /475--(0((- 6/40),(-)+(* ,(- 50
"#$%&', +7+7-,,+ %.'/**/,7 89%2(E( /40+)),()* 6/40),(-)+(* ,57 50
"#$%&') +7+7-,,+ %.'/**/,7 89%2(E( /4057*0**0, 6/40),(-)+(* ,-- 50
"#$%&'- +7+7-,,+ %.'/**/,7 89%2(E( /4--055+7)+ 6/40),(-)+(* )/0 50
"#$%&'0 +7+7-,,+ %.'/**/,7 89%2(E( /4-,,/(-,,+ 6/40),(-)+(* )(7 50
"#$%&'( -(0,,,,5 %.'/)*7,( @9925 (4)7-)*/+/0 6/40,-))+*, 0- 57
"#$%&'* -(0,,,,5 %.'/)*7,( @9925 (4*0**/-+,, 6/40,-))+*, (7* 57
"#$%&'5 -(0,,,,5 %.'/)*7,( @9925 (4*)/**-((7 6/40,-))+*, (+, 57
"#$%&', -(0,,,,5 %.'/)*7,( @9925 (4(-,/))/0) 6/40,-))+*, *,0 57
"#$%&') -(0,,,,5 %.'/)*7,( @9925 (4/,)0,/*)- 6/40,-))+*, 5(/ 57
"#$%&'- -(0,,,,5 %.'/)*7,( @9925 /47,7+(+00) 6/40,-))+*, ,(5 57
"#$%&'0 -(0,,,,5 %.'/)*7,( @9925 /40)*(70/,* 6/40,-))+*, ,-/ 57
"#$%&'7 -(0,,,,5 %.'/)*7,( @9925 /4-+)+*0-+- 6/40,-))+*, ,+- 57
"#$%&'+ -(0,,,,5 %.'/)*7,( @9925 /4-,,*)+0-0 6/40,-))+*, )(- 57
"#$%&'(/ -(0,,,,5 %.'/)*7,( @9925 /4)-*))*+(- 6/40,-))+*, ))+ 57
"#$%&'( *-*((7*7( %.'/5**,* 1BA%&( (4+5(0+0(57 6/40*)(/0055 *7 5+
"#$%&'* *-*((7*7( %.'/5**,* 1BA%&( (45/*//+/*0 6/40*)(/0055 (0* 5+
"#$%&'5 *-*((7*7( %.'/5**,* 1BA%&( (4(70((,++5 6/40*)(/0055 *5/ 5+
"#$%&', *-*((7*7( %.'/5**,* 1BA%&( (4((),-5-(5 6/40*)(/0055 *0/ 5+
"#$%&') *-*((7*7( %.'/5**,* 1BA%&( /4-5-0()0,, 6/40*)(/0055 )*5 5+
"#$%&'- *-*((7*7( %.'/5**,* 1BA%&( /4,+/++/,/5 6/40*)(/0055 )+- 5+
"#$%&'( ,70(05** %.'//(//(--0 =$-I( *45-*+()(7- 6/40(/5))5(5 7 ,/
"#$%&'* ,70(05** %.'//(//(--0 =$-I( (4*-(7,-*5 6/40(/5))5(5 (77 ,/
"#$%&'5 ,70(05** %.'//(//(--0 =$-I( (4(7(*/+++ 6/40(/5))5(5 *5( ,/
"#$%&', ,70(05** %.'//(//(--0 =$-I( (4((*/*7(55 6/40(/5))5(5 *05 ,/
"#$%&') ,70(05** %.'//(//(--0 =$-I( /40/7-+--)7 6/40(/5))5(5 ,7- ,/
"#$%&'- ,70(05** %.'//(//(--0 =$-I( /4-*,,7(+57 6/40(/5))5(5 )5, ,/
"#$%&'( ()5+,-,*/ %.'//(,55 F$%( (4*,)**7+5, 6/4-7,5,075( (+0 ,(
"#$%&'* ()5+,-,*/ %.'//(,55 F$%( (4(-,555/7+ 6/4-7,5,075( *,- ,(
"#$%&'5 ()5+,-,*/ %.'//(,55 F$%( (4(((07)/++ 6/4-7,5,075( *0, ,(
"#$%&', ()5+,-,*/ %.'//(,55 F$%( (4/()7,/,*, 6/4-7,5,075( 5*- ,(
"#$%&') ()5+,-,*/ %.'//(,55 F$%( /4+/77,7+,- 6/4-7,5,075( 57- ,(
"#$%&'- ()5+,-,*/ %.'//(,55 F$%( /4-05+0,707 6/4-7,5,075( )/* ,(
"#$%&'0 ()5+,-,*/ %.'//(,55 F$%( /4-/**5/07, 6/4-7,5,075( ),( ,(
"#$%&'7 ()5+,-,*/ %.'//(,55 F$%( /4)-*)+,0)- 6/4-7,5,075( ))7 ,(
"#$%&'+ ()5+,-,*/ %.'//(,55 F$%( /4))0)-(57 6/4-7,5,075( )-* ,(
"#$%&'(/ ()5+,-,*/ %.'//(,55 F$%( /4),07+-5/- 6/4-7,5,075( )-0 ,(
"#$%&'( 55*5+,,( %.'//-0), 9H1B( (4,,-0+-,,0 6/4-055(0,)+ ((- ,*
"#$%&'* 55*5+,,( %.'//-0), 9H1B( (45)+0(5-75 6/4-055(0,)+ (,- ,*
"#$%&'5 55*5+,,( %.'//-0), 9H1B( /4)))((5**) 6/4-055(0,)+ )-, ,*
"#$%&', 55*5+,,( %.'//-0), 9H1B( /45//-*-/+ 6/4-055(0,)+ -)0 ,*
"#$%&'( (7+/+)*0* %.'///*() G&25 (4-(-/7)7/, 6/4--(*,-,/0 -0 ,5
"#$%&'* (7+/+)*0* %.'///*() G&25 (4,0(*)()(( 6/4--(*,-,/0 ((/ ,5
"#$%&'5 (7+/+)*0* %.'///*() G&25 (4,(,7(+0+, 6/4--(*,-,/0 (*- ,5
"#$%&', (7+/+)*0* %.'///*() G&25 (45*/)/((+ 6/4--(*,-,/0 (-( ,5
"#$%&') (7+/+)*0* %.'///*() G&25 (4(0*,-//70 6/4--(*,-,/0 *5+ ,5
"#$%&'- (7+/+)*0* %.'///*() G&25 /4+07(,-(/( 6/4--(*,-,/0 5)5 ,5
"#$%&'0 (7+/+)*0* %.'///*() G&25 /4000/*5-+0 6/4--(*,-,/0 ,,0 ,5
"#$%&'7 (7+/+)*0* %.'///*() G&25 /40--(*()07 6/4--(*,-,/0 ,)( ,5
"#$%&'+ (7+/+)*0* %.'///*() G&25 /4--)/-),,+ 6/4--(*,-,/0 )/7 ,5
"#$%&'(/ (7+/+)*0* %.'///*() G&25 /4)507)/(-, 6/4--(*,-,/0 )0/ ,5
"#$%&'( (-7,7/(,0 %.'//)(-, &:83* (450(05(00- 6/4-)+50//, (,/ ,,
"#$%&'* (-7,7/(,0 %.'//)(-, &:83* (4*575)/557 6/4-)+50//, */) ,,
"#$%&'5 (-7,7/(,0 %.'//)(-, &:83* (4/000/-0+0 6/4-)+50//, *+) ,,
"#$%&', (-7,7/(,0 %.'//)(-, &:83* /40)*7/(*/7 6/4-)+50//, ,)7 ,,
"#$%&') (-7,7/(,0 %.'//)(-, &:83* /40*+0)(5-0 6/4-)+50//, ,05 ,,
"#$%&'- (-7,7/(,0 %.'//)(-, &:83* /40(-7*)0-5 6/4-)+50//, ,7/ ,,
"#$%&'0 (-7,7/(,0 %.'//)(-, &:83* /40/,00++-( 6/4-)+50//, ,+/ ,,
"#$%&'7 (-7,7/(,0 %.'//)(-, &:83* /4)7,-05(70 6/4-)+50//, ),+ ,,
"#$%&'( )(,-,/*5 A.',+0+*( B=85+()55 *4(75,+*55, 6/4-)00-77/7 (0 ,)
"#$%&'* )(,-,/*5 A.',+0+*( B=85+()55 (4--)*)/,55 6/4-)00-77/7 -/ ,)
"#$%&'5 )(,-,/*5 A.',+0+*( B=85+()55 (457*-(*)55 6/4-)00-77/7 (5, ,)
"#$%&', )(,-,/*5 A.',+0+*( B=85+()55 (450--)570- 6/4-)00-77/7 (5- ,)
"#$%&') )(,-,/*5 A.',+0+*( B=85+()55 (45)7+*7-)( 6/4-)00-77/7 (,0 ,)
"#$%&'- )(,-,/*5 A.',+0+*( B=85+()55 (45*-**05*( 6/4-)00-77/7 ()) ,)
"#$%&'0 )(,-,/*5 A.',+0+*( B=85+()55 (4**+/,57+* 6/4-)00-77/7 */0 ,)
"#$%&'7 )(,-,/*5 A.',+0+*( B=85+()55 (4(5/*/-(5 6/4-)00-77/7 *-* ,)
"#$%&'+ )(,-,/*5 A.',+0+*( B=85+()55 /4+/**(/**7 6/4-)00-77/7 5+/ ,)
"#$%&'(/ )(,-,/*5 A.',+0+*( B=85+()55 /40),,//,)) 6/4-)00-77/7 ,)- ,)
"#$%&'(( )(,-,/*5 A.',+0+*( B=85+()55 /40(-)(-*,+ 6/4-)00-77/7 ,7( ,)
"#$%&'(* )(,-,/*5 A.',+0+*( B=85+()55 /40/0+055*) 6/4-)00-77/7 ,70 ,)
"#$%&'(5 )(,-,/*5 A.',+0+*( B=85+()55 /4-/*(*)-7 6/4-)00-77/7 ),* ,)
"#$%&'(, )(,-,/*5 A.',+0+*( B=85+()55 /4)//,70//, 6/4-)00-77/7 )+* ,)
"#$%&'() )(,-,/*5 A.',+0+*( B=85+()55 /4,75*)7-(0 6/4-)00-77/7 -// ,)
"#$%&'( (+,5/--*0 %.'/**5)/ B$&1 (4)5,7,*-7- 6/4-)((5(/-7 +* ,-
"#$%&'* (+,5/--*0 %.'/**5)/ B$&1 (4*,)/057-- 6/4-)((5(/-7 (+7 ,-
"#$%&'5 (+,5/--*0 %.'/**5)/ B$&1 (4*(0+5(-)- 6/4-)((5(/-7 *(, ,-
"#$%&', (+,5/--*0 %.'/**5)/ B$&1 (4/-+0+(5(( 6/4-)((5(/-7 5// ,-
"#$%&') (+,5/--*0 %.'/**5)/ B$&1 /47+7-77//, 6/4-)((5(/-7 5+, ,-
"#$%&'- (+,5/--*0 %.'/**5)/ B$&1 /4,+-,77-70 6/4-)((5(/-7 )+, ,-
"#$%&'( *+)(,7/,* %.'(577(, 1%1B&) *4//+7*,5-+ 6/4-,7+7**+( *5 ,0
"#$%&'* *+)(,7/,* %.'(577(, 1%1B&) (45,/,/((+- 6/4-,7+7**+( ()( ,0
"#$%&'5 *+)(,7/,* %.'(577(, 1%1B&) /40**/-+,*5 6/4-,7+7**+( ,00 ,0
"#$%&', *+)(,7/,* %.'(577(, 1%1B&) /4,/*-)),0* 6/4-,7+7**+( -5- ,0
"#$%&'( */5/+00*5 %.'//(//0),/ 83?, *45)5)-57(+ 6/4-(/0*,50* + ,7
"#$%&'* */5/+00*5 %.'//(//0),/ 83?, (45/50/))7- 6/4-(/0*,50* (0( ,7
"#$%&'5 */5/+00*5 %.'//(//0),/ 83?, (4/,+0++)*5 6/4-(/0*,50* 5/+ ,7
"#$%&', */5/+00*5 %.'//(//0),/ 83?, /40,**5-5,5 6/4-(/0*,50* ,-, ,7
"#$%&') */5/+00*5 %.'//(//0),/ 83?, /4-075/)/(- 6/4-(/0*,50* )// ,7
"#$%&'- */5/+00*5 %.'//(//0),/ 83?, /4-557,*+(7 6/4-(/0*,50* )*) ,7
"#$%&'( ()5*-0,/- %.'//(//,(/) E$2- (457(,0(70* 6/4-/7,-00), (5) ,+
"#$%&'* ()5*-0,/- %.'//(//,(/) E$2- (4*+)+7-,0) 6/4-/7,-00), (0) ,+
"#$%&'5 ()5*-0,/- %.'//(//,(/) E$2- (4/)*7000(+ 6/4-/7,-00), 5/0 ,+
"#$%&', ()5*-0,/- %.'//(//,(/) E$2- /4++)/(55*) 6/4-/7,-00), 5,5 ,+
"#$%&') ()5*-0,/- %.'//(//,(/) E$2- /4+,*5(+)0 6/4-/7,-00), 50/ ,+
"#$%&'- ()5*-0,/- %.'//(//,(/) E$2- /405,,,/0- 6/4-/7,-00), ,0/ ,+
"#$%&'0 ()5*-0,/- %.'//(//,(/) E$2- /4-+*750-/) 6/4-/7,-00), ,+0 ,+
"#$%&'7 ()5*-0,/- %.'//(//,(/) E$2- /4-/+5(0**) 6/4-/7,-00), )5+ ,+
"#$%&'+ ()5*-0,/- %.'//(//,(/) E$2- /4)57//*,-+ 6/4-/7,-00), )-7 ,+
"#$%&'( (((/57((+ %.'(5+*,- @9@3* (4)0*+,/-/) 6/4)7--57/-5 7/ )/
"#$%&'* (((/57((+ %.'(5+*,- @9@3* (45,,-+55*0 6/4)7--57/-5 (,+ )/
"#$%&'5 (((/57((+ %.'(5+*,- @9@3* /47*))-)(7, 6/4)7--57/-5 ,*5 )/
"#$%&'( ()/507)5( %.'/(0)0* .2%2* (4))70*+/05 6/4)7)**-/,0 70 )(
"#$%&'* ()/507)5( %.'/(0)0* .2%2* (4*,/-07,5, 6/4)7)**-/,0 */5 )(
"#$%&'5 ()/507)5( %.'/(0)0* .2%2* (4**--*+/)) 6/4)7)**-/,0 */+ )(
"#$%&', ()/507)5( %.'/(0)0* .2%2* (4**-5/)0,, 6/4)7)**-/,0 *(/ )(
"#$%&') ()/507)5( %.'/(0)0* .2%2* (4(+5,*-)/7 6/4)7)**-/,0 **5 )(
"#$%&'- ()/507)5( %.'/(0)0* .2%2* (4/7(7+/()( 6/4)7)**-/,0 *+* )(
"#$%&'0 ()/507)5( %.'/(0)0* .2%2* (4//)*5/5/+ 6/4)7)**-/,0 55) )(
"#$%&'7 ()/507)5( %.'/(0)0* .2%2* /47/7*(),7) 6/4)7)**-/,0 ,5( )(
"#$%&'+ ()/507)5( %.'/(0)0* .2%2* /4),+-7+,55 6/4)7)**-/,0 )-) )(
"#$%&'(/ ()/507)5( %.'/(0)0* .2%2* /4,*+*0(-*5 6/4)7)**-/,0 -*, )(
"#$%&'( 75-*00*/ %.'(++*7+ %F2) (4-,0*/*70- 6/4)0-(,75() -( )*
"#$%&'* 75-*00*/ %.'(++*7+ %F2) (4)+7-+)5,, 6/4)0-(,75() 05 )*
"#$%&'5 75-*00*/ %.'(++*7+ %F2) (4)-+5-5)(, 6/4)0-(,75() 7( )*
"#$%&', 75-*00*/ %.'(++*7+ %F2) (4*+5(5+,(0 6/4)0-(,75() (0- )*
"#$%&') 75-*00*/ %.'(++*7+ %F2) (4*-/00)-)- 6/4)0-(,75() (7+ )*
"#$%&'- 75-*00*/ %.'(++*7+ %F2) (4()+0-/,-) 6/4)0-(,75() *,7 )*
"#$%&'0 75-*00*/ %.'(++*7+ %F2) (4/(7+700*- 6/4)0-(,75() 5** )*
"#$%&'7 75-*00*/ %.'(++*7+ %F2) (4/(,05++)7 6/4)0-(,75() 5*0 )*
"#$%&'+ 75-*00*/ %.'(++*7+ %F2) /4+*5*5+,*( 6/4)0-(,75() 50- )*
"#$%&'(/ 75-*00*/ %.'(++*7+ %F2) /40)*5)0, 6/4)0-(,75() ,)+ )*
"#$%&'(( 75-*00*/ %.'(++*7+ %F2) /4-05)570- 6/4)0-(,75() )/5 )*
"#$%&'(* 75-*00*/ %.'(++*7+ %F2) /4,5(50/-/0 6/4)0-(,75() -*5 )*
"#$%&'(5 75-*00*/ %.'(++*7+ %F2) /45,5((,(*5 6/4)0-(,75() -)/ )*
"#$%&'( 7+**(*+ %.'/(0))) FEB%* (40+)(,-(++ 6/4)-+70//0) ,/ )5
"#$%&'* 7+**(*+ %.'/(0))) FEB%* (45*-(-7/)7 6/4)-+70//0) ()- )5
"#$%&'5 7+**(*+ %.'/(0))) FEB%* /4+-/-//-)0 6/4)-+70//0) 5-, )5
"#$%&', 7+**(*+ %.'/(0))) FEB%* /40*(*,/5)( 6/4)-+70//0) ,07 )5
"#$%&'( ,-5+),+) %.'*/0(0* %19$( *4))505)5+- 6/4)-7+-)557 ) ),
"#$%&'* ,-5+),+) %.'*/0(0* %19$( (4*)50)+5*) 6/4)-7+-)557 (+* ),
"#$%&'5 ,-5+),+) %.'*/0(0* %19$( (4*(770*,*5 6/4)-7+-)557 *(5 ),
"#$%&', ,-5+),+) %.'*/0(0* %19$( (4/-5*/)5( 6/4)-7+-)557 5/( ),
"#$%&') ,-5+),+) %.'*/0(0* %19$( (4/-*/*5-+7 6/4)-7+-)557 5/* ),
"#$%&'- ,-5+),+) %.'*/0(0* %19$( /40(-55+((5 6/4)-7+-)557 ,7* ),
"#$%&'0 ,-5+),+) %.'*/0(0* %19$( /4-(075/()0 6/4)-7+-)557 )50 ),
"#$%&'7 ,-5+),+) %.'*/0(0* %19$( /4,57-))7( 6/4)-7+-)557 -(+ ),
"#$%&'( (,)7++5/ %.'//*)7+ 183?0 (4()-++7,-, 6/4)-*)5-500 *)/ ))
"#$%&'* (,)7++5/ %.'//*)7+ 183?0 (4//)5-/)0* 6/4)-*)5-500 55, ))
"#$%&'5 (,)7++5/ %.'//*)7+ 183?0 /4+(0(5)-7* 6/4)-*)5-500 575 ))
"#$%&', (,)7++5/ %.'//*)7+ 183?0 /47*,-0,0+- 6/4)-*)5-500 ,*, ))
"#$%&') (,)7++5/ %.'//*)7+ 183?0 /405*0,--)) 6/4)-*)5-500 ,0( ))
"#$%&'- (,)7++5/ %.'//*)7+ 183?0 /40*-75()( 6/4)-*)5-500 ,0) ))
"#$%&'0 (,)7++5/ %.'//*)7+ 183?0 /4-,-)7-5,- 6/4)-*)5-500 )() ))
"#$%&'7 (,)7++5/ %.'//*)7+ 183?0 /4)-5+*00+) 6/4)-*)5-500 ))- ))
"#$%&'+ (,)7++5/ %.'//*)7+ 183?0 /4)-*55)5-, 6/4)-*)5-500 )-/ ))
"#$%&'(/ (,)7++5/ %.'//*)7+ 183?0 /4)/-,(0)(7 6/4)-*)5-500 )75 ))
"#$%&'( 0((,5((( %.'/(7(*, $;>35 (40((7)07/0 6/4)(-77)-7* )* )-
"#$%&'* 0((,5((( %.'/(7(*, $;>35 (4-777((5(5 6/4)(-77)-7* )) )-
"#$%&'5 0((,5((( %.'/(7(*, $;>35 (4),+*0*,/+ 6/4)(-77)-7* 77 )-
"#$%&', 0((,5((( %.'/(7(*, $;>35 (4/+7/0,,++ 6/4)(-77)-7* *75 )-
"#$%&') 0((,5((( %.'/(7(*, $;>35 /47(-7-+), 6/4)(-77)-7* ,*- )-
"#$%&'- 0((,5((( %.'/(7(*, $;>35 /4)/,(/)-- 6/4)(-77)-7* )70 )-
"#$%&'( (-,--57/+ %.'(05-,* $<.2B& (4*0*70+57( 6/4,+)70/(+7 (7( )0
"#$%&'* (-,--57/+ %.'(05-,* $<.2B& (4*-,*-,//- 6/4,+)70/(+7 (7) )0
"#$%&'5 (-,--57/+ %.'(05-,* $<.2B& (4(*)7-,*5+ 6/4,+)70/(+7 *-- )0
"#$%&', (-,--57/+ %.'(05-,* $<.2B& (4/(7*70/)( 6/4,+)70/(+7 5*5 )0
"#$%&') (-,--57/+ %.'(05-,* $<.2B& /4)*75+,()) 6/4,+)70/(+7 )05 )0
"#$%&'- (-,--57/+ %.'(05-,* $<.2B& /4,,-//07() 6/4,+)70/(+7 -(- )0
"#$%&'( (,7-(577) %.'/**7,( $A;0 *4/500,7(*+ 6/4,+(70007( ** )7
"#$%&'* (,7-(577) %.'/**7,( $A;0 (4)7(-,-,0+ 6/4,+(70007( 00 )7
"#$%&'5 (,7-(577) %.'/**7,( $A;0 (4//,0005,* 6/4,+(70007( 55- )7
"#$%&', (,7-(577) %.'/**7,( $A;0 /4-0,-*-)*, 6/4,+(70007( )/( )7
"#$%&'( ((+-50757 %.'//*,+7 %F25 (47*-(),*** 6/4,+/7/7))( 5, )+
"#$%&'* ((+-50757 %.'//*,+7 %F25 (4-75*7+-)) 6/4,+/7/7))( )- )+
"#$%&'5 ((+-50757 %.'//*,+7 %F25 (4*/+,,,)-( 6/4,+/7/7))( *(- )+
"#$%&', ((+-50757 %.'//*,+7 %F25 (4/707/,,-, 6/4,+/7/7))( *7+ )+
"#$%&') ((+-50757 %.'//*,+7 %F25 (4/7))/-,-0 6/4,+/7/7))( *+/ )+
"#$%&'- ((+-50757 %.'//*,+7 %F25 /4+*-/+0*50 6/4,+/7/7))( 50) )+
"#$%&'0 ((+-50757 %.'//*,+7 %F25 /4+(7(,7),5 6/4,+/7/7))( 57* )+
"#$%&'7 ((+-50757 %.'//*,+7 %F25 /4--/50+*+7 6/4,+/7/7))( )(/ )+
"#$%&'+ ((+-50757 %.'//*,+7 %F25 /4)*/-+-/)- 6/4,+/7/7))( )0+ )+
"#$%&'(/ ((+-50757 %.'//*,+7 %F25 /4,+))-70,7 6/4,+/7/7))( )+) )+
"#$%&'( 750//*5- %.'//*)*( %11: (4,5((),+*- 6/4,7707+/5 (** -/
"#$%&'* 750//*5- %.'//*)*( %11: (457)/)+)7- 6/4,7707+/5 (55 -/
"#$%&'5 750//*5- %.'//*)*( %11: (4//,-)/)() 6/4,7707+/5 550 -/
"#$%&', 750//*5- %.'//*)*( %11: /4)-7,)*++7 6/4,7707+/5 )), -/
"#$%&'( (-+0+/7(* %.'//5*5+ @E;:5 (4,5/*05/0) 6/4,--+//-)( (*5 -/
"#$%&'* (-+0+/7(* %.'//5*5+ @E;:5 (4*,-+-/*(* 6/4,--+//-)( (+- -/
"#$%&'5 (-+0+/7(* %.'//5*5+ @E;:5 (4(*0)/5/-( 6/4,--+//-)( *-) -/
"#$%&', (-+0+/7(* %.'//5*5+ @E;:5 /4770(/0( 6/4,--+//-)( 5+0 -/
"#$%&') (-+0+/7(* %.'//5*5+ @E;:5 /40+*,75,,) 6/4,--+//-)( ,5+ -/
"#$%&'- (-+0+/7(* %.'//5*5+ @E;:5 /4,,),**5/5 6/4,--+//-)( -(0 -/
"#$%&'( 5/(7+0*,- %.'//-*+- I$2* (4,(,+07,,* 6/4,,0/)*-* (*) -(
"#$%&'* 5/(7+0*,- %.'//-*+- I$2* (4(*+5)7) 6/4,,0/)*-* *-, -(
"#$%&'5 5/(7+0*,- %.'//-*+- I$2* (4/+5/5/0,) 6/4,,0/)*-* *7) -(
"#$%&', 5/(7+0*,- %.'//-*+- I$2* (4/0*)*+)0- 6/4,,0/)*-* *++ -(
"#$%&') 5/(7+0*,- %.'//-*+- I$2* /4+-0+/*-(- 6/4,,0/)*-* 5-/ -(
"#$%&'- 5/(7+0*,- %.'//-*+- I$2* /47,++0//00 6/4,,0/)*-* ,(( -(
"#$%&'0 5/(7+0*,- %.'//-*+- I$2* /4)+55*/,, 6/4,,0/)*-* ),) -(
"#$%&'7 5/(7+0*,- %.'//-*+- I$2* /4,70,7,7-) 6/4,,0/)*-* )+7 -(
"#$%&'( *+0*+)-( A.'*+((/) @&3&*: (40+0/050/( 6/4,57*,,-- 5+ -*
"#$%&'* *+0*+)-( A.'*+((/) @&3&*: (4*,*+,0/70 6/4,57*,,-- (++ -*
"#$%&'5 *+0*+)-( A.'*+((/) @&3&*: (4(*++))--, 6/4,57*,,-- *-5 -*
"#$%&', *+0*+)-( A.'*+((/) @&3&*: (4//((*)575 6/4,57*,,-- 55+ -*
"#$%&') *+0*+)-( A.'*+((/) @&3&*: /4057*)055* 6/4,57*,,-- ,-0 -*
"#$%&'- *+0*+)-( A.'*+((/) @&3&*: /4,--(+())- 6/4,57*,,-- -(( -*
"#$%&'( *+-(0+5+5 %.'(0)7-- C?.2( (40+/(,55), 6/4,*+,-*5,7 ,5 -5
"#$%&'* *+-(0+5+5 %.'(0)7-- C?.2( (4),(()-/07 6/4,*+,-*5,7 +/ -5
"#$%&'5 *+-(0+5+5 %.'(0)7-- C?.2( (4(,+,((*(5 6/4,*+,-*5,7 *)) -5
"#$%&', *+-(0+5+5 %.'(0)7-- C?.2( (4/7,+)++/( 6/4,*+,-*5,7 *+( -5
"#$%&') *+-(0+5+5 %.'(0)7-- C?.2( (4/)),-)-)+ 6/4,*+,-*5,7 5/) -5
"#$%&'- *+-(0+5+5 %.'(0)7-- C?.2( /4777*-/7)7 6/4,*+,-*5,7 5+- -5
"#$%&'0 *+-(0+5+5 %.'(0)7-- C?.2( /407,/7(-(+ 6/4,*+,-*5,7 ,,, -5
"#$%&'7 *+-(0+5+5 %.'(0)7-- C?.2( /40*/)-+5++ 6/4,*+,-*5,7 ,0+ -5
"#$%&'+ *+-(0+5+5 %.'(0)7-- C?.2( /4-**07,7(( 6/4,*+,-*5,7 )5) -5
"#$%&'(/ *+-(0+5+5 %.'(0)7-- C?.2( /4,07,07,7( 6/4,*+,-*5,7 -/( -5
"#$%&'( *(+)*(+/) %.'(,)/*, 8F9)& (4,-)+*7(() 6/4,//7+/+)7 ((( -,
"#$%&'* *(+)*(+/) %.'(,)/*, 8F9)& (4,5+0)*0 6/4,//7+/+)7 ((7 -,
"#$%&'5 *(+)*(+/) %.'(,)/*, 8F9)& (45(*7*)5,0 6/4,//7+/+)7 (-) -,
"#$%&', *(+)*(+/) %.'(,)/*, 8F9)& (4*)(7++)7+ 6/4,//7+/+)7 (+5 -,
"#$%&') *(+)*(+/) %.'(,)/*, 8F9)& (4(/0-+(+* 6/4,//7+/+)7 *07 -,
"#$%&'- *(+)*(+/) %.'(,)/*, 8F9)& /4+*07((0)* 6/4,//7+/+)7 50, -,
"#$%&'0 *(+)*(+/) %.'(,)/*, 8F9)& /47,7(((5-) 6/4,//7+/+)7 ,(, -,
"#$%&'7 *(+)*(+/) %.'(,)/*, 8F9)& /405,0)(75+ 6/4,//7+/+)7 ,-7 -,
"#$%&'+ *(+)*(+/) %.'(,)/*, 8F9)& /4,-+0/-557 6/4,//7+/+)7 -(/ -,
"#$%&'(/ *(+)*(+/) %.'(,)/*, 8F9)& /4,-5--7,-) 6/4,//7+/+)7 -(* -,
"#$%&'( ()000+(55 %.'//(-++ &AB *4/77+(,/)) 6/45775+,(*( *( -)
"#$%&'* ()000+(55 %.'//(-++ &AB (4,0,,5(77, 6/45775+,(*( (/+ -)
"#$%&'5 ()000+(55 %.'//(-++ &AB (4*,*-)+5-* 6/45775+,(*( */( -)
"#$%&', ()000+(55 %.'//(-++ &AB (4**-(05++0 6/45775+,(*( *(( -)
"#$%&') ()000+(55 %.'//(-++ &AB (4/*+*-005( 6/45775+,(*( 5(7 -)
"#$%&'- ()000+(55 %.'//(-++ &AB (4/*0,0)(+( 6/45775+,(*( 5(+ -)
"#$%&'0 ()000+(55 %.'//(-++ &AB /47-0/5))0+ 6/45775+,(*( ,/) -)
"#$%&'7 ()000+(55 %.'//(-++ &AB /4,0/)-//), 6/45775+,(*( -/7 -)
"#$%&'+ ()000+(55 %.'//(-++ &AB /4,)5*,)77+ 6/45775+,(*( -() -)
"#$%&'(/ ()000+(55 %.'//(-++ &AB /45+-(-/7+0 6/45775+,(*( -57 -)
"#$%&'( *-/(----/ %.'//(//5077 9@$&3& (4)(7-+5((7 6/4500)77-,* +- --
"#$%&'* *-/(----/ %.'//(//5077 9@$&3& (45*(//0/(+ 6/4500)77-,* ()7 --
"#$%&'5 *-/(----/ %.'//(//5077 9@$&3& (4(/0+/7/)( 6/4500)77-,* *0- --
"#$%&', *-/(----/ %.'//(//5077 9@$&3& (4/+---*5*, 6/4500)77-,* *7, --
"#$%&') *-/(----/ %.'//(//5077 9@$&3& (4/)5*(+((- 6/4500)77-,* 5/- --
"#$%&'- *-/(----/ %.'//(//5077 9@$&3& /4+(7(-,**0 6/4500)77-,* 57( --
"#$%&'0 *-/(----/ %.'//(//5077 9@$&3& /4)(0)++755 6/4500)77-,* )7( --
"#$%&'7 *-/(----/ %.'//(//5077 9@$&3& /4)(((*),0- 6/4500)77-,* )7* --
"#$%&'+ *-/(----/ %.'//(//5077 9@$&3& /4,***+05+) 6/4500)77-,* -*0 --
"#$%&'( )(,000/- %.'/5*/50 @992- (40),+,,,(+ 6/450(-/*,)* ,7 -0
"#$%&'* )(,000/- %.'/5*/50 @992- (4-(0)//(5- 6/450(-/*,)* -- -0
"#$%&'5 )(,000/- %.'/5*/50 @992- (4-/+55(5/( 6/450(-/*,)* 0/ -0
"#$%&', )(,000/- %.'/5*/50 @992- (4)/,,5,/0* 6/450(-/*,)* (/( -0
"#$%&') )(,000/- %.'/5*/50 @992- /4+00,,/+5) 6/450(-/*,)* 5)) -0
"#$%&'- )(,000/- %.'/5*/50 @992- /47-57-0/,7 6/450(-/*,)* ,/- -0
"#$%&'0 )(,000/- %.'/5*/50 @992- /4-+/*57*/5 6/450(-/*,)* ,+7 -0
"#$%&'7 )(,000/- %.'/5*/50 @992- /4-,5/-,/5 6/450(-/*,)* )(+ -0
"#$%&'+ )(,000/- %.'/5*/50 @992- /4)+,--),)+ 6/450(-/*,)* ),, -0
"#$%&'(/ )(,000/- %.'/5*/50 @992- /4,0/,+5(0) 6/450(-/*,)* -/+ -0
"#$%&'( (,7+**750 %.'/*(+-- @8B(& (4-(,)+,*+5 6/45-5,-+-*( -7 -7
"#$%&'* (,7+**750 %.'/*(+-- @8B(& (4(+-75-(/( 6/45-5,-+-*( **( -7
"#$%&'5 (,7+**750 %.'/*(+-- @8B(& (4/07/*07*+ 6/45-5,-+-*( *+, -7
"#$%&', (,7+**750 %.'/*(+-- @8B(& /4+-,,0*5)) 6/45-5,-+-*( 5-* -7
"#$%&') (,7+**750 %.'/*(+-- @8B(& /4)-*00(,7( 6/45-5,-+-*( ))0 -7
"#$%&'- (,7+**750 %.'/*(+-- @8B(& /4,777+)0-* 6/45-5,-+-*( )+0 -7
"#$%&'( 5*(5/)5+ %.'/(*5+) 1;@2( 54-0+,)0(5( 6/45))(/*(*( * -+
"#$%&'* 5*(5/)5+ %.'/(*5+) 1;@2( (4-/)7,7*50 6/45))(/*(*( 0( -+
"#$%&'5 5*(5/)5+ %.'/(*5+) 1;@2( (4*7/(+7505 6/45))(/*(*( (7/ -+
"#$%&', 5*(5/)5+ %.'/(*5+) 1;@2( (4()-,*)0,, 6/45))(/*(*( *)( -+
"#$%&') 5*(5/)5+ %.'/(*5+) 1;@2( /4+*7*)*0*0 6/45))(/*(*( 505 -+
"#$%&'- 5*(5/)5+ %.'/(*5+) 1;@2( /4+/0,(5-- 6/45))(/*(*( 570 -+
"#$%&'0 5*(5/)5+ %.'/(*5+) 1;@2( /4)/57)(,+ 6/45))(/*(*( )77 -+
"#$%&'7 5*(5/)5+ %.'/(*5+) 1;@2( /45+0(,5,-0 6/45))(/*(*( -50 -+
"#$%&'+ 5*(5/)5+ %.'/(*5+) 1;@2( /45),*+)-0 6/45))(/*(*( -,0 0/
"#$%&'( 57)-+,)+ %.'/()(+( 9<2* (4)7+(/),0* 6/45),((-+7 0, 0/
"#$%&'* 57)-+,)+ %.'/()(+( 9<2* (4)/(/*)5,- 6/45),((-+7 (/5 0/
"#$%&'5 57)-+,)+ %.'/()(+( 9<2* (450(**070) 6/45),((-+7 (,( 0/
"#$%&', 57)-+,)+ %.'/()(+( 9<2* (4*(-7)*+*, 6/45),((-+7 *() 0/
"#$%&') 57)-+,)+ %.'/()(+( 9<2* /4+-0)+7+/, 6/45),((-+7 5-( 0/
"#$%&'- 57)-+,)+ %.'/()(+( 9<2* /47/-+7-*75 6/45),((-+7 ,5* 0/
"#$%&'0 57)-+,)+ %.'/()(+( 9<2* /47/()5*5*5 6/45),((-+7 ,55 0/
"#$%&'7 57)-+,)+ %.'/()(+( 9<2* /40+)05,//- 6/45),((-+7 ,50 0/
"#$%&'+ 57)-+,)+ %.'/()(+( 9<2* /4--*7/,,/) 6/45),((-+7 )/+ 0/
"#$%&'(/ 57)-+,)+ %.'/()(+( 9<2* /4)---7,-,( 6/45),((-+7 ))) 0/
"#$%&'(( 57)-+,)+ %.'/()(+( 9<2* /45-+///)*, 6/45),((-+7 -,- 0/
"#$%&'( ((*5-5/0+ %.'/()((* .&9@* (4+/*/0,/)- 6/45,+7057,* *+ 0(
"#$%&'* ((*5-5/0+ %.'/()((* .&9@* (4)*5/)-)50 6/45,+7057,* +) 0(
"#$%&'5 ((*5-5/0+ %.'/()((* .&9@* (4)/,)5,+*0 6/45,+7057,* (// 0(
"#$%&', ((*5-5/0+ %.'/()((* .&9@* (4(/**(0-0( 6/45,+7057,* *7( 0(
"#$%&') ((*5-5/0+ %.'/()((* .&9@* /4+//0)+5/+ 6/45,+7057,* 5+* 0(
"#$%&'- ((*5-5/0+ %.'/()((* .&9@* /47+70*7*,- 6/45,+7057,* 5+5 0(
"#$%&'0 ((*5-5/0+ %.'/()((* .&9@* /40/(5/*)+) 6/45,+7057,* ,+( 0(
"#$%&'7 ((*5-5/0+ %.'/()((* .&9@* /4-*,-)-0, 6/45,+7057,* )55 0(
"#$%&'+ ((*5-5/0+ %.'/()((* .&9@* /450+7(*505 6/45,+7057,* -,( 0(
"#$%&'( )(,--/77 A$'///*+* 8B2* *4*-,(**/50 6/45/*//)*5 (5 0*
"#$%&'* )(,--/77 A$'///*+* 8B2* /4+00--+5+5 6/45/*//)*5 5), 0*
"#$%&'5 )(,--/77 A$'///*+* 8B2* /4+57(,0(++ 6/45/*//)*5 50( 0*
"#$%&', )(,--/77 A$'///*+* 8B2* /4+/(+(0(77 6/45/*//)*5 5+( 0*
"#$%&') )(,--/77 A$'///*+* 8B2* /40(5)/(7/- 6/45/*//)*5 ,7, 0*
"#$%&'- )(,--/77 A$'///*+* 8B2* /4-*+((0*-0 6/45/*//)*5 )5/ 0*
"#$%&'0 )(,--/77 A$'///*+* 8B2* /4)500-)-5- 6/45/*//)*5 )0( 0*
"#$%&'7 )(,--/77 A$'///*+* 8B2* /4,05(-57,5 6/45/*//)*5 -/- 0*
"#$%&'+ )(,--/77 A$'///*+* 8B2* /4,)55*(705 6/45/*//)*5 -(, 0*
"#$%&'( (+(*)*0+/ %.'/*/5,( 1&20 (4(05(7),5- 6/4*-0,//777 *57 05
"#$%&'* (+(*)*0+/ %.'/*/5,( 1&20 (4(0/0,),0- 6/4*-0,//777 *,( 05
"#$%&'5 (+(*)*0+/ %.'/*/5,( 1&20 (4(),-5/,*, 6/4*-0,//777 *)* 05
"#$%&', (+(*)*0+/ %.'/*/5,( 1&20 (4(/000-(-5 6/4*-0,//777 *00 05
"#$%&') (+(*)*0+/ %.'/*/5,( 1&20 /4+-*+)7+)- 6/4*-0,//777 5-5 05
"#$%&'- (+(*)*0+/ %.'/*/5,( 1&20 /475//)-)-* 6/4*-0,//777 ,** 05
"#$%&'0 (+(*)*0+/ %.'/*/5,( 1&20 /40-)/57-7, 6/4*-0,//777 ,)* 05
"#$%&'7 (+(*)*0+/ %.'/*/5,( 1&20 /4-5)+)757, 6/4*-0,//777 )*, 05
"#$%&'+ (+(*)*0+/ %.'/*/5,( 1&20 /4)))))-,/7 6/4*-0,//777 )-5 05
"#$%&'(/ (+(*)*0+/ %.'/*/5,( 1&20 /45+,/+*(55 6/4*-0,//777 -5+ 05
"#$%&'( (55+/7-5* %.'//(/*,7,0 @E;:$* (4*7-0,(0-( 6/4*-50,--)0 (07 0,
"#$%&'* (55+/7-5* %.'//(/*,7,0 @E;:$* (4(7/,7(/+0 6/4*-50,--)0 *55 0,
"#$%&'5 (55+/7-5* %.'//(/*,7,0 @E;:$* (4/0)7/(0,, 6/4*-50,--)0 *+- 0,
"#$%&', (55+/7-5* %.'//(/*,7,0 @E;:$* /4000-7-/75 6/4*-50,--)0 ,,) 0,
"#$%&') (55+/7-5* %.'//(/*,7,0 @E;:$* /40---,,*/7 6/4*-50,--)0 ,)/ 0,
"#$%&'- (55+/7-5* %.'//(/*,7,0 @E;:$* /4-0**5+*)) 6/4*-50,--)0 )/, 0,
"#$%&'0 (55+/7-5* %.'//(/*,7,0 @E;:$* /4,7,(*0*-5 6/4*-50,--)0 )++ 0,
"#$%&'7 (55+/7-5* %.'//(/*,7,0 @E;:$* /4,0(007/+( 6/4*-50,--)0 -/0 0,
"#$%&'+ (55+/7-5* %.'//(/*,7,0 @E;:$* /4,5,,++/*) 6/4*-50,--)0 -*/ 0,
"#$%&'( -*+)*,+0 %.'/*/5+0 8&.2(3 (4)((-+0)*( 6/4***+5,(,- +7 0)
"#$%&'* -*+)*,+0 %.'/*/5+0 8&.2(3 (4*/+/5557, 6/4***+5,(,- *(0 0)
"#$%&'5 -*+)*,+0 %.'/*/5+0 8&.2(3 (4(+5/)()** 6/4***+5,(,- **, 0)
"#$%&', -*+)*,+0 %.'/*/5+0 8&.2(3 (4((0)/*/)* 6/4***+5,(,- *-+ 0)
"#$%&') -*+)*,+0 %.'/*/5+0 8&.2(3 (4//-7*)+() 6/4***+5,(,- 555 0)
"#$%&'- -*+)*,+0 %.'/*/5+0 8&.2(3 /4+/**+5/7+ 6/4***+5,(,- 57+ 0)
"#$%&'0 -*+)*,+0 %.'/*/5+0 8&.2(3 /4-+-,---(7 6/4***+5,(,- ,+) 0)
"#$%&'7 -*+)*,+0 %.'/*/5+0 8&.2(3 /4-70)-7*0* 6/4***+5,(,- ,++ 0)
"#$%&'+ -*+)*,+0 %.'/*/5+0 8&.2(3 /4,5(-0-0)) 6/4***+5,(,- -** 0)
"#$%&'(/ -*+)*,+0 %.'/*/5+0 8&.2(3 /4,*/0)/5,) 6/4***+5,(,- -*+ 0)
"#$%&'(( -*+)*,+0 %.'/*/5+0 8&.2(3 /4,(5/*5)7) 6/4***+5,(,- -55 0)
"#$%&'( (*-)(5(5) %.'//*005 1$997 *4(+/*--)/* 6/4(+5*-7007 (- 0-
"#$%&'* (*-)(5(5) %.'//*005 1$997 (4*/05(5((5 6/4(+5*-7007 *(7 0-
"#$%&'5 (*-)(5(5) %.'//*005 1$997 /4)*(+505/* 6/4(+5*-7007 )00 0-
"#$%&', (*-)(5(5) %.'//*005 1$997 /45(707,-/) 6/4(+5*-7007 -)5 0-
"#$%&') (*-)(5(5) %.'//*005 1$997 /4*+(0(*5++ 6/4(+5*-7007 -)7 0-
"#$%&'- (*-)(5(5) %.'//*005 1$997 /4*)57,7,,) 6/4(+5*-7007 --* 0-
"#$%&'( */0/*+()+ %.'//*05* 1$2&8E (4(0(++-,/* 6/4(+/))-++7 *,/ 00
"#$%&'* */0/*+()+ %.'//*05* 1$2&8E (4//,((*)/0 6/4(+/))-++7 557 00
"#$%&'5 */0/*+()+ %.'//*05* 1$2&8E /4++-/,(0*, 6/4(+/))-++7 5,* 00
"#$%&', */0/*+()+ %.'//*05* 1$2&8E /4+0,-5**)( 6/4(+/))-++7 5)- 00
"#$%&') */0/*+()+ %.'//*05* 1$2&8E /40/)+05)5 6/4(+/))-++7 ,7+ 00
"#$%&'- */0/*+()+ %.'//*05* 1$2&8E /4-++(-(7** 6/4(+/))-++7 ,+5 00
"#$%&'0 */0/*+()+ %.'//*05* 1$2&8E /4)-*/5(5-( 6/4(+/))-++7 )-( 00
"#$%&'7 */0/*+()+ %.'//*05* 1$2&8E /4505/-++(7 6/4(+/))-++7 -,5 00
"#$%&'( ()-()(,,/ %.'/*)(,, &B12( (45/))(*0/- 6/4(7/*0--(, (-+ 07
"#$%&'* ()-()(,,/ %.'/*)(,, &B12( (4//+,-,)-) 6/4(7/*0--(, 55* 07
"#$%&'5 ()-()(,,/ %.'/*)(,, &B12( /40/70-/-7+ 6/4(7/*0--(, ,7) 07
"#$%&', ()-()(,,/ %.'/*)(,, &B12( /4--00)-7/* 6/4(7/*0--(, )/- 07
"#$%&') ()-()(,,/ %.'/*)(,, &B12( /4)5070-75) 6/4(7/*0--(, )-+ 07
"#$%&'- ()-()(,,/ %.'/*)(,, &B12( /4,,/0)+7,( 6/4(7/*0--(, -(7 07
"#$%&'0 ()-()(,,/ %.'/*)(,, &B12( /4,*7577*(, 6/4(7/*0--(, -*) 07
"#$%&'( *),-0)(,( %.'(05-,+ 8*JKL-( (45/,7/(++0 6/4()+,(/0+- (0/ 0+
"#$%&'* *),-0)(,( %.'(05-,+ 8*JKL-( /40*7/((()* 6/4()+,(/0+- ,0, 0+
"#$%&'5 *),-0)(,( %.'(05-,+ 8*JKL-( /4-,,*555,7 6/4()+,(/0+- )(0 0+
"#$%&', *),-0)(,( %.'(05-,+ 8*JKL-( /4,0,(50+(5 6/4()+,(/0+- -/) 0+
"#$%&'( 57/(-+55 %.'//5055 =&9B (4*755(5/(- 6/4(,5*//++, (0+ 7/
"#$%&'* 57/(-+55 %.'//5055 =&9B (4(-+*/,0+) 6/4(,5*//++, *,* 7/
"#$%&'5 57/(-+55 %.'//5055 =&9B /4+-+/)7)- 6/4(,5*//++, 5)+ 7/
"#$%&', 57/(-+55 %.'//5055 =&9B /40))/+*/,+ 6/4(,5*//++, ,)) 7/
"#$%&') 57/(-+55 %.'//5055 =&9B /4,)7(+5(+0 6/4(,5*//++, -(5 7/
"#$%&'- 57/(-+55 %.'//5055 =&9B /4*)-,77//( 6/4(,5*//++, --( 7/
"#$%&'( (70+50(07 %.'//(/7/5+) &&@2 (45-))-7),0 6/4(557-*5,+ (,) 7(
"#$%&'* (70+50(07 %.'//(/7/5+) &&@2 (45,((**(,7 6/4(557-*5,+ ()/ 7(
"#$%&'5 (70+50(07 %.'//(/7/5+) &&@2 (4*/-5,+05) 6/4(557-*5,+ *(+ 7(
"#$%&', (70+50(07 %.'//(/7/5+) &&@2 (4(/(,(/-+, 6/4(557-*5,+ *7* 7(
"#$%&') (70+50(07 %.'//(/7/5+) &&@2 /47007)+05* 6/4(557-*5,+ ,/* 7(
"#$%&'- (70+50(07 %.'//(/7/5+) &&@2 /475(7()505 6/4(557-*5,+ ,(+ 7(
"#$%&'0 (70+50(07 %.'//(/7/5+) &&@2 /400)5-/7(5 6/4(557-*5,+ ,,7 7(
"#$%&'7 (70+50(07 %.'//(/7/5+) &&@2 /4-5//07705 6/4(557-*5,+ )*0 7(
"#$%&'+ (70+50(07 %.'//(/7/5+) &&@2 /4),+)*+) 6/4(557-*5,+ )-- 7(
"#$%&'(/ (70+50(07 %.'//(/7/5+) &&@2 /4,0,,,//), 6/4(557-*5,+ -/, 7(
"#$%&'(( (70+50(07 %.'//(/7/5+) &&@2 /45/*7*-7* 6/4(557-*5,+ -)- 7(
"#$%&'( *()5-,*- %.'/5/0)5 >%@5 (4,+5505(+, 6/4(/*+---/+ (/) 7*
"#$%&'* *()5-,*- %.'/5/0)5 >%@5 (4,5),55**, 6/4(/*+---/+ (*( 7*
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TAP – MS bench protocol (Rodrigo Villaseñor, FMI 2015) 
 
General points 
• Work during the isolation of protein complexes in cold room at 4°C. 
• Replace buffers (stock solutions) every 6 months to obtain optimal results. 
Where should be everything? 
 Where? Master stock 
TrypLE Tissue culture room, shelf Tissue culture room 
DMEM Tissue culture room, fridge Cold room 
PBS Tissue culture room, fridge Tissue culture room 
bMe Bottom drawer; dilution in fridge  
LIF -20 °C in a box (LIF enriched medium)  
mES FBS 50 ml aliquots (already heat inactivated) in 3rd 
drawer of -20 °C => should be thawed @ 4°C o/n 
Heat 56°C for 30 min then 
aliquot (45 ml) 
Na pyruvate Fridge Cold room 
Trypsin Fridge Freezer 
PBS Fridge Tissue culture room 
Pen strep Unlabelled; 3rd drawer of -20 °C Ground floor -20 °C 
Trypsin (V5111, Promega). Request at PAF, store at -20°C  10-ul aliquots [0.1 ug/ul] 
TCEP Request at PAF, store at -20°C  
 
Buffers 
 
TAP lysis buffer 
  
    Component Final concentration 
    NaCl 
 
150 mM 
 Tris-HCl (pH 7.5) 20 mM 
 NP-40 
 
0.5% (vol/vol) 
EDTA 
 
1 mM 
 Glycerol 
 
10% (vol/vol) 
DTT 
 
1 mM (add fresh) 
 
 
Digest buffer 
 !
   !Component Final concentration 
   !Tris-HCl (pH 8.0) 50 mM 
!CaCl 
 
1 mM 
!TCEP 
 
1 mM 
!Trypsin 
 
0.2 ug (per sample) 
 
Maintenance Of Cells 
Everything you need to know about maintenance of mouse ES cells can be found in the “cell cuture 
bench protocol” from Alex Tuck (Bühler lab protocols). Read it! 
Passaging And Expanding Cells 
1. With mES cells, aim for ~70% confluency. Passage the cells before medium gets orange (do not 
let medium get yellowish as it will affect the viability of your cells). Usually split 1:3-1:5. But to 
expand them, take all from a 10-cm dish and put into two 15-cm dishes. Then, split the cells with 
1:2 ratio into 15-cm dishes. Now you have 4 × 15-cm dishes for each cell line and ready for TAP-
purification. 
Note: The following numbers assume the passaging of cells in 15-cm culture dishes. 
2. Aspirate medium with Pasteur (flamed). 
3. Add 15 ml PBS, tilt plate a couple of times, then aspirate. 
4. Washing step is not needed when using TrypLE reagent but recommended. The crucial 
advantage of TrypLE over conventional trypsin is that it is very gentle on cells and dilution alone 
inactivates TrypLE, avoiding the need for trypsin inhibitors. 
5. Add 2 ml TrypLE, then put at 37 °C for 1-2 min. 
6. Add 10 ml pre-warmed PBS. Resuspend cells gently on plate to break clumps. 
7. Repeat step to collect all cells. 
8. Transfer to 50-ml Falcon tube.  
9. Spin at 1,000 rpm for 3-5 min. 
10. Aspirate supernatant, and resuspend in 10-ml of new medium. 
11. Optional – count cells (See Alex´s cell culture bench protocol). 
12. Take appropriate amount of cells and add to new 15-cm plate (gelatin-coated) containing pre-
warmed ES medium.  
Note: mES cells require fresh media every day. 
 
Protein Extraction 
13. ES cells should be ~80% confluent on the day of protein extraction. One 15cm dish per sample 
usually yields sufficient material for one TAP-purification. 
14. Follow the steps 2-8 to harvest cells by trypsinization. 
15. Keep cells on ice during the next steps! 
16. Centrifuge the cells in 50-ml conical tubes for 15 min using an Eppendorf centrifuge at 4 °C and 
2,400g. 
17. Carefully decant the supernatant, resuspend the cell pellet with 10 ml of ice-cold PBS (from media 
kitchen). Optional: count cells. 
18. Centrifuge the cells in 50-ml conical tubes for 10 min using an Eppendorf centrifuge at 4 °C and 
2,400g. 
19. Carefully decant the supernatant and aspirate the remaining supernatant with a disposable 0.2-ml 
tip. Change tip for every sample. 
20. Resuspend with 1 ml of ice-cold TAP lysis buffer with freshly added 1 mM DTT (final conc.) and 
protease inhibitor cocktail (for 50-ml buffer, dissolve 1 complete EDTA-free tablet). I usually 
prepared the supplemented TAP lysis buffer during the washing steps. See first page to prepare 
TAP lysis buffers. 
21. Transfer lysate to a cold 1.5-ml tube. Shake tube at 1,000 rpm in cold room for 30 min. 
22. Clear lysate by centrifugation at 4 °C and max. speed. 
23. Carefully take supernatant (try not to take pieces from pellet) and transfer to a new cold 1.5-ml 
tube. 
24. Determine the protein concentration of each sample using the Bradford assay (Bio-Rad Dye). 
Bradford Assay 
• Make BSA standards: 
 
• 2 mg/ml BSA • H2O • Final conc (ug/ml) 
• 5 ul • 495 ul • 20 
• 5 ul • 245 ul • 40 
• 6 ul • 194 ul • 60 
• 5 ul • 120 ul • 80 
• 5 ul • 95 ul • 100 
• 7.5 ul • 92.5 ul • 150 
 
• Add 3x 10 ul of each standard, and 3x 10 ul of each of your samples (diluted 1:50 in water) to 
a 96-well plate, then add 200 ul of working conc Bradford reagent (stock diluted 1 in 5 in 
water) 
• Incubate 5 min and read absorbance (595 nm) in plate reader. 
 
25. Use equal amounts of lysate (as determined by Bradford assay) from the control sample (parental 
cells, RosaB) and the bait-protein sample (gene tagged cells). Transfer required input material to 
new tube. 
Critical step: Optimal results are obtained with 5 mg of input material for some proteins. 
However, input amount might need adjustment. Equal amount of input material for ALL samples is 
important for MS-data analysis. A good starting point is 5 mg of input material, but can be 
adjusted depending on the expression level of bait-protein.  
 
26. Add an appropriate amount of cold TAP lysis buffer to each sample to adjust the final sample 
concentration to be ~5 mg/ml.  
27. This should be carried out just before the beads are required. Equilibrate FLAG M2 beads (10 µl 
of packed beads ~ 20 ul of slurry per 5 mg protein / sample) in tubes containing 1 ml of cold TAP 
lysis buffer. Rotate in cold room for 5-10 min, place tube on magnet and decant buffer. Repeat 
once. Resuspend packed beads in 50 µl of cold TAP lysis. 
28. Transfer 50 ul of pre-equilibrated FLAG M2 beads to pre-cleared lysate from step 26. Place tube 
on end-over-end rotating wheel at 4°C overnight. 
 
Tandem Affinity Purification Of Protein Complexes (TAP) 
 
29. Place tubes from overnight incubation on magnet and remove supernatant (unbound material). 
Optional: aliquot from unbound material can be loaded on gel to check purification efficiency. 
30. Wash FLAG-beads four times with 1ml of ice-cold TAP lysis buffer (add protease inhibitors). 
Rotate tubes at 4°C for 15 min per wash (first wash can be done for 5 min). 
31. After the final wash, remove most of supernatant with 200-ul tip. 
32. Elute bound material from beads with 250 ul of 0.3 mg/ml FLAG peptide. Elute beads four times, 
each time rotating tubes for 1-1.5 h at 4°C. Combine total 1 ml of each sample. Discard beads. 
Optional: aliquot of discarded beads can be boiled and loaded on gel to check how much material 
remains bound. 
33. Proceed with streptavidin purification immediately. 
34. Prepare streptavidin beads: equilibrate streptavidin dynabeads (10 µl of packed beads ~ 20 ul of 
slurry per 5 mg protein / sample) in tubes containing 1 ml of cold TAP lysis buffer. Rotate in cold 
room for 5-10 min, place tube on magnet and decant buffer. Repeat once. Resuspend packed 
beads in 50 µl of cold TAP lysis. 
35. Add 50 ul of pre-equilibrated streptavidin dynabeads to 1 ml of FLAG-eluate from step 32 and 
place on end-over-end rotating wheel at 4°C overnight. 
36. Place tubes from overnight incubation on magnet and remove supernatant (unbound material).  
37. Wash FLAG-beads two times with 1ml of ice-cold TAP lysis buffer (add protease inhibitors). 
Rotate tubes at 4°C for 15 min per wash (first wash can be done for 5 min). 
38. After the final wash, remove all supernatant with 200-ul tip. 
39. Pause Point: quick-freeze samples in liquid N2 at this point and store at – 80°C (fine for weeks) 
 
Trypsin-Digest Of Protein Complexes On Beads 
 
Note: I recommend doing this step one day before MS analysis. Plan accordingly with PAF 
facility. 
40. Wash beads two times with ice-cold TAP lysis buffer (without NP-40 detergent!!!, add protease 
inhibitors). Rotate tubes at 4°C for 15 min per wash.  
41. Resuspend beads in 20-ul of Digest buffer with added Trypsin 
42. Digest protein complexes over-night at 37°C 
43. Next day: samples are ready for further processing. 
